<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Vasopressors for hypotensive shock - Gamper, G - 2016 | Cochrane Library</title> <meta content="Vasopressors for hypotensive shock - Gamper, G - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003709.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Vasopressors for hypotensive shock - Gamper, G - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003709.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003709.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Vasopressors for hypotensive shock" name="citation_title"/> <meta content="Gunnar Gamper" name="citation_author"/> <meta content="Universitätsklinikum Sankt Pölten" name="citation_author_institution"/> <meta content="Christof Havel" name="citation_author"/> <meta content="Medical University of Vienna" name="citation_author_institution"/> <meta content="Jasmin Arrich" name="citation_author"/> <meta content="Medical University of Vienna" name="citation_author_institution"/> <meta content="Heidrun Losert" name="citation_author"/> <meta content="Medical University of Vienna" name="citation_author_institution"/> <meta content="Nathan L Pace" name="citation_author"/> <meta content="University of Utah" name="citation_author_institution"/> <meta content="Marcus Müllner" name="citation_author"/> <meta content="Internistisches Zentrum Brigittenau" name="citation_author_institution"/> <meta content="Harald Herkner" name="citation_author"/> <meta content="Medical University of Vienna" name="citation_author_institution"/> <meta content="harald.herkner@meduniwien.ac.at" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD003709.pub4" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/02/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003709.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003709.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003709.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Drug Therapy, Combination; Hypotension [*drug therapy, mortality]; Randomized Controlled Trials as Topic; Shock [*drug therapy, mortality]; Shock, Septic [drug therapy, mortality]; Vasoconstrictor Agents [adverse effects, *therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003709.pub4&amp;doi=10.1002/14651858.CD003709.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003709.pub4&amp;doi=10.1002/14651858.CD003709.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003709.pub4&amp;doi=10.1002/14651858.CD003709.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003709.pub4&amp;doi=10.1002/14651858.CD003709.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003709.pub4&amp;doi=10.1002/14651858.CD003709.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003709.pub4&amp;doi=10.1002/14651858.CD003709.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003709.pub4&amp;doi=10.1002/14651858.CD003709.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003709.pub4&amp;doi=10.1002/14651858.CD003709.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003709.pub4&amp;doi=10.1002/14651858.CD003709.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003709.pub4&amp;doi=10.1002/14651858.CD003709.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003709.pub4&amp;doi=10.1002/14651858.CD003709.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003709.pub4&amp;doi=10.1002/14651858.CD003709.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003709.pub4&amp;doi=10.1002/14651858.CD003709.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003709.pub4&amp;doi=10.1002/14651858.CD003709.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003709.pub4&amp;doi=10.1002/14651858.CD003709.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003709.pub4&amp;doi=10.1002/14651858.CD003709.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003709.pub4&amp;doi=10.1002/14651858.CD003709.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003709.pub4&amp;doi=10.1002/14651858.CD003709.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003709.pub4&amp;doi=10.1002/14651858.CD003709.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003709.pub4&amp;doi=10.1002/14651858.CD003709.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003709.pub4&amp;doi=10.1002/14651858.CD003709.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003709.pub4&amp;doi=10.1002/14651858.CD003709.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003709.pub4&amp;doi=10.1002/14651858.CD003709.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="Ko3zGe0H";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003709\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003709\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003709\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003709\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fa","fr","zh_HANS","de","ru","ms","ja","zh_HANT","hr","pt","th","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003709.pub4",title:"Vasopressors for hypotensive shock",firstPublishedDate:"Feb 15, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Emergency and Critical Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Ko3zGe0H&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003709.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003709.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003709.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003709.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003709.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003709.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003709.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003709.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003709.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003709.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>30643 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003709.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003709.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003709.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003709.pub4/full#CD003709-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003709.pub4/full#CD003709-sec-0091"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003709.pub4/full#CD003709-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003709.pub4/full#CD003709-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003709.pub4/full#CD003709-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003709.pub4/full#CD003709-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003709.pub4/full#CD003709-sec-0060"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003709.pub4/full#CD003709-sec-0085"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003709.pub4/appendices#CD003709-sec-0096"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/table_n/CD003709StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/table_n/CD003709StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003709.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003709.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003709.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003709.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003709.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003709.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Vasopressors for hypotensive shock</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003709.pub4/information#CD003709-cr-0002">Gunnar Gamper</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003709.pub4/information#CD003709-cr-0003">Christof Havel</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003709.pub4/information#CD003709-cr-0004">Jasmin Arrich</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003709.pub4/information#CD003709-cr-0005">Heidrun Losert</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003709.pub4/information#CD003709-cr-0006">Nathan L Pace</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003709.pub4/information#CD003709-cr-0007">Marcus Müllner</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003709.pub4/information#CD003709-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>Harald Herkner</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/information/en#CD003709-sec-0107">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 February 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003709.pub4">https://doi.org/10.1002/14651858.CD003709.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003709-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003709-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003709-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003709-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003709-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD003709-abs-0017">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD003709-abs-0019">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003709-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003709-abs-0001" lang="en"> <section id="CD003709-sec-0001"> <h3 class="title" id="CD003709-sec-0001">Background</h3> <p>Initial goal‐directed resuscitation for hypotensive shock usually includes administration of intravenous fluids, followed by initiation of vasopressors. Despite obvious immediate effects of vasopressors on haemodynamics, their effect on patient‐relevant outcomes remains controversial. This review was published originally in 2004 and was updated in 2011 and again in 2016. </p> </section> <section id="CD003709-sec-0002"> <h3 class="title" id="CD003709-sec-0002">Objectives</h3> <p>Our objective was to compare the effect of one vasopressor regimen (vasopressor alone, or in combination) versus another vasopressor regimen on mortality in critically ill participants with shock. We further aimed to investigate effects on other patient‐relevant outcomes and to assess the influence of bias on the robustness of our effect estimates. </p> </section> <section id="CD003709-sec-0003"> <h3 class="title" id="CD003709-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2015 Issue 6), MEDLINE, EMBASE, PASCAL BioMed, CINAHL, BIOSIS and PsycINFO (from inception to June 2015). We performed the original search in November 2003. We also asked experts in the field and searched meta‐registries to identify ongoing trials. </p> </section> <section id="CD003709-sec-0004"> <h3 class="title" id="CD003709-sec-0004">Selection criteria</h3> <p>Randomized controlled trials (RCTs) comparing various vasopressor regimens for hypotensive shock. </p> </section> <section id="CD003709-sec-0005"> <h3 class="title" id="CD003709-sec-0005">Data collection and analysis</h3> <p>Two review authors abstracted data independently. They discussed disagreements between them and resolved differences by consulting with a third review author. We used a random‐effects model to combine quantitative data. </p> </section> <section id="CD003709-sec-0006"> <h3 class="title" id="CD003709-sec-0006">Main results</h3> <p>We identified 28 RCTs (3497 participants) with 1773 mortality outcomes. Six different vasopressors, given alone or in combination, were studied in 12 different comparisons. </p> <p>All 28 studies reported mortality outcomes; 12 studies reported length of stay. Investigators reported other morbidity outcomes in a variable and heterogeneous way. No data were available on quality of life nor on anxiety and depression outcomes. We classified 11 studies as having low risk of bias for the primary outcome of mortality; only four studies fulfilled all trial quality criteria. </p> <p>In summary, researchers reported no differences in total mortality in any comparisons of different vasopressors or combinations in any of the pre‐defined analyses (evidence quality ranging from high to very low). More arrhythmias were observed in participants treated with dopamine than in those treated with norepinephrine (high‐quality evidence). These findings were consistent among the few large studies and among studies with different levels of within‐study bias risk. </p> </section> <section id="CD003709-sec-0007"> <h3 class="title" id="CD003709-sec-0007">Authors' conclusions</h3> <p>We found no evidence of substantial differences in total mortality between several vasopressors. Dopamine increases the risk of arrhythmia compared with norepinephrine and might increase mortality. Otherwise, evidence of any other differences between any of the six vasopressors examined is insufficient. We identified low risk of bias and high‐quality evidence for the comparison of norepinephrine versus dopamine and moderate to very low‐quality evidence for all other comparisons, mainly because single comparisons occasionally were based on only a few participants. Increasing evidence indicates that the treatment goals most often employed are of limited clinical value. Our findings suggest that major changes in clinical practice are not needed, but that selection of vasopressors could be better individualised and could be based on clinical variables reflecting hypoperfusion. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003709-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003709-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD003709-abs-0007">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD003709-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003709-abs-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003709-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD003709-abs-0014">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD003709-abs-0010">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003709-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD003709-abs-0021">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD003709-abs-0018">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD003709-abs-0008">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD003709-abs-0020">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003709-abs-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD003709-abs-0013">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003709-abs-0005" lang="en"> <h3>Vasopressors for hypotensive shock</h3> <p><b>Review question</b> </p> <p>This review seeks unbiased evidence about the effects of different drugs that enhance blood pressure on risk of dying in critically ill patients with impaired blood circulation. </p> <p><b>Background</b> </p> <p>● Circulatory shock is broadly defined as a life‐threatening condition of impaired blood flow resulting in inability of the body to maintain blood delivery to body tissue and to meet oxygen demands. </p> <p>● Typical signs of shock include low blood pressure, rapid heartbeat and poor organ perfusion indicated by low urine output, confusion or loss of consciousness. </p> <p>● Death in the intensive care unit ranges from 16% to 60%, depending on the underlying condition: treatment includes fluid replacement followed by use of vasopressor agents, if necessary. </p> <p>● A vasopressor agent is a drug that causes a rise in blood pressure. Six vasopressor drugs are available and are used successfully to increase blood pressure to reverse circulatory failure in critical care. Differences in their effects on survival are discussed with controversy and must be investigated. </p> <p>● This review aims to discover whether any of the drugs given alone or in combination were better or worse than the others. </p> <p><b>Search date</b> </p> <p>Evidence is current to June 2015.</p> <p><b>Study characteristics</b> </p> <p>Review authors identified 28 randomized controlled trials involving 3497 critically ill patients with circulatory failure, among whom 1773 died. Patients were followed up to one year. </p> <p>The following drugs, given alone or in combination, were studied in 12 different comparisons: dopamine, norepinephrine, epinephrine, phenylephrine, vasopressin, and terlipressin. </p> <p><b>Key results</b> </p> <p>In summary, researchers found no significant differences in risk of dying in any comparisons of different drugs given alone or in combination when latest reported death was considered. </p> <p>Disturbances in the rhythm of the heart were observed more frequently in people treated with dopamine than in those treated with norepinephrine. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of the evidence was high for the comparison of norepinephrine and dopamine, and was very low to moderate for the other comparisons. </p> <p>Findings were consistent among the few large studies and studies of different quality.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003709-sec-0091" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003709-sec-0091">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003709-sec-0137">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003709-sec-0091"></div> <h3 class="title" id="CD003709-sec-0092">Implications for practice</h3> <section id="CD003709-sec-0092"> <p>Vasopressor therapy is an important part of haemodynamic support for patients with shock (<a href="./references#CD003709-bbs2-0077" title="DellingerRP , LevyMM , RhodesA , AnnaneD , GerlachH , OpalSM , et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Critical Care Medicine2013;41(2):580‐637. ">Dellinger 2013</a>). Several different vasopressors are available, and for six vasopressors, the effect was assessed in randomized controlled trials. The quality of evidence differs greatly between several comparisons, but, in summary, evidence is insufficient to prove that any of the vasopressors at assessed doses are superior over others in terms of mortality. Dopamine increases the risk for arrhythmia and might confer a mortality disadvantage versus norepinephrine. Most available data involve norepinephrine. The choice of the specific vasopressor may therefore be individualized and left to the discretion of the treating physician. Factors such as experience, physiological effects (e.g. heart rate, intrinsic inotropic effects, splanchnic perfusion), drug interaction with other therapeutics (especially vasopressin and concomitant use of corticosteroids) (<a href="./references#CD003709-bbs2-0100" title="RussellJA , WalleyKR , GordonAC , CooperDJ , HébertPC , SingerJ , et al. Interaction of vasopressin infusion, corticosteroid treatment, and the mortality of septic shock. Critical Care Medicine2009;37(3):811‐8. ">Russell 2009</a>), availability and cost should be considered. </p> </section> <h3 class="title" id="CD003709-sec-0093">Implications for research</h3> <section id="CD003709-sec-0093"> <p>A large number of randomized trials have been conducted, but the sample population for specific comparisons is small. We hope that our review encourages the scientific community to design future studies in a way that outcomes that matter to patients, such as survival, but also long‐term health‐related quality of life, can be evaluated. Such studies ideally would be large, multi‐centre trials based on simple and pragmatic study protocols. Such studies are also needed to evaluate whether surrogate endpoints, such as filling pressures, are of clinical use and, if so, how they should be used. In this context, special concern arises about use of target blood pressure as an endpoint of resuscitation, as achievement of specific blood pressure values may not reflect reversal of the underlying condition, as is shown in the group of participants with persisting "cryptogenic" shock despite normalization of blood pressure (<a href="./references#CD003709-bbs2-0099" title="RiversE , NguyenB , HavstadS , ResslerJ , MuzzinA , KnoblichB , et al. Early goal‐directed therapy in the treatment of severe sepsis and septic shock. The New England Journal of Medicine2001;345:1368‐77. [PUBMED: 11794169] ">Rivers 2001</a>). A single universally valid blood pressure goal appropriate for all patients with shock probably does not exist at all (<a href="./references#CD003709-bbs2-0069" title="AsfarP , MezianiF , HamelJF , GrelonF , MegarbaneB , AnguelN , et al. High versus low blood‐pressure target in patients with septic shock. New England Journal of Medicine2014;370(17):1583‐93. ">Asfar 2014</a>). Furthermore, it is known that blood pressure targets often are not reached in controlled clinical trials (<a href="./references#CD003709-bbs2-0107" title="TakalaJ . Should we target blood pressures in Sepsis?. Critical Care Medicine2010;38:S609‐13. ">Takala 2010</a>). Moreover, increasing evidence does not support superiority of strict goal‐directed therapy protocols (<a href="./references#CD003709-bbs2-0068" title="The ARISE Investigators and the ANZICS Clinical Trials Group. Goal‐directed resuscitation for patients with early septic shock. New England Journal of Medicine2014;371:1496‐506. ">ARISE 2014</a>; <a href="./references#CD003709-bbs2-0094" title="The ProCESS Investigators. A randomized trial of protocol‐based care for early septic shock. New England Journal of Medicine2014;370:1683‐93. ">ProCESS 2014</a>). </p> <p>In the light of currently available evidence, additional well‐designed studies with individualized goals of resuscitation including clinical parameters of end‐organ perfusion and appropriate patient‐relevant outcomes endpoints are urgently needed. </p> <p>As with all Cochrane reviews, this review will be updated regularly. It is hoped that answers to the questions under study will be found over the next few years. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003709-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003709-sec-0029"></div> <div class="table" id="CD003709-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Dopamine compared with norepinephrine for hypotensive shock</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Dopamine compared with norepinephrine for hypotensive shock</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> hypotensive shock<br/> <b>Settings:</b> critical care units<br/> <b>Intervention:</b> dopamine<br/> <b>Comparison:</b> norepinephrine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Norepinephrine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Dopamine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total mortality<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.07<br/> (0.99 to 1.16)<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1400<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH<sup>d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>380 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>407 per 1000<br/> (376 to 441) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Arrhythmia &lt; BR/&gt; follow‐up: <br/> range 28 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<sup>f,g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.33<br/> (1.45 to 3.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1931<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH<sup>h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>177 per 1000<br/> (110 to 293) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The largest study reported 12‐month mortality, one study reported 28‐day mortality and one hospital mortality. For the remaining 3 studies, the time point of mortality assessment was undetermined. A sensitivity analysis indicates no influence on effects by differences in mortality definition<br/> <sup>b</sup><a href="./references#CD003709-bbs2-0103" title="SakrY , ReinhartK , VincentJL , SprungCL , MorenoR , RanieriVM , et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Critical Care Medicine2006;34(3):589‐97. [PUBMED: 16505643] ">Sakr 2006</a> </p> <p><sup>c</sup>Estimate from the network meta‐analysis integrating direct and indirect comparisons<br/> <sup>d</sup>Four smaller studies included up to 50 participants, each of whom did not fulfil some of the quality criteria and one high risk of bias study that contributed 252 participants. However, the summary result is mainly made up by the largest study of more than 1000 participants that fulfils all low risk of bias criteria<br/> <sup>e</sup>The main outcomes of the four smaller studies are haemodynamics and metabolic measures. Mortality is reported only at the end of the results and often is unclear timepoint‐wise. However, the study by <a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a> (which contributes mainly to the summary result) clearly defines mortality endpoints<br/> <sup>f</sup><a href="./references#CD003709-bbs2-0097" title="ReineltP Karth DG , GeppertA , HeinzG . Incidence and type of cardiac arrhythmias in critically ill patients: a single center experience in a medical‐cardiological ICU. Intensive Care Medicine2001;27:1466‐73. [PUBMED: 11685339] ">Reinelt 2001</a><br/> <sup>g</sup><a href="./references#CD003709-bbs2-0067" title="AnnaneD , SébilleV , DubocD , LeHeuzeyJY , SadoulN , BouvierE , et al. Incidence and prognosis of sustained arrhythmias in critically ill patients. American Journal of Respiratory and Critical Care Medicine2008;178:20‐5. [PUBMED: 18388358] ">Annane 2008</a><br/> <sup>h</sup>Information was obtained from 992 participants, 86% of whom were studied in a low risk of bias study (<a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>); remaining participants were included in a high risk of bias study (<a href="./references#CD003709-bbs2-0022" title="PatelGP , GraheJS , SperryM , SinglaS , ElpernE , LateefO , et al. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock2010;33(4):375‐80. [PUBMED: 19851126] ">Patel 2010</a>). Effects show into the same direction </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003709-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Terlipressin compared with norepinephrine for hypotensive shock</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Terlipressin compared with norepinephrine for hypotensive shock</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> hypotensive shock<br/> <b>Settings:</b> critical care units<br/> <b>Intervention:</b> terlipressin<br/> <b>Comparison:</b> norepinephrine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Norepinephrine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Terlipressin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total mortality<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.93<br/> (0.69 to 1.26)<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>231<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>380 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>353 per 1000<br/> (262 to 479) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> <b>CI:</b> Confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Direct comparisons based on in‐hospital mortality and mortality at an undetermined point in time. A sensitivity analysis indicates no influence on effects by differences in mortality definition.<br/> <sup>b</sup><a href="./references#CD003709-bbs2-0103" title="SakrY , ReinhartK , VincentJL , SprungCL , MorenoR , RanieriVM , et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Critical Care Medicine2006;34(3):589‐97. [PUBMED: 16505643] ">Sakr 2006</a> </p> <p><sup>c</sup>Estimate from the network meta‐analysis integrating direct and indirect comparisons </p> <p><sup>d</sup>Risk of bias was serious with adequate allocation concealment in one small study that contributed to the estimates only; imprecision of the estimates was very serious, as direct comparisons are based on two small studies only, whereas only one contributed to the estimates </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003709-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Vasopressin compared with norepinephrine for hypotensive shock</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Vasopressin compared with norepinephrine for hypotensive shock</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> hypotensive shock<br/> <b>Settings:</b> critical care units<br/> <b>Intervention:</b> vasopressin<br/> <b>Comparison:</b> norepinephrine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Norepinephrine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Vasopressin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total mortality<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/> (0.78 to 1.03)<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1108<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>380 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>342 per 1000<br/> (296 to 391) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> <b>CI:</b> Confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>For the direct comparison, the largest study reported 90‐day mortality, and 2 studies contributed ICU mortality. A sensitivity analysis indicates no influence on effects by differences in mortality definition<br/> <sup>b</sup><a href="./references#CD003709-bbs2-0103" title="SakrY , ReinhartK , VincentJL , SprungCL , MorenoR , RanieriVM , et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Critical Care Medicine2006;34(3):589‐97. [PUBMED: 16505643] ">Sakr 2006</a> </p> <p><sup>c</sup>Estimate from the network meta‐analysis integrating direct and indirect comparisons </p> <p><sup>d</sup>The effect is based mainly on 1 moderately large RCT, and direct evidence comes from 3 RCTS including 812 individuals overall </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003709-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Phenylephrine compared with norepinephrine for hypotensive shock</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phenylephrine compared with norepinephrine for hypotensive shock</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> hypotensive shock<br/> <b>Settings:</b> critical care units<br/> <b>Intervention:</b> phenylephrine<br/> <b>Comparison:</b> norepinephrine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Norepinephrine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Phenylephrine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total mortality<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.08<br/> (0.76 to 1.55)<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>86<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>380 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>410 per 1000<br/> (289 to 589) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> <b>CI:</b> Confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>For the direct comparison, one study measured ICU mortality; for the other study, the time point of mortality assessment was undetermined<br/> <sup>b</sup><a href="./references#CD003709-bbs2-0103" title="SakrY , ReinhartK , VincentJL , SprungCL , MorenoR , RanieriVM , et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Critical Care Medicine2006;34(3):589‐97. [PUBMED: 16505643] ">Sakr 2006</a> </p> <p><sup>c</sup>Estimate from the network meta‐analysis integrating direct and indirect comparisons </p> <p><sup>d</sup>Two small studies, with 1 having unclear allocation concealment and an open intervention </p> <p><sup>e</sup>Two small studies with 86 individuals overall for the direct comparison </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003709-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Epinephrine compared with norepinephrine for hypotensive shock</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Epinephrine compared with norepinephrine for hypotensive shock</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> hypotensive shock<br/> <b>Settings:</b> critical care units<br/> <b>Intervention:</b> epinephrine<br/> <b>Comparison:</b> norepinephrine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Norepinephrine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Epinephrine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total mortality<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/> (0.63 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>269<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>380 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>334 per 1000<br/> (239 to 475) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> <b>CI:</b> Confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>90‐Day mortality<br/> <sup>b</sup><a href="./references#CD003709-bbs2-0103" title="SakrY , ReinhartK , VincentJL , SprungCL , MorenoR , RanieriVM , et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Critical Care Medicine2006;34(3):589‐97. [PUBMED: 16505643] ">Sakr 2006</a> </p> <p><sup>c</sup>Effect from only 1 moderately large single RCT </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003709-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003709-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003709-sec-0117">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD003709-sec-0030"></div> <section id="CD003709-sec-0031"> <h3 class="title" id="CD003709-sec-0031">Description of the condition</h3> <p>Shock is a state of severe systemic deterioration in tissue perfusion, characterized by decreased cellular oxygen delivery and utilization, as well as decreased removal of waste byproducts of metabolism. Hypotension, although common in shock, is not synonymous with shock. Individuals can have hypotension and normal perfusion, whereas patients who have a history of hypertension can have shock without hypotension in the early phase of cardiogenic shock. Shock is the final pre‐terminal event in many diseases. Progressive tissue hypoxia results in loss of cellular membrane integrity, reversion to a catabolic state of anaerobic metabolism and loss of energy‐dependent ion pumps and chemical and electrical gradients. Mitochondrial energy production begins to fail. Multiple organ dysfunction follows localized cellular death, and this is followed by death of the organism (<a href="./references#CD003709-bbs2-0108" title="YoungWF . SHOCK. In: StoneCK , HumphriesR editor(s). CURRENT Diagnosis and Treatment Emergency Medicine. 6th Edition. New York: LANGE CURRENT Series/McGraw‐Hill, 2008:160. ">Young 2008</a>). A widely used classification for mechanisms of shock consists of hypovolaemic, cardiogenic, obstructive and distributive (<a href="./references#CD003709-bbs2-0083" title="HinshawLB , CoxBG . The Fundamental Mechanisms of Shock. New York: Plenum Press, 1972. ">Hinshaw 1972</a>). Septic shock, a form of distributive shock, is the most common form of shock among patients admitted to the intensive care unit, followed by cardiogenic and hypovolaemic shock; obstructive shock is rare. As an example, in a trial of 1600 patients with undifferentiated shock, septic shock occurred in 62%, cardiogenic shock in 16%, hypovolaemic shock in 16%, other types of distributive shock in 4% (e.g. neurogenic shock, anaphylaxis) and obstructive shock in 2% (<a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>). </p> <p>Currently, the definition of septic shock is more pragmatic because hypotension instead of hypoperfusion is the main clinical criterion. The current standard definition for septic shock (<a href="./references#CD003709-bbs2-0076" title="DellingerRP , LevyMM , CarletJM , BionJ , ParkerMM , JaeschkeR , et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Critical Care Medicine2008;36(1):296‐327. [PUBMED: 18158437] ">Dellinger 2008</a>) in adults refers to a state of acute circulatory failure characterized by persistent arterial hypotension that is not explained by other causes. Hypotension is defined by systolic blood pressure &lt; 90 mm Hg, mean arterial pressure &lt; 60 mm Hg or a reduction in systolic blood pressure &gt; 40 mm Hg despite adequate volume resuscitation in the absence of other causes for hypotension (<a href="./references#CD003709-bbs2-0090" title="LevyMM , FinkMP , MarshallJC , AbrahamE , AngusD , CookD , et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Critical Care Medicine2003;31(4):1250‐6. [PUBMED: 12682500] ">Levy 2003</a>). A large study defined shock even more pragmatically, as haemodynamic compromise necessitating administration of vasopressor catecholamines (<a href="./references#CD003709-bbs2-0103" title="SakrY , ReinhartK , VincentJL , SprungCL , MorenoR , RanieriVM , et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Critical Care Medicine2006;34(3):589‐97. [PUBMED: 16505643] ">Sakr 2006</a>). </p> <p>Estimates of the incidence of shock in the general population vary considerably. From an observational study, 31 cases of septic shock per 100,000 population/y (<a href="./references#CD003709-bbs2-0078" title="EstebanA , Frutos‐VivarF , FergusonND , PenuelasO , LorenteJA , GordoF , et al. Sepsis incidence and outcome: contrasting the intensive care unit with the hospital ward. Critical Care Medicine2007;35(5):1284‐9. [PUBMED: 17414725] ">Esteban 2007</a>) were reported. Many patients develop shock from severe sepsis, which has an incidence of 25 to 300 cases per 100,000 population/y (<a href="./references#CD003709-bbs2-0066" title="AngusDC , Linde‐ZwirbleWT , LidickerJ , ClermontG , CarcilloJ , PinskyMR . Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Critical Care Medicine2001;29(7):1303‐10. [PUBMED: 11445675] ">Angus 2001</a>; <a href="./references#CD003709-bbs2-0073" title="BlancoJ , Muriel‐BombinA , SagredoV , TaboadaF , GandiaF , TamayoL , et al. Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicentre study. Critical Care (London, England)2008;12(6):R158. [PUBMED: 19091069] ">Blanco 2008</a>; <a href="./references#CD003709-bbs2-0106" title="SundararajanV , MacisaacCM , PresneillJJ , CadeJF , VisvanathanK . Epidemiology of sepsis in Victoria, Australia. Critical Care Medicine2005;33(1):71‐80. [PUBMED: 15644651] ">Sundararajan 2005</a>); among those, 30% are expected to develop septic shock (<a href="./references#CD003709-bbs2-0078" title="EstebanA , Frutos‐VivarF , FergusonND , PenuelasO , LorenteJA , GordoF , et al. Sepsis incidence and outcome: contrasting the intensive care unit with the hospital ward. Critical Care Medicine2007;35(5):1284‐9. [PUBMED: 17414725] ">Esteban 2007</a>). </p> <p>The frequency of shock at healthcare facilities is somewhat better described. In the large observational study of sepsis occurrence in acutely Ill patients (SOAP), among 3147 critically ill participants from 198 intensive care units (ICUs), 34% had shock; of those, 15% had septic shock (<a href="./references#CD003709-bbs2-0103" title="SakrY , ReinhartK , VincentJL , SprungCL , MorenoR , RanieriVM , et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Critical Care Medicine2006;34(3):589‐97. [PUBMED: 16505643] ">Sakr 2006</a>). Recently a large French observational study published similar numbers indicating that among 10,941 patients admitted to participating ICUs between October 2009 and September 2011, 1495 (13.7%) presented with inclusion criteria for septic shock (<a href="./references#CD003709-bbs2-0095" title="QuenotJ‐P , BinquetC , KaraF , MartinetO , GansterF , NavellouJ‐C , et al. The epidemiology of septic shock in French intensive care units: the prospective multicenter cohort EPISS study. Critical Care2013;17(R65):1‐10. [DOI: doi:10.1186/cc12598] ">Quenot 2013</a>). In another large European ICU cohort study, 32% were found to have septic shock. In a prospective observational study of 293,633 participants with ST‐elevation myocardial infarction from 775 US hospitals, 9% developed cardiogenic shock (<a href="./references#CD003709-bbs2-0071" title="BabaevA , FrederickPD , PastaDJ , EveryN , SichrovskyT , HochmanJS . Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA2005;294(4):448‐54. [PUBMED: 16046651] ">Babaev 2005</a>). From an observational study on 2445 participants admitted to a trauma level I centre, 22% were reported to already have shock on admission to the emergency department (ED) (<a href="./references#CD003709-bbs2-0074" title="CannonCM , BraxtonCC , Kling‐SmithM , MahnkenJD , CarltonE , MoncureM . Utility of the shock index in predicting mortality in traumatically injured patients. The Journal of Trauma2009;67(6):1426‐30. [PUBMED: 20009697] ">Cannon 2009</a>). </p> <p>Hospital mortality is high, at around 38% (<a href="./references#CD003709-bbs2-0103" title="SakrY , ReinhartK , VincentJL , SprungCL , MorenoR , RanieriVM , et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Critical Care Medicine2006;34(3):589‐97. [PUBMED: 16505643] ">Sakr 2006</a>), among patients with shock but seems to depend much on shock type. For patients with septic shock, mortality ranges from 46% (<a href="./references#CD003709-bbs2-0078" title="EstebanA , Frutos‐VivarF , FergusonND , PenuelasO , LorenteJA , GordoF , et al. Sepsis incidence and outcome: contrasting the intensive care unit with the hospital ward. Critical Care Medicine2007;35(5):1284‐9. [PUBMED: 17414725] ">Esteban 2007</a>; <a href="./references#CD003709-bbs2-0103" title="SakrY , ReinhartK , VincentJL , SprungCL , MorenoR , RanieriVM , et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Critical Care Medicine2006;34(3):589‐97. [PUBMED: 16505643] ">Sakr 2006</a>) to 61% (<a href="./references#CD003709-bbs2-0065" title="AlbertiC , Brun‐BuissonC , ChevretS , AntonelliM , GoodmanSV , MartinC , et al. Systemic inflammatory response and progression to severe sepsis in critically ill infected patients. American Journal of Respiratory and Critical Care Medicine2005;171(5):461‐8. [PUBMED: 15531752] ">Alberti 2005</a>). Mortality in patients with traumatic shock was somewhat lower, at 16% (<a href="./references#CD003709-bbs2-0074" title="CannonCM , BraxtonCC , Kling‐SmithM , MahnkenJD , CarltonE , MoncureM . Utility of the shock index in predicting mortality in traumatically injured patients. The Journal of Trauma2009;67(6):1426‐30. [PUBMED: 20009697] ">Cannon 2009</a>). Whereas the incidence of cardiogenic shock was almost constant between 1995 and 2004, mortality has decreased from 60% in 1995 to 48% over the years (<a href="./references#CD003709-bbs2-0071" title="BabaevA , FrederickPD , PastaDJ , EveryN , SichrovskyT , HochmanJS . Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA2005;294(4):448‐54. [PUBMED: 16046651] ">Babaev 2005</a>). </p> </section> <section id="CD003709-sec-0032"> <h3 class="title" id="CD003709-sec-0032">Description of the intervention</h3> <p>Vasopressors are a heterogeneous class of drugs with powerful and immediate haemodynamic effects. Vasopressors can be classified according to their adrenergic and non‐adrenergic actions. </p> <p>Catecholamines are sympathomimetics that act directly or indirectly on adrenergic receptors. Their haemodynamic effects depend on their varying pharmacological properties. They may increase the contractility of myocardial muscle fibres and heart rate (via beta‐adrenergic receptors), but they may also, and sometimes exclusively, increase vascular resistance (via alpha‐adrenergic receptors). Many good textbooks have outlined the detailed mechanisms of action (e.g. see <a href="./references#CD003709-bbs2-0084" title="HoffmanB , LefkowitzRJ . Catecholamines and sympathomimetic drugs. In: A Goodman Gilman editor(s). The Pharmacological Basis of Therapeutics. 8th Edition. Singapore: McGraw‐Hill, 1992:187‐220. ">Hoffman 1992</a>; <a href="./references#CD003709-bbs2-0109" title="ZaritskyAL . Catecholamines, inotropic medications, and vasopressor agents. In: ChernowB editor(s). Essentials of Critical Care Pharmacology. 2nd Edition. Baltimore, MD: Williams &amp; Wilkins, 1994:255‐72. ">Zaritsky 1994</a>). </p> <p>The haemodynamic properties of vasopressin, a neurohypophysial peptide hormone, were first reported in 1926 (<a href="./references#CD003709-bbs2-0079" title="GeilingEMK , CampbellDJ . Variations in blood pressure induced by repeated injections of extracts of the posterior lobe of the pituitary gland. Journal of Pharmacological and Experimental Therapeutics1926;29:449–60. ">Geiling 1926</a>). Vasopressin and analogues like terlipressin display their vasopressor effects via vasopressin receptors and serve as newer treatments for patients with shock (<a href="./references#CD003709-bbs2-0091" title="LevyB , CollinS , SennounN , DucrocqN , KimmounA , AsfarP , et al. Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside. Intensive Care Medicine2010;36(12):2019‐29. [PUBMED: 20862451] ">Levy 2010</a>). </p> <p>Utilisation of different vasopressors was described recently in a large European multi‐centre cohort study conducted in 198 ICUs (<a href="./references#CD003709-bbs2-0103" title="SakrY , ReinhartK , VincentJL , SprungCL , MorenoR , RanieriVM , et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Critical Care Medicine2006;34(3):589‐97. [PUBMED: 16505643] ">Sakr 2006</a>). The most frequently used vasopressor was norepinephrine (80%), followed by dopamine (35%) and epinephrine (23%), given alone or in combination. Single‐agent use was reported for norepinephrine (32%), dopamine (9%) and epinephrine (5%). A combination of norepinephrine, dopamine and epinephrine was used in only 2% of patients with shock. Vasopressin and terlipressin were not described in this report. Currently the choice of vasopressors seems to be based mainly on physicians' preferences (<a href="./references#CD003709-bbs2-0088" title="LeoneM , ValletB , TeboulJL , MateoJ , BastienO , MartinC . Survey of the use of catecholamines by French physicians. Intensive Care Medicine2004;30(5):984‐8. [PUBMED: 14997293] ">Leone 2004</a>). Additionally, clinical guidelines suggest norepinephrine as the first‐line vasopressor in shock states, such as septic shock (<a href="./references#CD003709-bbs2-0077" title="DellingerRP , LevyMM , RhodesA , AnnaneD , GerlachH , OpalSM , et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Critical Care Medicine2013;41(2):580‐637. ">Dellinger 2013</a>). </p> </section> <section id="CD003709-sec-0033"> <h3 class="title" id="CD003709-sec-0033">How the intervention might work</h3> <p>Initial goal‐directed resuscitation to support vital functions is essential in the management of shock. First‐line treatment for the manifestation of circulatory failure usually consists of administration of intravenous fluids. If fluid treatment does not restore circulatory function, vasopressors such as norepinephrine, dopamine, epinephrine and vasopressin are recommended. </p> </section> <section id="CD003709-sec-0034"> <h3 class="title" id="CD003709-sec-0034">Why it is important to do this review</h3> <p>Effects of vasopressors on the cardiovascular system are largely undisputed. However, it remains unclear whether a vasopressor of choice is known for the treatment of patients with particular forms of shock or for the treatment of patients with shock in general. We are conducting this systematic review to explore uncertainty arising from conflicting results reported by several studies in this area. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003709-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003709-sec-0035">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003709-sec-0122">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003709-sec-0035"></div> <p>Our objective was to compare the effect of one vasopressor regimen (vasopressor alone, or in combination) versus another vasopressor regimen on mortality in critically ill participants with shock. We further aimed to investigate effects on other patient‐relevant outcomes and to assess the influence of bias on the robustness of our effect estimates. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003709-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003709-sec-0036">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003709-sec-0123">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003709-sec-0036"></div> <section id="CD003709-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003709-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included randomized controlled trials (RCTs) undertaken to investigate the effects of vasopressors in the treatment of patients with any kind of circulatory failure. For simplicity, we refer to circulatory failure as 'shock' (see also search terms for shock). We were exclusively interested in patient‐relevant outcomes (see below). Such endpoints, particularly death, can be assessed only through parallel‐group trials. Therefore, we excluded cross‐over trials. </p> </section> <section id="CD003709-sec-0039"> <h4 class="title">Types of participants</h4> <p>We included trials with acutely and critically ill adult and paediatric participants. We excluded trials looking at pre‐term infants with hypotension, as this patient group is covered in another Cochrane review (<a href="./references#CD003709-bbs2-0105" title="SubhedarNV , ShawNJ . Dopamine versus dobutamine for hypotensive preterm infants. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD001242; CD001242] ">Subhedar 2003</a>). We excluded animal experiments. The definition of 'hypotensive shock' used was that given by study authors. </p> </section> <section id="CD003709-sec-0040"> <h4 class="title">Types of interventions</h4> <p>The intervention consisted of administration of different vasopressors, vasopressors versus intravenous fluids and vasopressors versus placebo with or without non‐protocol vasoactive drugs (NPVDs). </p> </section> <section id="CD003709-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD003709-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD003709-list-0001"> <li> <p>We looked at total mortality (in the ICU, in hospital and at one year) as the main endpoint. If mortality was assessed at several time points in a study, we used data derived from the latest follow‐up time. </p> </li> </ul> </p> </section> <section id="CD003709-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p>Other pre‐defined outcomes included the following.</p> <p> <ul id="CD003709-list-0002"> <li> <p>Morbidity, given as:</p> <ul id="CD003709-list-0003"> <li> <p>ICU length of stay (LOS);</p> </li> <li> <p>hospital LOS;</p> </li> <li> <p>duration of vasopressor treatment;</p> </li> <li> <p>duration of mechanical ventilation;</p> </li> <li> <p>renal failure (as defined by study authors, such as oliguria or need for renal replacement therapy); and </p> </li> <li> <p>other.</p> </li> </ul> </li> <li> <p>Measures of health‐related quality of life at any given time, and measures of anxiety and depression (together or separately) at any given time. </p> </li> </ul> </p> </section> </section> </section> <section id="CD003709-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003709-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 6) (see <a href="./appendices#CD003709-sec-0097">Appendix 1</a>, Search filter for CENTRAL); MEDLINE (1966 to June 2015) (see <a href="./appendices#CD003709-sec-0098">Appendix 2</a>); EMBASE (1989 to June 2015) (see <a href="./appendices#CD003709-sec-0099">Appendix 3</a>, Search filter for EMBASE); PASCAL BioMed (1996 to June 2015); and BIOSIS (1990 to June 2015) (see <a href="./appendices#CD003709-sec-0100">Appendix 4</a> and <a href="./appendices#CD003709-sec-0101">Appendix 5</a>, Search filter for PASCAL BioMed, CINAHL and BIOSIS); PsycINFO (1978 to June 2015) (see <a href="./appendices#CD003709-sec-0102">Appendix 6</a>, Search filter for PsycINFO) using the Ovid platform. We searched CINAHL (1984 to June 2015) via EBCSO. </p> <p>We searched for key words describing the condition or describing the intervention and combined the results by using a methodological filter (RCT filter). </p> <p>We used a validated RCT filter for MEDLINE and EMBASE (<a href="./references#CD003709-bbs2-0082" title="Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p>We applied no language restrictions.</p> </section> <section id="CD003709-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We searched ongoing clinical trials and unpublished studies via the Internet (date of latest search, 24 June 2015) on <a href="http://www.controlled-trials.com" target="_blank">www.controlled‐trials.com</a> by using the multiple database search option <i>meta</i>Register of Controlled Trials. This register includes International Standard Randomised Controlled Trial Number (ISRCTN) Register, Action Medical Research, Leukaemia Research Fund, Medical Research Council (UK), NHS Research and Development HTA Programme, ClinicalTrials.gov, Wellcome Trust and UK Clinical Trials Gateway. </p> <p>Further, we searched textbooks and references of papers selected during the electronic search to look for relevant references. Finally, we contacted experts in the field to identify additional trials (see <a href="#CD003709-sec-0094">Acknowledgements</a>). </p> </section> </section> <section id="CD003709-sec-0047"> <h3 class="title" id="CD003709-sec-0047">Data collection and analysis</h3> <section id="CD003709-sec-0048"> <h4 class="title">Selection of studies</h4> <p>We entered all search results into bibliographic software (Endnote X7, The Thomson Corp, USA); we then removed duplicates. At least two review authors (GG, CH, JA, HL, HH) independently screened the studies by title and abstract for exclusion using a template that included inclusion and exclusion criteria. We recorded reasons for exclusion. For the remaining studies, we retrieved full papers. Two review authors independently recorded the inclusion and exclusion criteria in the first section of the data extraction form. We resolved all disagreements through arbitration by a third review author (GG, CH, JA, HL, HH). </p> </section> <section id="CD003709-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>At least two review authors (GG, CH, JA, HL, HH) abstracted data independently onto a pre‐defined data extraction form and entered the data into RevMan 5.3. We compared results and resolved disagreements by discussion amongst at least three review authors (GG, CH, JA, HL, HH). </p> <p>Besides data on intervention and outcome, we recorded study and participant characteristics such as age; gender; severity of illness, as given (e.g. acute physiology and chronic health evaluation (APACHE), multiple organ failure (MOF) score, simplified acute physiology score (SAPS)); underlying diagnosis and particular type of shock, given definition of shock; duration of ICU stay before enrolment into study; duration of mechanical ventilation before enrolment; and study setting. </p> </section> <section id="CD003709-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently abstracted data onto a pre‐defined data extraction form. We abstracted whether adequate methods were used to generate a random sequence, whether allocation to treatment was concealed, whether inclusion and exclusion criteria were explicit, if data had been analysed by intention‐to‐treat, whether participant descriptions were adequate, whether care provided during the study period was identical in both groups, whether the outcome description was adequate, whether involved clinical staff were blinded to the intervention and whether the assessor of the outcome was blinded to the intervention. Noteworthy, for some interventions, is that performance bias is inevitable. We compared results and resolved disagreements by discussion amongst at least three review authors. We then entered data into RevMan. We produced a risk of bias graph and a risk of bias table. </p> </section> <section id="CD003709-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>For binary outcomes, we used risk ratio as the standard effect measure. For continuous outcomes, we used the difference in means as the standard effect measure. </p> </section> <section id="CD003709-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>We did not include cluster‐randomized or cross‐over trials in any of the analyses; in the case of multiple treatment groups, we refrained from combining groups to create a single pair‐wise summary comparison; and we declared studies as multi‐arm comparisons to allow for adequate network meta‐analyses. </p> </section> <section id="CD003709-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>We did not replace missing data by using any algorithm, but we contacted study authors if we considered missing data essential. </p> </section> <section id="CD003709-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical and methodological heterogeneity by performing an informal inspection of study characteristics and clinical judgement. We measured statistical heterogeneity with the I<sup>2</sup> statistic and heterogeneity with Cochrane Q tests. We did not use a specific threshold of I<sup>2</sup> to judge heterogeneity, but as a general rule, we considered an I<sup>2</sup> statistic greater than 50% as showing substantial heterogeneity (<a href="./references#CD003709-bbs2-0082" title="Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD003709-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess reporting bias and small‐study effects graphically by using funnel plots of standard errors versus effect estimates for the primary outcome. We also planned to formally test funnel plot asymmetry by using the arcsine test (<a href="./references#CD003709-bbs2-0101" title="RuckerG , SchwarzerG , CarpenterJ . Arcsine test for publication bias in meta‐analyses with binary outcomes. Statistics in Medicine2008;27(5):746‐63. [PUBMED: 17592831] ">Rücker 2008</a>) if 10 or more studies per comparison were available for the primary outcome. </p> </section> <section id="CD003709-sec-0056"> <h4 class="title">Data synthesis</h4> <p>We combined data quantitatively only if clinical heterogeneity was assumed to be negligible. For standard meta‐analyses, we used <a href="./references#CD003709-bbs2-0098" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 5.3</a>. We used a random‐effects model to combine risk ratios by default because we expected several different comparisons to show at least some heterogeneity. In two trials (<a href="./references#CD003709-bbs2-0006" title="DünserMW , MayrAJ , UlmerH , KnotzerH , SumannG , PajkW , et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation2003;107:2313‐9. [PUBMED: 12732600] ">Dünser 2003</a>; <a href="./references#CD003709-bbs2-0016" title="MartinC , PapazianL , PerrinG , SauxP , GouinF . Norepinephrine or dopamine for the treatment of hyperdynamic septic shock?. Chest1993;103:1826‐31. [PUBMED: 8404107] ">Martin 1993</a>), some participants crossed over to the other treatment; these participants were analysed according to the intention‐to‐treat principle, that is, according to the group to which they were initially assigned. </p> <p>In this update, we decided to add a network meta‐analysis to demonstrate direct and indirect effects simultaneously (<a href="./references#CD003709-bbs2-0104" title="SalantiG , DelGiovaneC , ChaimaniA , CaldwellDM , HigginsJPT . Evaluating the quality of evidence from a network meta‐analysis. PLOS ONE2014;9(7):1‐14. ">Salanti 2014</a>). For the analysis, we used the R package netmeta version 0.7 (<a href="./references#CD003709-bbs2-0096" title="R Core Team. R: A language and environment for statistical computing.. Vienna, Austria: R Foundation for Statistical Computing, 2014. ">R Core Team 2014</a>). Network meta‐analysis is a generalization of pair‐wise meta‐analysis, whereby all pairs of treatments are compared on the basis of the graph‐theoretical method originally developed in electrical network theory. This method is considered equivalent to the frequentist approach to network meta‐analysis (<a href="./references#CD003709-bbs2-0102" title="RückerG . Network meta‐analysis, electrical networks and graph theory. Research Synthesis Methods2012;3:312‐24. ">Rücker 2012</a>). For network meta‐analyses, we estimated both fixed‐effect and random‐effects models. </p> <p>Conceptually, we identified two networks: one comparing different vasopressors or combinations of vasopressors (<a href="#CD003709-fig-0001">Figure 1</a>, left‐hand side), and the other comparing vasopressors in combination with otherwise vasoactive catecholamines (<a href="#CD003709-fig-0001">Figure 1</a>, right‐hand side). In both networks, the reference group was norepinephrine. We produced network plots indicating available direct comparisons, calculated effects relative to a baseline intervention and present network forest plots. </p> <div class="figure" id="CD003709-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Comparisons including vasopressors identified from the systematic review. The 10 interventions with 31 direct comparisons were derived from 28 studies. Line thickness is proportional to the number of included participants. Boxes indicate the two networks that we formally assessed in our network meta‐analysis. npvd/'placebo' denotes non‐protocol vasoactive drugs or placebo." data-id="CD003709-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparisons including vasopressors identified from the systematic review. The 10 interventions with 31 direct comparisons were derived from 28 studies. Line thickness is proportional to the number of included participants. Boxes indicate the two networks that we formally assessed in our network meta‐analysis. <i>npvd/'placebo'</i> denotes <i>non‐protocol vasoactive drugs or placebo</i>. </p> </div> </div> </div> <p>We calculated metrics for consistency/homogeneity. Using Rücker's frequentist approach, we derived this content from decomposition of the Q statistic and from the net heat plot (<a href="./references#CD003709-bbs2-0086" title="KrahnU , BinderH , KönigJ . A graphical tool for locating inconsistency in network meta‐analyses. BMC Medical Research Methodology2013;13(35):1‐18. ">Krahn 2013</a>). We also present analyses on the strength of evidence obtained from matrices derived by the <i>netmeasures</i> function in R (<a href="./references#CD003709-bbs2-0087" title="KönigJ , KrahnU , BinderH . Visualizing the flow of evidence in network meta‐analysis and characterizing mixed treatment comparisons. Statistics in Medicine2012;32:5414‐29. ">König 2012</a>). </p> </section> <section id="CD003709-sec-0057"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned no a priori subgroup analyses. We performed a post hoc subgroup analysis of participants with septic shock. We included studies performed in participants with septic shock and studies for which estimates were available for subgroups with septic shock. For this subgroup, we performed a network meta‐analysis comparing different vasopressors or combinations of vasopressors. We used norepinephrine as the reference group because it is currently considered the vasopressor of first choice (<a href="./references#CD003709-bbs2-0077" title="DellingerRP , LevyMM , RhodesA , AnnaneD , GerlachH , OpalSM , et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Critical Care Medicine2013;41(2):580‐637. ">Dellinger 2013</a>). We did not perform a subgroup analysis for the network including otherwise vasoactive catecholamines because of the limited number of available studies. </p> </section> <section id="CD003709-sec-0058"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform a sensitivity analysis to assess the influence of risk of bias on the main effects of interventions, and thereby on the robustness of our estimates. We classified studies as 'low risk of bias' and 'no low risk of bias'. We classified studies as having low risk of bias if they had adequate allocation concealment, and if the other bias items in the summary were not believed to have a major influence on the robustness of the single study effect. Unclear or inadequate allocation concealment in any case resulted in classification as a 'study with no low risk of bias'. Our primary outcome was mortality, which was generally considered robust against outcome assessor knowledge of treatment allocation. Lack of blinding of outcome assessors therefore had less influence on assessment of risk of bias for this outcome. On the contrary, this risk of bias item had a strong effect on outcomes for which assessment included individual judgement, as for measures of quality of life. In the sensitivity analysis, we grouped studies according to our classification of 'low risk of bias' and 'no low risk of bias' in a forest plot. </p> <p>We also performed a post hoc sensitivity analysis to investigate the influence of different time points on mortality outcome assessment. </p> <section id="CD003709-sec-0059"> <h5 class="title">'Summary of findings'</h5> <p>We used the principles of the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach (<a href="./references#CD003709-bbs2-0080" title='GuyattGH , OxmanAD , KunzR , VistGE , Falck‐YtterY , SchunemannHJ . What is "quality of evidence" and why is it important to clinicians?. BMJ (Clinical research ed.)2008;336(7651):995‐8. [PUBMED: 18456631] '>Guyatt 2008</a>) to grade the quality of the body of evidence assessed in our review and constructed a 'Summary of findings' (SOF) table using GRADE software. The GRADE approach appraises the quality of a body of evidence according to the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. The quality of a body of evidence considers within‐study risk of bias (methodological quality), directness of the evidence, heterogeneity of the data, precision of effect estimates and risk of publication bias. </p> <p>We constructed ‘Summary of findings’ tables that included information about (1) populations (including specification of medium‐risk populations), interventions and comparisons for the standard meta‐analysis of norepinephrine versus dopamine on mortality and for results of the network meta‐analysis on mortality; (2) the source of external information used in the ‘Assumed risk’ column; (3) the GRADE approach to assess the quality of the body of evidence as briefly described above; and (4) any departures from standard methods. We included information on the primary outcome (total mortality) and on arrhythmia within 28 days. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003709-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003709-sec-0060"></div> <section id="CD003709-sec-0061"> <h3 class="title">Description of studies</h3> <section id="CD003709-sec-0062"> <h4 class="title">Results of the search</h4> <section id="CD003709-sec-0063"> <h5 class="title">Search result</h5> <p>The electronic search resulted in 1776 hits after removal of duplicates with bibliographic software and one reference from other sources (<a href="#CD003709-fig-0002">Figure 2</a>). We identified and retrieved 168 potentially relevant articles (this number included 12 articles identified by reading the references of potentially relevant articles and writing to 14 specialists in the field, five of whom replied; see <a href="#CD003709-sec-0094">Acknowledgements</a>). Two trials were not retrievable (<a href="./references#CD003709-bbs2-0046" title="Hai BoQ , YiY , Shao XiaZ , Ying ZiH , Rui QiangZ . Renal effect of dopamine, norepinephrine, epinephrine, or norepinephrine‐dobutamine in septic shock. Critical Care and Shock2002;5:9‐14. ">Hai Bo 2002</a>; <a href="./references#CD003709-bbs2-0053" title="SinghS , MalhotraRP . Comparative study of angiotensin and nor‐adrenaline in hypotensive states (shock). The Journal of the Association of Physicians of India1966;14:639‐45. [PUBMED: 4292372] ">Singh 1966</a>; see <a href="./references#CD003709-sec-0115" title="">Characteristics of studies awaiting classification</a>). Of these 168 articles, 140 did not meet our inclusion criteria after closer inspection for the following reasons. </p> <div class="figure" id="CD003709-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Search flow diagram." data-id="CD003709-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Search flow diagram.</p> </div> </div> </div> <p> <ul id="CD003709-list-0004"> <li> <p>54 trials involved other interventions.</p> </li> <li> <p>49 were not randomized.</p> </li> <li> <p>24 were cross‐over trials.</p> </li> <li> <p>Three were animal studies.</p> </li> <li> <p>Two trials were duplicates (abstract was presented at a scientific meeting and the report was subsequently published (<a href="./references#CD003709-bbs2-0016" title="MartinC , PapazianL , PerrinG , SauxP , GouinF . Norepinephrine or dopamine for the treatment of hyperdynamic septic shock?. Chest1993;103:1826‐31. [PUBMED: 8404107] ">Martin 1993</a>)). </p> </li> <li> <p>Four other publications (<a href="./references#CD003709-bbs2-0024" title="GordonAC , RussellJA , WalleyKR , SingerJ , AyersD , StormsMM , et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Medicine2010;36(1):83‐91. GordonAC , WangN , WalleyKR , AshbyD , RussellJA . The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest2012;142(3):593‐605. RussellJA , FjellC , HsuJL , LeeT , BoydJ , ThairS , et al. Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. American Journal of Respiratory and Critical Care Medicine2013;188:356‐64. RussellJA , WalleyKR , GordonAC , CooperDJ , HébertPC , SingerJ , et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Critical Care Medicine2009;37(3):811‐8. [PUBMED: 19237882] RussellJA , WalleyKR , SingerJ , GordonAC , HébertPC , CooperDJ , et al. Vasopressin versus norepinephrine infusion in patients with septic shock. New England Journal of Medicine2008;358(9):877‐87. [PUBMED: 18305265] ">Russell 2008</a>) did not meet criteria. </p> <ul id="CD003709-list-0005"> <li> <p>Two were systematic reviews.</p> </li> <li> <p>Two eligible RCTs provided none of the pre‐defined outcomes (<a href="./references#CD003709-bbs2-0034" title="MorelliA , DonatiA , ErtmerC , RehbergS , KampmeierT , OrecchioniA . Effect of vasopressinergic receptor agonists on sublingual microcirculation in norepinephrine‐dependent septic shock. Critical Care2011;15:R217. ">Morelli 2011</a>; <a href="./references#CD003709-bbs2-0035" title="MorelliA . Short term effects of terlipressin bolus infusion on sublingual microcirculatory blood flow during septic shock. Intensive Care Medicine2011;37:963‐9. ">Morelli 2011a</a>). </p> </li> </ul> </li> </ul> </p> <p>Of these 140 excluded reports, we identified 13 potentially relevant studies (see <a href="./references#CD003709-sec-0114" title="">Characteristics of excluded studies</a>). Finally, we included 28 studies in our review (<a href="./references#CD003709-sec-0113" title="">Characteristics of included studies</a>). </p> </section> </section> <section id="CD003709-sec-0064"> <h4 class="title">Included studies</h4> <p>In our original review (<a href="./references#CD003709-bbs2-0113" title="MüllnerM , UrbanekB , HavelC , LosertH , GamperG , HerknerH . Vasopressors for shock. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD003709] ">Müllner 2004</a>), we included eight studies. In the updated review (<a href="./references#CD003709-bbs2-0111" title="HavelC , ArrichJ , LosertH , GamperG , MüllnerM , HerknerH . Vasopressors for hypotensive shock. Cochrane Database of Systematic Reviews2011, Issue 5. [DOI: 10.1002/14651858.CD003709.pub3] ">Havel 2011</a>), we included 15 new studies. This current update adds five new studies. In total, we have included 28 studies investigating several comparisons among 3497 participants (<a href="#CD003709-fig-0001">Figure 1</a>). Six different vasopressors, alone or in combination, were studied in 12 different comparisons. Details are presented in the table <a href="./references#CD003709-sec-0113" title="">Characteristics of included studies</a>. Among these studies, eight were multi‐centre studies (<a href="./references#CD003709-bbs2-0002" title="AnnaneD , VignonP , RenaultA , BollaertPE , CharpentierC , MartinC , et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet2007;370(9588):676‐84. [PUBMED: 17720019] ">Annane 2007</a>; <a href="./references#CD003709-bbs2-0004" title="ChoongK , BohnD , FraserDD , GabouryI , HutchisonJS , JoffeAR , et al. Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2009;180(7):632‐9. [PUBMED: 19608718] ">Choong 2009</a>; <a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>; <a href="./references#CD003709-bbs2-0007" title="HanX‐D , SunH , HuangX‐Y , ZhangS‐Y , WangY‐D , RenK , et al. [A clinical study of pituitrin versus norepinephrine in the treatment of patients with septic shock]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue/Chinese Critical Care Medicine/Zhongguo Weizhongbing Jijiuyixue2012;24(1):33‐7. ">Han 2012</a>; <a href="./references#CD003709-bbs2-0010" title="LauzierF , LevyB , LamarreP , LesurO . Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Medicine2006;32(11):1782‐9. [PUBMED: 17019548] ">Lauzier 2006</a>; <a href="./references#CD003709-bbs2-0014" title="MalayMB , AshtonRCJr , LandryDW , TownsendRN . Low‐dose vasopressin in the treatment of vasodilatory septic shock. Journal of Trauma1999;47:699‐703. [PUBMED: 10528604] ">Malay 1999</a>; <a href="./references#CD003709-bbs2-0021" title="MyburghJA , HigginsA , JovanovskaA , LipmanJ , RamakrishnanN , SantamariaJ , et al. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Medicine2008;34(12):2226‐34. [PUBMED: 18654759] ">Myburgh 2008</a>; <a href="./references#CD003709-bbs2-0024" title="GordonAC , RussellJA , WalleyKR , SingerJ , AyersD , StormsMM , et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Medicine2010;36(1):83‐91. GordonAC , WangN , WalleyKR , AshbyD , RussellJA . The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest2012;142(3):593‐605. RussellJA , FjellC , HsuJL , LeeT , BoydJ , ThairS , et al. Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. American Journal of Respiratory and Critical Care Medicine2013;188:356‐64. RussellJA , WalleyKR , GordonAC , CooperDJ , HébertPC , SingerJ , et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Critical Care Medicine2009;37(3):811‐8. [PUBMED: 19237882] RussellJA , WalleyKR , SingerJ , GordonAC , HébertPC , CooperDJ , et al. Vasopressin versus norepinephrine infusion in patients with septic shock. New England Journal of Medicine2008;358(9):877‐87. [PUBMED: 18305265] ">Russell 2008</a>) and all but five (<a href="./references#CD003709-bbs2-0002" title="AnnaneD , VignonP , RenaultA , BollaertPE , CharpentierC , MartinC , et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet2007;370(9588):676‐84. [PUBMED: 17720019] ">Annane 2007</a>; <a href="./references#CD003709-bbs2-0007" title="HanX‐D , SunH , HuangX‐Y , ZhangS‐Y , WangY‐D , RenK , et al. [A clinical study of pituitrin versus norepinephrine in the treatment of patients with septic shock]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue/Chinese Critical Care Medicine/Zhongguo Weizhongbing Jijiuyixue2012;24(1):33‐7. ">Han 2012</a>; <a href="./references#CD003709-bbs2-0014" title="MalayMB , AshtonRCJr , LandryDW , TownsendRN . Low‐dose vasopressin in the treatment of vasodilatory septic shock. Journal of Trauma1999;47:699‐703. [PUBMED: 10528604] ">Malay 1999</a>; <a href="./references#CD003709-bbs2-0021" title="MyburghJA , HigginsA , JovanovskaA , LipmanJ , RamakrishnanN , SantamariaJ , et al. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Medicine2008;34(12):2226‐34. [PUBMED: 18654759] ">Myburgh 2008</a>; <a href="./references#CD003709-bbs2-0027" title="SvobodaP , ScheerP , KantorovaI , DoubekJ , DudraJ , RadvanM , et al. Terlipressin in the treatment of late phase catecholamine‐resistant septic shock. Hepato‐Gastroenterology2012;59(116):1043‐7. ">Svoboda 2012</a>) were performed at university hospitals only. </p> <p>Eighteen studies were performed in participants with septic shock (<a href="./references#CD003709-bbs2-0001" title="AlbaneseJ , LeoneM , DelmasA , MartinC . Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Critical Care Medicine2005;33(9):1897‐902. [PUBMED: 16148457] ">Albanese 2005</a>; <a href="./references#CD003709-bbs2-0002" title="AnnaneD , VignonP , RenaultA , BollaertPE , CharpentierC , MartinC , et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet2007;370(9588):676‐84. [PUBMED: 17720019] ">Annane 2007</a>; <a href="./references#CD003709-bbs2-0007" title="HanX‐D , SunH , HuangX‐Y , ZhangS‐Y , WangY‐D , RenK , et al. [A clinical study of pituitrin versus norepinephrine in the treatment of patients with septic shock]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue/Chinese Critical Care Medicine/Zhongguo Weizhongbing Jijiuyixue2012;24(1):33‐7. ">Han 2012</a>; <a href="./references#CD003709-bbs2-0009" title="JainG , SinghDK . Comparison of phenylephrine and norepinephrine in the management of dopamine‐resistant septic shock. Indian Journal of Critical Care Medicine2010;14(1):29‐34. [MEDLINE: 20606906] ">Jain 2010</a>; <a href="./references#CD003709-bbs2-0010" title="LauzierF , LevyB , LamarreP , LesurO . Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Medicine2006;32(11):1782‐9. [PUBMED: 17019548] ">Lauzier 2006</a>; <a href="./references#CD003709-bbs2-0014" title="MalayMB , AshtonRCJr , LandryDW , TownsendRN . Low‐dose vasopressin in the treatment of vasodilatory septic shock. Journal of Trauma1999;47:699‐703. [PUBMED: 10528604] ">Malay 1999</a>; <a href="./references#CD003709-bbs2-0015" title="MarikPE , MohedinM . The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA1994;272:1354‐7. [PUBMED: 7933396] ">Marik 1994</a>; <a href="./references#CD003709-bbs2-0016" title="MartinC , PapazianL , PerrinG , SauxP , GouinF . Norepinephrine or dopamine for the treatment of hyperdynamic septic shock?. Chest1993;103:1826‐31. [PUBMED: 8404107] ">Martin 1993</a>; <a href="./references#CD003709-bbs2-0018" title="MorelliA , ErtmerC , LangeM , DuenserM , RehbergS , VanAkenH , et al. Effects of short‐term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. British Journal of Anaesthesia2008;100(4):494‐503. [PUBMED: 18308741] ">Morelli 2008a</a>; <a href="./references#CD003709-bbs2-0019" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , LaderchiA , et al. Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. Critical Care2008;12(6)(R143):1‐11. [PUBMED: 19017409 ] ">Morelli 2008b</a>; <a href="./references#CD003709-bbs2-0020" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , CecchiniV , et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Critical Care2009;13(4):R130. [PUBMED: 19664253] ">Morelli 2009</a>; <a href="./references#CD003709-bbs2-0022" title="PatelGP , GraheJS , SperryM , SinglaS , ElpernE , LateefO , et al. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock2010;33(4):375‐80. [PUBMED: 19851126] ">Patel 2010</a>; <a href="./references#CD003709-bbs2-0023" title="RuokonenE , TakalaJ , KariA , SaxenH , MertsolaJ , HansenEJ . Regional blood flow and oxygen transport in septic shock. Critical Care Medicine1993;21:1296‐303. [PUBMED: 8370292] ">Ruokonen 1993</a>; <a href="./references#CD003709-bbs2-0024" title="GordonAC , RussellJA , WalleyKR , SingerJ , AyersD , StormsMM , et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Medicine2010;36(1):83‐91. GordonAC , WangN , WalleyKR , AshbyD , RussellJA . The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest2012;142(3):593‐605. RussellJA , FjellC , HsuJL , LeeT , BoydJ , ThairS , et al. Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. American Journal of Respiratory and Critical Care Medicine2013;188:356‐64. RussellJA , WalleyKR , GordonAC , CooperDJ , HébertPC , SingerJ , et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Critical Care Medicine2009;37(3):811‐8. [PUBMED: 19237882] RussellJA , WalleyKR , SingerJ , GordonAC , HébertPC , CooperDJ , et al. Vasopressin versus norepinephrine infusion in patients with septic shock. New England Journal of Medicine2008;358(9):877‐87. [PUBMED: 18305265] ">Russell 2008</a>; <a href="./references#CD003709-bbs2-0025" title="SeguinP , BellissantE , Le‐TulzoY , LaviolleB , LessardY , ThomasR , et al. Effects of epinephrine compared with the combination of dobutamine and norepinephrine on gastric perfusion in septic shock. Clinical Pharmacology and Therapeutics2002;71:381‐8. [MEDLINE: 12011824] ">Seguin 2002</a>; <a href="./references#CD003709-bbs2-0026" title="SeguinP , LaviolleB , GuinetP , MorelI , MalledantY , BellissantE . Dopexamine and norepinephrine versus epinephrine on gastric perfusion in patients with septic shock: a randomized study [NCT00134212]. Critical Care2006;10(1)(R32):1‐8. ">Seguin 2006</a>; <a href="./references#CD003709-bbs2-0028" title="YildizdasD , YapiciogluH , CelikU , SertdemirY , AlhanE . Terlipressin as a rescue therapy for catecholamine‐resistant septic shock in children. Intensive Care Medicine2008;34(3):511‐7. [PUBMED: 18092150] ">Yildizdas 2008</a>; <a href="./references#CD003709-bbs2-0027" title="SvobodaP , ScheerP , KantorovaI , DoubekJ , DudraJ , RadvanM , et al. Terlipressin in the treatment of late phase catecholamine‐resistant septic shock. Hepato‐Gastroenterology2012;59(116):1043‐7. ">Svoboda 2012</a>). Three studies included participants with peri‐operative shock (<a href="./references#CD003709-bbs2-0003" title="BoccaraG , OuattaraA , GodetG , DufresneE , BertrandM , RiouB , et al. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin‐angiotensin system inhibitors. Anesthesiology2003;98:1338‐44. [PUBMED: 12766641] ">Boccara 2003</a>; <a href="./references#CD003709-bbs2-0006" title="DünserMW , MayrAJ , UlmerH , KnotzerH , SumannG , PajkW , et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation2003;107:2313‐9. [PUBMED: 12732600] ">Dünser 2003</a>; <a href="./references#CD003709-bbs2-0013" title="LucknerG , DunserMW , StadlbauerKH , MayrVD , JochbergerS , WenzelV , et al. Cutaneous vascular reactivity and flow motion response to vasopressin in advanced vasodilatory shock and severe postoperative multiple organ dysfunction syndrome. Critical Care2006;10(2):R40. [PUBMED: 16542484] ">Luckner 2006</a>). Two studies were performed in paediatric participants (<a href="./references#CD003709-bbs2-0004" title="ChoongK , BohnD , FraserDD , GabouryI , HutchisonJS , JoffeAR , et al. Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2009;180(7):632‐9. [PUBMED: 19608718] ">Choong 2009</a>; <a href="./references#CD003709-bbs2-0028" title="YildizdasD , YapiciogluH , CelikU , SertdemirY , AlhanE . Terlipressin as a rescue therapy for catecholamine‐resistant septic shock in children. Intensive Care Medicine2008;34(3):511‐7. [PUBMED: 18092150] ">Yildizdas 2008</a>). </p> <p>Seventeen studies provided norepinephrine as an intervention (<a href="./references#CD003709-bbs2-0001" title="AlbaneseJ , LeoneM , DelmasA , MartinC . Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Critical Care Medicine2005;33(9):1897‐902. [PUBMED: 16148457] ">Albanese 2005</a>; <a href="./references#CD003709-bbs2-0003" title="BoccaraG , OuattaraA , GodetG , DufresneE , BertrandM , RiouB , et al. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin‐angiotensin system inhibitors. Anesthesiology2003;98:1338‐44. [PUBMED: 12766641] ">Boccara 2003</a>; <a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>; <a href="./references#CD003709-bbs2-0006" title="DünserMW , MayrAJ , UlmerH , KnotzerH , SumannG , PajkW , et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation2003;107:2313‐9. [PUBMED: 12732600] ">Dünser 2003</a>; <a href="./references#CD003709-bbs2-0007" title="HanX‐D , SunH , HuangX‐Y , ZhangS‐Y , WangY‐D , RenK , et al. [A clinical study of pituitrin versus norepinephrine in the treatment of patients with septic shock]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue/Chinese Critical Care Medicine/Zhongguo Weizhongbing Jijiuyixue2012;24(1):33‐7. ">Han 2012</a>; <a href="./references#CD003709-bbs2-0009" title="JainG , SinghDK . Comparison of phenylephrine and norepinephrine in the management of dopamine‐resistant septic shock. Indian Journal of Critical Care Medicine2010;14(1):29‐34. [MEDLINE: 20606906] ">Jain 2010</a>; <a href="./references#CD003709-bbs2-0010" title="LauzierF , LevyB , LamarreP , LesurO . Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Medicine2006;32(11):1782‐9. [PUBMED: 17019548] ">Lauzier 2006</a>; <a href="./references#CD003709-bbs2-0013" title="LucknerG , DunserMW , StadlbauerKH , MayrVD , JochbergerS , WenzelV , et al. Cutaneous vascular reactivity and flow motion response to vasopressin in advanced vasodilatory shock and severe postoperative multiple organ dysfunction syndrome. Critical Care2006;10(2):R40. [PUBMED: 16542484] ">Luckner 2006</a>; <a href="./references#CD003709-bbs2-0015" title="MarikPE , MohedinM . The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA1994;272:1354‐7. [PUBMED: 7933396] ">Marik 1994</a>; <a href="./references#CD003709-bbs2-0016" title="MartinC , PapazianL , PerrinG , SauxP , GouinF . Norepinephrine or dopamine for the treatment of hyperdynamic septic shock?. Chest1993;103:1826‐31. [PUBMED: 8404107] ">Martin 1993</a>; <a href="./references#CD003709-bbs2-0017" title="MathurS , DhunnaR , ChakrabortyA . Comparison of norepinephrine and dopamine in the management of septic shock using impedance cardiography. Indian Journal of Critical Care Medicine2007;11(4):186‐91. [EMBASE: 2008016347] ">Mathur 2007</a>; <a href="./references#CD003709-bbs2-0018" title="MorelliA , ErtmerC , LangeM , DuenserM , RehbergS , VanAkenH , et al. Effects of short‐term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. British Journal of Anaesthesia2008;100(4):494‐503. [PUBMED: 18308741] ">Morelli 2008a</a>; <a href="./references#CD003709-bbs2-0019" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , LaderchiA , et al. Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. Critical Care2008;12(6)(R143):1‐11. [PUBMED: 19017409 ] ">Morelli 2008b</a>; <a href="./references#CD003709-bbs2-0021" title="MyburghJA , HigginsA , JovanovskaA , LipmanJ , RamakrishnanN , SantamariaJ , et al. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Medicine2008;34(12):2226‐34. [PUBMED: 18654759] ">Myburgh 2008</a>; <a href="./references#CD003709-bbs2-0022" title="PatelGP , GraheJS , SperryM , SinglaS , ElpernE , LateefO , et al. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock2010;33(4):375‐80. [PUBMED: 19851126] ">Patel 2010</a>; <a href="./references#CD003709-bbs2-0023" title="RuokonenE , TakalaJ , KariA , SaxenH , MertsolaJ , HansenEJ . Regional blood flow and oxygen transport in septic shock. Critical Care Medicine1993;21:1296‐303. [PUBMED: 8370292] ">Ruokonen 1993</a>; <a href="./references#CD003709-bbs2-0024" title="GordonAC , RussellJA , WalleyKR , SingerJ , AyersD , StormsMM , et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Medicine2010;36(1):83‐91. GordonAC , WangN , WalleyKR , AshbyD , RussellJA . The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest2012;142(3):593‐605. RussellJA , FjellC , HsuJL , LeeT , BoydJ , ThairS , et al. Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. American Journal of Respiratory and Critical Care Medicine2013;188:356‐64. RussellJA , WalleyKR , GordonAC , CooperDJ , HébertPC , SingerJ , et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Critical Care Medicine2009;37(3):811‐8. [PUBMED: 19237882] RussellJA , WalleyKR , SingerJ , GordonAC , HébertPC , CooperDJ , et al. Vasopressin versus norepinephrine infusion in patients with septic shock. New England Journal of Medicine2008;358(9):877‐87. [PUBMED: 18305265] ">Russell 2008</a>); another four studies examined the combination of norepinephrine + dobutamine (<a href="./references#CD003709-bbs2-0002" title="AnnaneD , VignonP , RenaultA , BollaertPE , CharpentierC , MartinC , et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet2007;370(9588):676‐84. [PUBMED: 17720019] ">Annane 2007</a>; <a href="./references#CD003709-bbs2-0011" title="LevyB , BollaertPE , CharpentierC , NaceL , AudibertG , BauerP , et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Medicine1997;23:282‐7. [PUBMED: 9083230] ">Levy 1997</a>; <a href="./references#CD003709-bbs2-0012" title="LevyB , PerezP , PernyJ , ThivilierC , GerardA . Comparison of norepinephrine‐dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine2011;39(3):450‐5. [PUBMED: 21037469] ">Levy 2011</a>; <a href="./references#CD003709-bbs2-0025" title="SeguinP , BellissantE , Le‐TulzoY , LaviolleB , LessardY , ThomasR , et al. Effects of epinephrine compared with the combination of dobutamine and norepinephrine on gastric perfusion in septic shock. Clinical Pharmacology and Therapeutics2002;71:381‐8. [MEDLINE: 12011824] ">Seguin 2002</a>); and one study used the combination of norepinephrine + dopexamine (<a href="./references#CD003709-bbs2-0026" title="SeguinP , LaviolleB , GuinetP , MorelI , MalledantY , BellissantE . Dopexamine and norepinephrine versus epinephrine on gastric perfusion in patients with septic shock: a randomized study [NCT00134212]. Critical Care2006;10(1)(R32):1‐8. ">Seguin 2006</a>). </p> <p>Nine studies used dopamine (<a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>; <a href="./references#CD003709-bbs2-0007" title="HanX‐D , SunH , HuangX‐Y , ZhangS‐Y , WangY‐D , RenK , et al. [A clinical study of pituitrin versus norepinephrine in the treatment of patients with septic shock]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue/Chinese Critical Care Medicine/Zhongguo Weizhongbing Jijiuyixue2012;24(1):33‐7. ">Han 2012</a>; <a href="./references#CD003709-bbs2-0008" title="HuaF , WangX , ZhuL . Terlipressin decreases vascular endothelial growth factor expression and improves oxygenation in patients with acute respiratory distress syndrome and shock. Journal of Emergency Medicine2013;44(2):434‐9. ">Hua 2013</a>; <a href="./references#CD003709-bbs2-0009" title="JainG , SinghDK . Comparison of phenylephrine and norepinephrine in the management of dopamine‐resistant septic shock. Indian Journal of Critical Care Medicine2010;14(1):29‐34. [MEDLINE: 20606906] ">Jain 2010</a>; <a href="./references#CD003709-bbs2-0015" title="MarikPE , MohedinM . The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA1994;272:1354‐7. [PUBMED: 7933396] ">Marik 1994</a>; <a href="./references#CD003709-bbs2-0016" title="MartinC , PapazianL , PerrinG , SauxP , GouinF . Norepinephrine or dopamine for the treatment of hyperdynamic septic shock?. Chest1993;103:1826‐31. [PUBMED: 8404107] ">Martin 1993</a>; <a href="./references#CD003709-bbs2-0017" title="MathurS , DhunnaR , ChakrabortyA . Comparison of norepinephrine and dopamine in the management of septic shock using impedance cardiography. Indian Journal of Critical Care Medicine2007;11(4):186‐91. [EMBASE: 2008016347] ">Mathur 2007</a>; <a href="./references#CD003709-bbs2-0022" title="PatelGP , GraheJS , SperryM , SinglaS , ElpernE , LateefO , et al. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock2010;33(4):375‐80. [PUBMED: 19851126] ">Patel 2010</a>; <a href="./references#CD003709-bbs2-0023" title="RuokonenE , TakalaJ , KariA , SaxenH , MertsolaJ , HansenEJ . Regional blood flow and oxygen transport in septic shock. Critical Care Medicine1993;21:1296‐303. [PUBMED: 8370292] ">Ruokonen 1993</a>), and six studies used epinephrine (<a href="./references#CD003709-bbs2-0002" title="AnnaneD , VignonP , RenaultA , BollaertPE , CharpentierC , MartinC , et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet2007;370(9588):676‐84. [PUBMED: 17720019] ">Annane 2007</a>; <a href="./references#CD003709-bbs2-0011" title="LevyB , BollaertPE , CharpentierC , NaceL , AudibertG , BauerP , et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Medicine1997;23:282‐7. [PUBMED: 9083230] ">Levy 1997</a>; <a href="./references#CD003709-bbs2-0012" title="LevyB , PerezP , PernyJ , ThivilierC , GerardA . Comparison of norepinephrine‐dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine2011;39(3):450‐5. [PUBMED: 21037469] ">Levy 2011</a>; <a href="./references#CD003709-bbs2-0021" title="MyburghJA , HigginsA , JovanovskaA , LipmanJ , RamakrishnanN , SantamariaJ , et al. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Medicine2008;34(12):2226‐34. [PUBMED: 18654759] ">Myburgh 2008</a>; <a href="./references#CD003709-bbs2-0025" title="SeguinP , BellissantE , Le‐TulzoY , LaviolleB , LessardY , ThomasR , et al. Effects of epinephrine compared with the combination of dobutamine and norepinephrine on gastric perfusion in septic shock. Clinical Pharmacology and Therapeutics2002;71:381‐8. [MEDLINE: 12011824] ">Seguin 2002</a>; <a href="./references#CD003709-bbs2-0026" title="SeguinP , LaviolleB , GuinetP , MorelI , MalledantY , BellissantE . Dopexamine and norepinephrine versus epinephrine on gastric perfusion in patients with septic shock: a randomized study [NCT00134212]. Critical Care2006;10(1)(R32):1‐8. ">Seguin 2006</a>). Eight studies used vasopressin (<a href="./references#CD003709-bbs2-0004" title="ChoongK , BohnD , FraserDD , GabouryI , HutchisonJS , JoffeAR , et al. Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2009;180(7):632‐9. [PUBMED: 19608718] ">Choong 2009</a>; <a href="./references#CD003709-bbs2-0006" title="DünserMW , MayrAJ , UlmerH , KnotzerH , SumannG , PajkW , et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation2003;107:2313‐9. [PUBMED: 12732600] ">Dünser 2003</a>; <a href="./references#CD003709-bbs2-0007" title="HanX‐D , SunH , HuangX‐Y , ZhangS‐Y , WangY‐D , RenK , et al. [A clinical study of pituitrin versus norepinephrine in the treatment of patients with septic shock]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue/Chinese Critical Care Medicine/Zhongguo Weizhongbing Jijiuyixue2012;24(1):33‐7. ">Han 2012</a>; <a href="./references#CD003709-bbs2-0010" title="LauzierF , LevyB , LamarreP , LesurO . Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Medicine2006;32(11):1782‐9. [PUBMED: 17019548] ">Lauzier 2006</a>; <a href="./references#CD003709-bbs2-0013" title="LucknerG , DunserMW , StadlbauerKH , MayrVD , JochbergerS , WenzelV , et al. Cutaneous vascular reactivity and flow motion response to vasopressin in advanced vasodilatory shock and severe postoperative multiple organ dysfunction syndrome. Critical Care2006;10(2):R40. [PUBMED: 16542484] ">Luckner 2006</a>; <a href="./references#CD003709-bbs2-0014" title="MalayMB , AshtonRCJr , LandryDW , TownsendRN . Low‐dose vasopressin in the treatment of vasodilatory septic shock. Journal of Trauma1999;47:699‐703. [PUBMED: 10528604] ">Malay 1999</a>; <a href="./references#CD003709-bbs2-0020" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , CecchiniV , et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Critical Care2009;13(4):R130. [PUBMED: 19664253] ">Morelli 2009</a>; <a href="./references#CD003709-bbs2-0024" title="GordonAC , RussellJA , WalleyKR , SingerJ , AyersD , StormsMM , et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Medicine2010;36(1):83‐91. GordonAC , WangN , WalleyKR , AshbyD , RussellJA . The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest2012;142(3):593‐605. RussellJA , FjellC , HsuJL , LeeT , BoydJ , ThairS , et al. Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. American Journal of Respiratory and Critical Care Medicine2013;188:356‐64. RussellJA , WalleyKR , GordonAC , CooperDJ , HébertPC , SingerJ , et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Critical Care Medicine2009;37(3):811‐8. [PUBMED: 19237882] RussellJA , WalleyKR , SingerJ , GordonAC , HébertPC , CooperDJ , et al. Vasopressin versus norepinephrine infusion in patients with septic shock. New England Journal of Medicine2008;358(9):877‐87. [PUBMED: 18305265] ">Russell 2008</a>), and another seven studies used terlipressin (<a href="./references#CD003709-bbs2-0001" title="AlbaneseJ , LeoneM , DelmasA , MartinC . Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Critical Care Medicine2005;33(9):1897‐902. [PUBMED: 16148457] ">Albanese 2005</a>; <a href="./references#CD003709-bbs2-0003" title="BoccaraG , OuattaraA , GodetG , DufresneE , BertrandM , RiouB , et al. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin‐angiotensin system inhibitors. Anesthesiology2003;98:1338‐44. [PUBMED: 12766641] ">Boccara 2003</a>; <a href="./references#CD003709-bbs2-0008" title="HuaF , WangX , ZhuL . Terlipressin decreases vascular endothelial growth factor expression and improves oxygenation in patients with acute respiratory distress syndrome and shock. Journal of Emergency Medicine2013;44(2):434‐9. ">Hua 2013</a>; <a href="./references#CD003709-bbs2-0018" title="MorelliA , ErtmerC , LangeM , DuenserM , RehbergS , VanAkenH , et al. Effects of short‐term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. British Journal of Anaesthesia2008;100(4):494‐503. [PUBMED: 18308741] ">Morelli 2008a</a>; <a href="./references#CD003709-bbs2-0020" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , CecchiniV , et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Critical Care2009;13(4):R130. [PUBMED: 19664253] ">Morelli 2009</a>; <a href="./references#CD003709-bbs2-0027" title="SvobodaP , ScheerP , KantorovaI , DoubekJ , DudraJ , RadvanM , et al. Terlipressin in the treatment of late phase catecholamine‐resistant septic shock. Hepato‐Gastroenterology2012;59(116):1043‐7. ">Svoboda 2012</a>; <a href="./references#CD003709-bbs2-0028" title="YildizdasD , YapiciogluH , CelikU , SertdemirY , AlhanE . Terlipressin as a rescue therapy for catecholamine‐resistant septic shock in children. Intensive Care Medicine2008;34(3):511‐7. [PUBMED: 18092150] ">Yildizdas 2008</a>). Two studies used phenylephrine (<a href="./references#CD003709-bbs2-0009" title="JainG , SinghDK . Comparison of phenylephrine and norepinephrine in the management of dopamine‐resistant septic shock. Indian Journal of Critical Care Medicine2010;14(1):29‐34. [MEDLINE: 20606906] ">Jain 2010</a>; <a href="./references#CD003709-bbs2-0019" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , LaderchiA , et al. Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. Critical Care2008;12(6)(R143):1‐11. [PUBMED: 19017409 ] ">Morelli 2008b</a>), and five studies compared vasopressors versus placebo or non‐protocolized vasopressors as add‐on therapy (<a href="./references#CD003709-bbs2-0004" title="ChoongK , BohnD , FraserDD , GabouryI , HutchisonJS , JoffeAR , et al. Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2009;180(7):632‐9. [PUBMED: 19608718] ">Choong 2009</a>; <a href="./references#CD003709-bbs2-0014" title="MalayMB , AshtonRCJr , LandryDW , TownsendRN . Low‐dose vasopressin in the treatment of vasodilatory septic shock. Journal of Trauma1999;47:699‐703. [PUBMED: 10528604] ">Malay 1999</a>; <a href="./references#CD003709-bbs2-0018" title="MorelliA , ErtmerC , LangeM , DuenserM , RehbergS , VanAkenH , et al. Effects of short‐term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. British Journal of Anaesthesia2008;100(4):494‐503. [PUBMED: 18308741] ">Morelli 2008a</a>; <a href="./references#CD003709-bbs2-0027" title="SvobodaP , ScheerP , KantorovaI , DoubekJ , DudraJ , RadvanM , et al. Terlipressin in the treatment of late phase catecholamine‐resistant septic shock. Hepato‐Gastroenterology2012;59(116):1043‐7. ">Svoboda 2012</a>; <a href="./references#CD003709-bbs2-0028" title="YildizdasD , YapiciogluH , CelikU , SertdemirY , AlhanE . Terlipressin as a rescue therapy for catecholamine‐resistant septic shock in children. Intensive Care Medicine2008;34(3):511‐7. [PUBMED: 18092150] ">Yildizdas 2008</a>). </p> </section> <section id="CD003709-sec-0065"> <h4 class="title">Excluded studies</h4> <p>In total, we excluded 140 studies after full‐text assessment, among which 13 studies are listed by reference. We have presented some details of the 13 excluded studies in the table <a href="./references#CD003709-sec-0114" title="">Characteristics of excluded studies</a>. We excluded 10 studies because they reported not on any of our pre‐defined endpoints but on haemodynamic variables and other surrogate endpoints instead (<a href="./references#CD003709-bbs2-0029" title="ArgenzianoM , ChoudhriAF , OzMC , RoseEA , SmithCR , LandryDW . A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation1997;96 Suppl II:286‐90. [PUBMED: 9386112] ">Argenziano 1997</a>; <a href="./references#CD003709-bbs2-0030" title="HentschelR , HenselD , BruneT , RabeH , JorchG . Impact on blood pressure and intestinal perfusion of dobutamine or dopamine in hypotensive preterm infants. Biology of the Neonate1995;68:318‐24. [PUBMED: 8835086] ">Hentschel 1995</a>; <a href="./references#CD003709-bbs2-0031" title="KinstnerC , GermannP , UllrichR , LandryD , SladenR . Infusion of arginine‐vasopressin (AVP) enhances blood pressure and renal function while preserving cerebral and splanchnic perfusion in patients in septic shock. Anesthesiology Abstracts of Scientific Papers, Annual Meeting. 2002:Abstract No A‐439. ">Kinstner 2002</a>; <a href="./references#CD003709-bbs2-0032" title="LevyB , NaceL , BollaertPE , DoussetB , MallieJP , LarcanA . Comparison of systemic and regional effects of dobutamine and dopexamine in norepinephrine‐treated septic shock. Intensive Care Medicine1999;25:942‐8. [PUBMED: 10501749] ">Levy 1999</a>; <a href="./references#CD003709-bbs2-0033" title="MajerusTC , ChodoffP , BorelCO . Dopamine and dobutamine in septic shock. A comparison. Archives Internationales de Physiologie et de Biochimie1984;92:S65‐7. [PUBMED: 6085242] ">Majerus 1984</a>; <a href="./references#CD003709-bbs2-0034" title="MorelliA , DonatiA , ErtmerC , RehbergS , KampmeierT , OrecchioniA . Effect of vasopressinergic receptor agonists on sublingual microcirculation in norepinephrine‐dependent septic shock. Critical Care2011;15:R217. ">Morelli 2011</a>; <a href="./references#CD003709-bbs2-0035" title="MorelliA . Short term effects of terlipressin bolus infusion on sublingual microcirculatory blood flow during septic shock. Intensive Care Medicine2011;37:963‐9. ">Morelli 2011a</a>; <a href="./references#CD003709-bbs2-0036" title="PatelBM , ChittockDR , RussellJA , WalleyKR . Beneficial effects of short‐term vasopressin infusion during severe septic shock. Anesthesiology2002;96:576‐82. [PUBMED: 11873030] ">Patel 2002</a>; <a href="./references#CD003709-bbs2-0040" title="TotaroRJ , RaperRF . Epinephrine‐induced lactic acidosis following cardiopulmonary bypass. Critical Care Medicine1997;25:1693‐9. [PUBMED: 9377884] ">Totaro 1997</a>; <a href="./references#CD003709-bbs2-0041" title="ZhouSX , QiuHB , HuangYZ , YangY , ZhengRQ . Effects of norepinephrine, epinephrine, and norepinephrine‐dobutamine on systemic and gastric mucosal oxygenation in septic shock. Acta Pharmacologica Sinica2002;23:654‐8. [PUBMED: 12100762 ] ">Zhou 2002</a>). We excluded one trial in which investigators looked at pre‐term infants with hypotension (<a href="./references#CD003709-bbs2-0037" title="RozeJC , TohierC , MaingueneauC , LefevreM , MouzardA . Response to dobutamine and dopamine in the hypotensive very preterm infant. Archives of Disease in Childhood1993;69:59‐63. [PUBMED: 8346957] ">Rozé 1993</a>), as this topic is covered in another Cochrane review (<a href="./references#CD003709-bbs2-0105" title="SubhedarNV , ShawNJ . Dopamine versus dobutamine for hypotensive preterm infants. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD001242; CD001242] ">Subhedar 2003</a>). One study was a non‐randomized multi‐centre prospective cohort study and therefore was excluded (<a href="./references#CD003709-bbs2-0039" title="SperryJL , MineiJP , FrankelHL , WestMA , HarbrechtB G , MooreEE , et al. Early use of vasopressors after injury: caution before constriction. Journal of Trauma2008;64(1):9‐14. [PUBMED: 18188092] ">Sperry 2008</a>). Another study compared low‐dose dopamine versus dopexamine and versus placebo added to norepinephrine with the intention of improving renal and splanchnic blood flow. Low‐dose dopamine at 3 µg/kg/min is not considered to have relevant vasopressor properties; therefore we also excluded this study (<a href="./references#CD003709-bbs2-0038" title="SchmoelzM , SchellingG , DunkerM , IrlbeckM . Comparison of systemic and renal effects of dopexamine and dopamine in norepinephrine‐treated septic shock. Journal of Cardiothoracic and Vascular Anesthesia2006;20(2):173‐8. [PUBMED: 16616656] ">Schmoelz 2006</a>). </p> <section id="CD003709-sec-0066"> <h5 class="title">Studies waiting to be assessed</h5> <p>We have not yet been able to retrieve two particular studies. One, which was published in 1966 (<a href="./references#CD003709-bbs2-0053" title="SinghS , MalhotraRP . Comparative study of angiotensin and nor‐adrenaline in hypotensive states (shock). The Journal of the Association of Physicians of India1966;14:639‐45. [PUBMED: 4292372] ">Singh 1966</a>), is a 'comparative study of angiotensin and norepinephrine in hypotensive states', according to the title. As no abstract is available, we do not know how many participants were enrolled. The second study, published in the journal <i>Critical Care Shock</i> in 2002 (<a href="./references#CD003709-bbs2-0046" title="Hai BoQ , YiY , Shao XiaZ , Ying ZiH , Rui QiangZ . Renal effect of dopamine, norepinephrine, epinephrine, or norepinephrine‐dobutamine in septic shock. Critical Care and Shock2002;5:9‐14. ">Hai Bo 2002</a>), also could not be retrieved. This paper is on the 'renal effect of dopamine, norepinephrine, epinephrine, or norepinephrine‐dobutamine in septic shock'. We do not know whether this study contained original data from human experiments, whether it was randomized and, if so, whether researchers reported relevant outcomes. </p> </section> <section id="CD003709-sec-0067"> <h5 class="title">Ongoing studies</h5> <p>Our search resulted in 52 potentially relevant ongoing studies. We considered five ongoing studies (<a href="./references#CD003709-bbs2-0058" title="ChoudharyA . Efficacy and safety of monotherapy with noradrenaline and terlipressin in patients of cirrhosis with septic shock admitted to intensive care unit. NCT01836224. ">Choudhary 2013</a>; <a href="./references#CD003709-bbs2-0045" title="CohnSM , McCarthyJ , StewartRM , JonasRB , DentDL , MichalekJE . Impact of low‐dose vasopressin on trauma outcome: prospective randomized study. World Journal of Surgery2011;35(2):430‐9. [DOI: 10.1007/s00268‐010‐0875‐8] ">Cohn 2007</a>a; <a href="./references#CD003709-bbs2-0059" title="Terlipressin in Septic Shock in Cirrhosis; Effects on Survival of Terlipressin Administration in Cirrhotic Patients With Severe Sepsis or Septic Shock. A Randomized, Open Labelled Controlled Trial. Ongoing studyOctober 2006. ">Fernandez 2006</a>; <a href="./references#CD003709-bbs2-0060" title="GordonAC , MasonAJ , PerkinsGD , AshbyD , BrettSJ . Protocol for a randomised controlled trial of VAsopressin versus Noradrenaline as Initial therapy in Septic sHock (VANISH). BMJ open2014;4(7):e005866. ">Gordon 2014</a>; <a href="./references#CD003709-bbs2-0061" title="LienhartH G , WenzelV , BraunJ , DorgesV , DunserM , GriesA , et al. Vasopressin for therapy of persistent traumatic hemorrhagic shock. The VITRIS.at study. [German]. Anaesthetist2007;56(2):145‐50. ">Lienhart 2007</a>) as relevant (<a href="./references#CD003709-sec-0116" title="">Characteristics of ongoing studies</a>). </p> </section> </section> </section> <section id="CD003709-sec-0068"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD003709-sec-0069"> <h4 class="title">Methodological quality of included studies</h4> <p>We have presented risk of bias in <a href="#CD003709-fig-0003">Figure 3</a> and <a href="#CD003709-fig-0004">Figure 4</a>. </p> <div class="figure" id="CD003709-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003709-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD003709-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003709-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <p>GRADE evidence quality varied considerably between comparisons and ranged from high to very low. </p> <p>Generally, risk of bias in the included studies was moderate. For the comparison of norepinephrine versus dopamine, risk of bias was low, but for the other comparisons, risk of bias was moderate to high. We classified 11 studies as having low risk of bias for the primary outcome of mortality (<a href="./references#CD003709-bbs2-0002" title="AnnaneD , VignonP , RenaultA , BollaertPE , CharpentierC , MartinC , et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet2007;370(9588):676‐84. [PUBMED: 17720019] ">Annane 2007</a>; <a href="./references#CD003709-bbs2-0003" title="BoccaraG , OuattaraA , GodetG , DufresneE , BertrandM , RiouB , et al. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin‐angiotensin system inhibitors. Anesthesiology2003;98:1338‐44. [PUBMED: 12766641] ">Boccara 2003</a>; <a href="./references#CD003709-bbs2-0004" title="ChoongK , BohnD , FraserDD , GabouryI , HutchisonJS , JoffeAR , et al. Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2009;180(7):632‐9. [PUBMED: 19608718] ">Choong 2009</a>; <a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>; <a href="./references#CD003709-bbs2-0010" title="LauzierF , LevyB , LamarreP , LesurO . Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Medicine2006;32(11):1782‐9. [PUBMED: 17019548] ">Lauzier 2006</a>; <a href="./references#CD003709-bbs2-0014" title="MalayMB , AshtonRCJr , LandryDW , TownsendRN . Low‐dose vasopressin in the treatment of vasodilatory septic shock. Journal of Trauma1999;47:699‐703. [PUBMED: 10528604] ">Malay 1999</a>; <a href="./references#CD003709-bbs2-0019" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , LaderchiA , et al. Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. Critical Care2008;12(6)(R143):1‐11. [PUBMED: 19017409 ] ">Morelli 2008b</a>; <a href="./references#CD003709-bbs2-0021" title="MyburghJA , HigginsA , JovanovskaA , LipmanJ , RamakrishnanN , SantamariaJ , et al. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Medicine2008;34(12):2226‐34. [PUBMED: 18654759] ">Myburgh 2008</a>; <a href="./references#CD003709-bbs2-0024" title="GordonAC , RussellJA , WalleyKR , SingerJ , AyersD , StormsMM , et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Medicine2010;36(1):83‐91. GordonAC , WangN , WalleyKR , AshbyD , RussellJA . The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest2012;142(3):593‐605. RussellJA , FjellC , HsuJL , LeeT , BoydJ , ThairS , et al. Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. American Journal of Respiratory and Critical Care Medicine2013;188:356‐64. RussellJA , WalleyKR , GordonAC , CooperDJ , HébertPC , SingerJ , et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Critical Care Medicine2009;37(3):811‐8. [PUBMED: 19237882] RussellJA , WalleyKR , SingerJ , GordonAC , HébertPC , CooperDJ , et al. Vasopressin versus norepinephrine infusion in patients with septic shock. New England Journal of Medicine2008;358(9):877‐87. [PUBMED: 18305265] ">Russell 2008</a>; <a href="./references#CD003709-bbs2-0026" title="SeguinP , LaviolleB , GuinetP , MorelI , MalledantY , BellissantE . Dopexamine and norepinephrine versus epinephrine on gastric perfusion in patients with septic shock: a randomized study [NCT00134212]. Critical Care2006;10(1)(R32):1‐8. ">Seguin 2006</a>; <a href="./references#CD003709-bbs2-0027" title="SvobodaP , ScheerP , KantorovaI , DoubekJ , DudraJ , RadvanM , et al. Terlipressin in the treatment of late phase catecholamine‐resistant septic shock. Hepato‐Gastroenterology2012;59(116):1043‐7. ">Svoboda 2012</a>); only four studies fulfilled all trial quality items (<a href="./references#CD003709-bbs2-0002" title="AnnaneD , VignonP , RenaultA , BollaertPE , CharpentierC , MartinC , et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet2007;370(9588):676‐84. [PUBMED: 17720019] ">Annane 2007</a>; <a href="./references#CD003709-bbs2-0004" title="ChoongK , BohnD , FraserDD , GabouryI , HutchisonJS , JoffeAR , et al. Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2009;180(7):632‐9. [PUBMED: 19608718] ">Choong 2009</a>; <a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>; <a href="./references#CD003709-bbs2-0024" title="GordonAC , RussellJA , WalleyKR , SingerJ , AyersD , StormsMM , et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Medicine2010;36(1):83‐91. GordonAC , WangN , WalleyKR , AshbyD , RussellJA . The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest2012;142(3):593‐605. RussellJA , FjellC , HsuJL , LeeT , BoydJ , ThairS , et al. Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. American Journal of Respiratory and Critical Care Medicine2013;188:356‐64. RussellJA , WalleyKR , GordonAC , CooperDJ , HébertPC , SingerJ , et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Critical Care Medicine2009;37(3):811‐8. [PUBMED: 19237882] RussellJA , WalleyKR , SingerJ , GordonAC , HébertPC , CooperDJ , et al. Vasopressin versus norepinephrine infusion in patients with septic shock. New England Journal of Medicine2008;358(9):877‐87. [PUBMED: 18305265] ">Russell 2008</a>). </p> </section> <section id="CD003709-sec-0070"> <h4 class="title">Allocation</h4> <p>Random sequence generation was reported in all but four studies (<a href="./references#CD003709-bbs2-0012" title="LevyB , PerezP , PernyJ , ThivilierC , GerardA . Comparison of norepinephrine‐dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine2011;39(3):450‐5. [PUBMED: 21037469] ">Levy 2011</a>; <a href="./references#CD003709-bbs2-0017" title="MathurS , DhunnaR , ChakrabortyA . Comparison of norepinephrine and dopamine in the management of septic shock using impedance cardiography. Indian Journal of Critical Care Medicine2007;11(4):186‐91. [EMBASE: 2008016347] ">Mathur 2007</a>; <a href="./references#CD003709-bbs2-0022" title="PatelGP , GraheJS , SperryM , SinglaS , ElpernE , LateefO , et al. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock2010;33(4):375‐80. [PUBMED: 19851126] ">Patel 2010</a>; <a href="./references#CD003709-bbs2-0025" title="SeguinP , BellissantE , Le‐TulzoY , LaviolleB , LessardY , ThomasR , et al. Effects of epinephrine compared with the combination of dobutamine and norepinephrine on gastric perfusion in septic shock. Clinical Pharmacology and Therapeutics2002;71:381‐8. [MEDLINE: 12011824] ">Seguin 2002</a>). Allocation concealment was appropriate in 11 studies (<a href="./references#CD003709-bbs2-0002" title="AnnaneD , VignonP , RenaultA , BollaertPE , CharpentierC , MartinC , et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet2007;370(9588):676‐84. [PUBMED: 17720019] ">Annane 2007</a>; <a href="./references#CD003709-bbs2-0003" title="BoccaraG , OuattaraA , GodetG , DufresneE , BertrandM , RiouB , et al. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin‐angiotensin system inhibitors. Anesthesiology2003;98:1338‐44. [PUBMED: 12766641] ">Boccara 2003</a>; <a href="./references#CD003709-bbs2-0004" title="ChoongK , BohnD , FraserDD , GabouryI , HutchisonJS , JoffeAR , et al. Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2009;180(7):632‐9. [PUBMED: 19608718] ">Choong 2009</a>; <a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>; <a href="./references#CD003709-bbs2-0010" title="LauzierF , LevyB , LamarreP , LesurO . Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Medicine2006;32(11):1782‐9. [PUBMED: 17019548] ">Lauzier 2006</a>; <a href="./references#CD003709-bbs2-0014" title="MalayMB , AshtonRCJr , LandryDW , TownsendRN . Low‐dose vasopressin in the treatment of vasodilatory septic shock. Journal of Trauma1999;47:699‐703. [PUBMED: 10528604] ">Malay 1999</a>; <a href="./references#CD003709-bbs2-0019" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , LaderchiA , et al. Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. Critical Care2008;12(6)(R143):1‐11. [PUBMED: 19017409 ] ">Morelli 2008b</a>; <a href="./references#CD003709-bbs2-0021" title="MyburghJA , HigginsA , JovanovskaA , LipmanJ , RamakrishnanN , SantamariaJ , et al. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Medicine2008;34(12):2226‐34. [PUBMED: 18654759] ">Myburgh 2008</a>; <a href="./references#CD003709-bbs2-0024" title="GordonAC , RussellJA , WalleyKR , SingerJ , AyersD , StormsMM , et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Medicine2010;36(1):83‐91. GordonAC , WangN , WalleyKR , AshbyD , RussellJA . The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest2012;142(3):593‐605. RussellJA , FjellC , HsuJL , LeeT , BoydJ , ThairS , et al. Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. American Journal of Respiratory and Critical Care Medicine2013;188:356‐64. RussellJA , WalleyKR , GordonAC , CooperDJ , HébertPC , SingerJ , et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Critical Care Medicine2009;37(3):811‐8. [PUBMED: 19237882] RussellJA , WalleyKR , SingerJ , GordonAC , HébertPC , CooperDJ , et al. Vasopressin versus norepinephrine infusion in patients with septic shock. New England Journal of Medicine2008;358(9):877‐87. [PUBMED: 18305265] ">Russell 2008</a>; <a href="./references#CD003709-bbs2-0026" title="SeguinP , LaviolleB , GuinetP , MorelI , MalledantY , BellissantE . Dopexamine and norepinephrine versus epinephrine on gastric perfusion in patients with septic shock: a randomized study [NCT00134212]. Critical Care2006;10(1)(R32):1‐8. ">Seguin 2006</a>; <a href="./references#CD003709-bbs2-0027" title="SvobodaP , ScheerP , KantorovaI , DoubekJ , DudraJ , RadvanM , et al. Terlipressin in the treatment of late phase catecholamine‐resistant septic shock. Hepato‐Gastroenterology2012;59(116):1043‐7. ">Svoboda 2012</a>) and was not appropriate in three studies (<a href="./references#CD003709-bbs2-0007" title="HanX‐D , SunH , HuangX‐Y , ZhangS‐Y , WangY‐D , RenK , et al. [A clinical study of pituitrin versus norepinephrine in the treatment of patients with septic shock]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue/Chinese Critical Care Medicine/Zhongguo Weizhongbing Jijiuyixue2012;24(1):33‐7. ">Han 2012</a>; <a href="./references#CD003709-bbs2-0022" title="PatelGP , GraheJS , SperryM , SinglaS , ElpernE , LateefO , et al. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock2010;33(4):375‐80. [PUBMED: 19851126] ">Patel 2010</a>; <a href="./references#CD003709-bbs2-0028" title="YildizdasD , YapiciogluH , CelikU , SertdemirY , AlhanE . Terlipressin as a rescue therapy for catecholamine‐resistant septic shock in children. Intensive Care Medicine2008;34(3):511‐7. [PUBMED: 18092150] ">Yildizdas 2008</a>). </p> <p>All but eight studies presented intention‐to‐treat analyses; for six studies this item was unclear (<a href="./references#CD003709-bbs2-0003" title="BoccaraG , OuattaraA , GodetG , DufresneE , BertrandM , RiouB , et al. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin‐angiotensin system inhibitors. Anesthesiology2003;98:1338‐44. [PUBMED: 12766641] ">Boccara 2003</a>; <a href="./references#CD003709-bbs2-0011" title="LevyB , BollaertPE , CharpentierC , NaceL , AudibertG , BauerP , et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Medicine1997;23:282‐7. [PUBMED: 9083230] ">Levy 1997</a>; <a href="./references#CD003709-bbs2-0014" title="MalayMB , AshtonRCJr , LandryDW , TownsendRN . Low‐dose vasopressin in the treatment of vasodilatory septic shock. Journal of Trauma1999;47:699‐703. [PUBMED: 10528604] ">Malay 1999</a>; <a href="./references#CD003709-bbs2-0016" title="MartinC , PapazianL , PerrinG , SauxP , GouinF . Norepinephrine or dopamine for the treatment of hyperdynamic septic shock?. Chest1993;103:1826‐31. [PUBMED: 8404107] ">Martin 1993</a>; <a href="./references#CD003709-bbs2-0023" title="RuokonenE , TakalaJ , KariA , SaxenH , MertsolaJ , HansenEJ . Regional blood flow and oxygen transport in septic shock. Critical Care Medicine1993;21:1296‐303. [PUBMED: 8370292] ">Ruokonen 1993</a>; <a href="./references#CD003709-bbs2-0025" title="SeguinP , BellissantE , Le‐TulzoY , LaviolleB , LessardY , ThomasR , et al. Effects of epinephrine compared with the combination of dobutamine and norepinephrine on gastric perfusion in septic shock. Clinical Pharmacology and Therapeutics2002;71:381‐8. [MEDLINE: 12011824] ">Seguin 2002</a>), and for four studies this was not fulfilled (<a href="./references#CD003709-bbs2-0009" title="JainG , SinghDK . Comparison of phenylephrine and norepinephrine in the management of dopamine‐resistant septic shock. Indian Journal of Critical Care Medicine2010;14(1):29‐34. [MEDLINE: 20606906] ">Jain 2010</a>; <a href="./references#CD003709-bbs2-0013" title="LucknerG , DunserMW , StadlbauerKH , MayrVD , JochbergerS , WenzelV , et al. Cutaneous vascular reactivity and flow motion response to vasopressin in advanced vasodilatory shock and severe postoperative multiple organ dysfunction syndrome. Critical Care2006;10(2):R40. [PUBMED: 16542484] ">Luckner 2006</a>; <a href="./references#CD003709-bbs2-0018" title="MorelliA , ErtmerC , LangeM , DuenserM , RehbergS , VanAkenH , et al. Effects of short‐term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. British Journal of Anaesthesia2008;100(4):494‐503. [PUBMED: 18308741] ">Morelli 2008a</a>; <a href="./references#CD003709-bbs2-0027" title="SvobodaP , ScheerP , KantorovaI , DoubekJ , DudraJ , RadvanM , et al. Terlipressin in the treatment of late phase catecholamine‐resistant septic shock. Hepato‐Gastroenterology2012;59(116):1043‐7. ">Svoboda 2012</a>). </p> </section> <section id="CD003709-sec-0071"> <h4 class="title">Blinding</h4> <p>From the available information, identical care for the intervention group and the control group could be assumed for 12 studies (<a href="./references#CD003709-bbs2-0001" title="AlbaneseJ , LeoneM , DelmasA , MartinC . Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Critical Care Medicine2005;33(9):1897‐902. [PUBMED: 16148457] ">Albanese 2005</a>; <a href="./references#CD003709-bbs2-0002" title="AnnaneD , VignonP , RenaultA , BollaertPE , CharpentierC , MartinC , et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet2007;370(9588):676‐84. [PUBMED: 17720019] ">Annane 2007</a>; <a href="./references#CD003709-bbs2-0004" title="ChoongK , BohnD , FraserDD , GabouryI , HutchisonJS , JoffeAR , et al. Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2009;180(7):632‐9. [PUBMED: 19608718] ">Choong 2009</a>; <a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>; <a href="./references#CD003709-bbs2-0015" title="MarikPE , MohedinM . The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA1994;272:1354‐7. [PUBMED: 7933396] ">Marik 1994</a>; <a href="./references#CD003709-bbs2-0017" title="MathurS , DhunnaR , ChakrabortyA . Comparison of norepinephrine and dopamine in the management of septic shock using impedance cardiography. Indian Journal of Critical Care Medicine2007;11(4):186‐91. [EMBASE: 2008016347] ">Mathur 2007</a>; <a href="./references#CD003709-bbs2-0019" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , LaderchiA , et al. Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. Critical Care2008;12(6)(R143):1‐11. [PUBMED: 19017409 ] ">Morelli 2008b</a>; <a href="./references#CD003709-bbs2-0020" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , CecchiniV , et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Critical Care2009;13(4):R130. [PUBMED: 19664253] ">Morelli 2009</a>; <a href="./references#CD003709-bbs2-0022" title="PatelGP , GraheJS , SperryM , SinglaS , ElpernE , LateefO , et al. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock2010;33(4):375‐80. [PUBMED: 19851126] ">Patel 2010</a>; <a href="./references#CD003709-bbs2-0024" title="GordonAC , RussellJA , WalleyKR , SingerJ , AyersD , StormsMM , et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Medicine2010;36(1):83‐91. GordonAC , WangN , WalleyKR , AshbyD , RussellJA . The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest2012;142(3):593‐605. RussellJA , FjellC , HsuJL , LeeT , BoydJ , ThairS , et al. Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. American Journal of Respiratory and Critical Care Medicine2013;188:356‐64. RussellJA , WalleyKR , GordonAC , CooperDJ , HébertPC , SingerJ , et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Critical Care Medicine2009;37(3):811‐8. [PUBMED: 19237882] RussellJA , WalleyKR , SingerJ , GordonAC , HébertPC , CooperDJ , et al. Vasopressin versus norepinephrine infusion in patients with septic shock. New England Journal of Medicine2008;358(9):877‐87. [PUBMED: 18305265] ">Russell 2008</a>; <a href="./references#CD003709-bbs2-0025" title="SeguinP , BellissantE , Le‐TulzoY , LaviolleB , LessardY , ThomasR , et al. Effects of epinephrine compared with the combination of dobutamine and norepinephrine on gastric perfusion in septic shock. Clinical Pharmacology and Therapeutics2002;71:381‐8. [MEDLINE: 12011824] ">Seguin 2002</a>; <a href="./references#CD003709-bbs2-0026" title="SeguinP , LaviolleB , GuinetP , MorelI , MalledantY , BellissantE . Dopexamine and norepinephrine versus epinephrine on gastric perfusion in patients with septic shock: a randomized study [NCT00134212]. Critical Care2006;10(1)(R32):1‐8. ">Seguin 2006</a>). An appropriate outcome description was present in 20 studies; for the remaining eight studies, this was unclear (<a href="./references#CD003709-bbs2-0001" title="AlbaneseJ , LeoneM , DelmasA , MartinC . Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Critical Care Medicine2005;33(9):1897‐902. [PUBMED: 16148457] ">Albanese 2005</a>; <a href="./references#CD003709-bbs2-0009" title="JainG , SinghDK . Comparison of phenylephrine and norepinephrine in the management of dopamine‐resistant septic shock. Indian Journal of Critical Care Medicine2010;14(1):29‐34. [MEDLINE: 20606906] ">Jain 2010</a>; <a href="./references#CD003709-bbs2-0010" title="LauzierF , LevyB , LamarreP , LesurO . Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Medicine2006;32(11):1782‐9. [PUBMED: 17019548] ">Lauzier 2006</a>; <a href="./references#CD003709-bbs2-0017" title="MathurS , DhunnaR , ChakrabortyA . Comparison of norepinephrine and dopamine in the management of septic shock using impedance cardiography. Indian Journal of Critical Care Medicine2007;11(4):186‐91. [EMBASE: 2008016347] ">Mathur 2007</a>; <a href="./references#CD003709-bbs2-0018" title="MorelliA , ErtmerC , LangeM , DuenserM , RehbergS , VanAkenH , et al. Effects of short‐term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. British Journal of Anaesthesia2008;100(4):494‐503. [PUBMED: 18308741] ">Morelli 2008a</a>; <a href="./references#CD003709-bbs2-0019" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , LaderchiA , et al. Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. Critical Care2008;12(6)(R143):1‐11. [PUBMED: 19017409 ] ">Morelli 2008b</a>; <a href="./references#CD003709-bbs2-0023" title="RuokonenE , TakalaJ , KariA , SaxenH , MertsolaJ , HansenEJ . Regional blood flow and oxygen transport in septic shock. Critical Care Medicine1993;21:1296‐303. [PUBMED: 8370292] ">Ruokonen 1993</a>; <a href="./references#CD003709-bbs2-0025" title="SeguinP , BellissantE , Le‐TulzoY , LaviolleB , LessardY , ThomasR , et al. Effects of epinephrine compared with the combination of dobutamine and norepinephrine on gastric perfusion in septic shock. Clinical Pharmacology and Therapeutics2002;71:381‐8. [MEDLINE: 12011824] ">Seguin 2002</a>). Treating personnel were blinded in nine studies (<a href="./references#CD003709-bbs2-0002" title="AnnaneD , VignonP , RenaultA , BollaertPE , CharpentierC , MartinC , et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet2007;370(9588):676‐84. [PUBMED: 17720019] ">Annane 2007</a>; <a href="./references#CD003709-bbs2-0004" title="ChoongK , BohnD , FraserDD , GabouryI , HutchisonJS , JoffeAR , et al. Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2009;180(7):632‐9. [PUBMED: 19608718] ">Choong 2009</a>; <a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>; <a href="./references#CD003709-bbs2-0014" title="MalayMB , AshtonRCJr , LandryDW , TownsendRN . Low‐dose vasopressin in the treatment of vasodilatory septic shock. Journal of Trauma1999;47:699‐703. [PUBMED: 10528604] ">Malay 1999</a>; <a href="./references#CD003709-bbs2-0016" title="MartinC , PapazianL , PerrinG , SauxP , GouinF . Norepinephrine or dopamine for the treatment of hyperdynamic septic shock?. Chest1993;103:1826‐31. [PUBMED: 8404107] ">Martin 1993</a>; <a href="./references#CD003709-bbs2-0017" title="MathurS , DhunnaR , ChakrabortyA . Comparison of norepinephrine and dopamine in the management of septic shock using impedance cardiography. Indian Journal of Critical Care Medicine2007;11(4):186‐91. [EMBASE: 2008016347] ">Mathur 2007</a>; <a href="./references#CD003709-bbs2-0019" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , LaderchiA , et al. Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. Critical Care2008;12(6)(R143):1‐11. [PUBMED: 19017409 ] ">Morelli 2008b</a>; <a href="./references#CD003709-bbs2-0021" title="MyburghJA , HigginsA , JovanovskaA , LipmanJ , RamakrishnanN , SantamariaJ , et al. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Medicine2008;34(12):2226‐34. [PUBMED: 18654759] ">Myburgh 2008</a>; <a href="./references#CD003709-bbs2-0024" title="GordonAC , RussellJA , WalleyKR , SingerJ , AyersD , StormsMM , et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Medicine2010;36(1):83‐91. GordonAC , WangN , WalleyKR , AshbyD , RussellJA . The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest2012;142(3):593‐605. RussellJA , FjellC , HsuJL , LeeT , BoydJ , ThairS , et al. Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. American Journal of Respiratory and Critical Care Medicine2013;188:356‐64. RussellJA , WalleyKR , GordonAC , CooperDJ , HébertPC , SingerJ , et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Critical Care Medicine2009;37(3):811‐8. [PUBMED: 19237882] RussellJA , WalleyKR , SingerJ , GordonAC , HébertPC , CooperDJ , et al. Vasopressin versus norepinephrine infusion in patients with septic shock. New England Journal of Medicine2008;358(9):877‐87. [PUBMED: 18305265] ">Russell 2008</a>). In the same nine studies, outcome assessors were blinded too. In one study, only outcome assessors were blinded (<a href="./references#CD003709-bbs2-0009" title="JainG , SinghDK . Comparison of phenylephrine and norepinephrine in the management of dopamine‐resistant septic shock. Indian Journal of Critical Care Medicine2010;14(1):29‐34. [MEDLINE: 20606906] ">Jain 2010</a>). </p> </section> <section id="CD003709-sec-0072"> <h4 class="title">Incomplete outcome data</h4> <p>Generally, studies included critically ill participants, for whom follow‐up usually is not of major concern. </p> </section> <section id="CD003709-sec-0073"> <h4 class="title">Selective reporting</h4> <p>Given the large number of comparisons, each with a few studies only, proper assessment of between‐study reporting bias was not possible. However, when looking at the funnel plot in <a href="#CD003709-fig-0005">Figure 5</a>, we could not spot major asymmetry. Within‐study reporting bias: Many of the included studies were performed several years ago, when it was not standard to publish trial protocols. Accordingly, we could not systematically assess selective outcome data reporting because protocols were not available. However, for the primary outcome of 'mortality', we assumed that selective omission of this outcome was unlikely in the ICU setting because this is one of the standard clinical outcomes. Choice of outcome usually is determined by the design (short‐term haemodynamic studies vs longer‐term studies with clinical outcomes). </p> <div class="figure" id="CD003709-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 norepinephrine, outcome: 1.1 mortality." data-id="CD003709-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 norepinephrine, outcome: 1.1 mortality.</p> </div> </div> </div> </section> <section id="CD003709-sec-0074"> <h4 class="title">Other potential sources of bias</h4> <p>All but two studies explicitly described inclusion and exclusion criteria (<a href="./references#CD003709-bbs2-0003" title="BoccaraG , OuattaraA , GodetG , DufresneE , BertrandM , RiouB , et al. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin‐angiotensin system inhibitors. Anesthesiology2003;98:1338‐44. [PUBMED: 12766641] ">Boccara 2003</a>; <a href="./references#CD003709-bbs2-0023" title="RuokonenE , TakalaJ , KariA , SaxenH , MertsolaJ , HansenEJ . Regional blood flow and oxygen transport in septic shock. Critical Care Medicine1993;21:1296‐303. [PUBMED: 8370292] ">Ruokonen 1993</a>). Participants were adequately described in all but three studies (<a href="./references#CD003709-bbs2-0007" title="HanX‐D , SunH , HuangX‐Y , ZhangS‐Y , WangY‐D , RenK , et al. [A clinical study of pituitrin versus norepinephrine in the treatment of patients with septic shock]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue/Chinese Critical Care Medicine/Zhongguo Weizhongbing Jijiuyixue2012;24(1):33‐7. ">Han 2012</a>; <a href="./references#CD003709-bbs2-0013" title="LucknerG , DunserMW , StadlbauerKH , MayrVD , JochbergerS , WenzelV , et al. Cutaneous vascular reactivity and flow motion response to vasopressin in advanced vasodilatory shock and severe postoperative multiple organ dysfunction syndrome. Critical Care2006;10(2):R40. [PUBMED: 16542484] ">Luckner 2006</a>; <a href="./references#CD003709-bbs2-0023" title="RuokonenE , TakalaJ , KariA , SaxenH , MertsolaJ , HansenEJ . Regional blood flow and oxygen transport in septic shock. Critical Care Medicine1993;21:1296‐303. [PUBMED: 8370292] ">Ruokonen 1993</a>). </p> </section> </section> <section id="CD003709-sec-0075"> <h3 class="title" id="CD003709-sec-0075">Effects of interventions</h3> <p>See: <a href="./full#CD003709-tbl-0001"><b>Summary of findings for the main comparison</b> Dopamine compared with norepinephrine for hypotensive shock</a>; <a href="./full#CD003709-tbl-0002"><b>Summary of findings 2</b> Terlipressin compared with norepinephrine for hypotensive shock</a>; <a href="./full#CD003709-tbl-0003"><b>Summary of findings 3</b> Vasopressin compared with norepinephrine for hypotensive shock</a>; <a href="./full#CD003709-tbl-0004"><b>Summary of findings 4</b> Phenylephrine compared with norepinephrine for hypotensive shock</a>; <a href="./full#CD003709-tbl-0005"><b>Summary of findings 5</b> Epinephrine compared with norepinephrine for hypotensive shock</a> </p> <p>In total, six vasopressors were compared in several combinations and directions (<a href="#CD003709-fig-0002">Figure 2</a>). Therefore, we have organized our comparisons to present each vasopressor against all comparators in a separate analysis per outcome. Vasopressors that were used in both study arms were considered as constant between groups and generally were not explicitly described in analyses. For studies with more than two study arms, we used each comparison separately. We refrained from including overall summary effects within analyses to address considerable clinical heterogeneity due to major differences in comparators and,when applicable, to avoid a unit of analysis error. </p> <section id="CD003709-sec-0076"> <h4 class="title">Main analyses</h4> <section id="CD003709-sec-0077"> <h5 class="title">Primary outcomes</h5> <section id="CD003709-sec-0078"> <h6 class="title">Total mortality</h6> <p>Total mortality was assessed in all included studies. If mortality was assessed at several time points in a study we used data from the latest follow‐up time. Mortality was assessed at an undetermined time point in seven studies (<a href="./references#CD003709-bbs2-0003" title="BoccaraG , OuattaraA , GodetG , DufresneE , BertrandM , RiouB , et al. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin‐angiotensin system inhibitors. Anesthesiology2003;98:1338‐44. [PUBMED: 12766641] ">Boccara 2003,</a>; <a href="./references#CD003709-bbs2-0009" title="JainG , SinghDK . Comparison of phenylephrine and norepinephrine in the management of dopamine‐resistant septic shock. Indian Journal of Critical Care Medicine2010;14(1):29‐34. [MEDLINE: 20606906] ">Jain 2010</a>; <a href="./references#CD003709-bbs2-0011" title="LevyB , BollaertPE , CharpentierC , NaceL , AudibertG , BauerP , et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Medicine1997;23:282‐7. [PUBMED: 9083230] ">Levy 1997,</a>; <a href="./references#CD003709-bbs2-0015" title="MarikPE , MohedinM . The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA1994;272:1354‐7. [PUBMED: 7933396] ">Marik 1994,</a>; <a href="./references#CD003709-bbs2-0017" title="MathurS , DhunnaR , ChakrabortyA . Comparison of norepinephrine and dopamine in the management of septic shock using impedance cardiography. Indian Journal of Critical Care Medicine2007;11(4):186‐91. [EMBASE: 2008016347] ">Mathur 2007,</a>; <a href="./references#CD003709-bbs2-0025" title="SeguinP , BellissantE , Le‐TulzoY , LaviolleB , LessardY , ThomasR , et al. Effects of epinephrine compared with the combination of dobutamine and norepinephrine on gastric perfusion in septic shock. Clinical Pharmacology and Therapeutics2002;71:381‐8. [MEDLINE: 12011824] ">Seguin 2002</a>,; <a href="./references#CD003709-bbs2-0023" title="RuokonenE , TakalaJ , KariA , SaxenH , MertsolaJ , HansenEJ . Regional blood flow and oxygen transport in septic shock. Critical Care Medicine1993;21:1296‐303. [PUBMED: 8370292] ">Ruokonen 1993</a>). </p> <p><i>Norepinephrine was compared with dopamine, epinephrine, terlipressin, vasopressin, phenylephrine and norepinephrine + terlipressin + dobutamine</i> (14 studies; 2607 participants) (<a href="#CD003709-fig-0006">Figure 6</a>). In addition, <a href="./references#CD003709-bbs2-0020" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , CecchiniV , et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Critical Care2009;13(4):R130. [PUBMED: 19664253] ">Morelli 2009</a> compared norepinephrine versus norepinephrine + vasopressin and norepinephrine versus norepinephrine + terlipressin and found no differences in both comparisons (risk ratio (RR) 1.25, 95% confidence interval (CI) 0.69 to 2.26; and RR 1.43, 95% CI 0.75 to 2.70 ‐ data from the single study not presented in analyses). Studies were performed in participants with septic shock (<a href="./references#CD003709-bbs2-0001" title="AlbaneseJ , LeoneM , DelmasA , MartinC . Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Critical Care Medicine2005;33(9):1897‐902. [PUBMED: 16148457] ">Albanese 2005</a>; <a href="./references#CD003709-bbs2-0009" title="JainG , SinghDK . Comparison of phenylephrine and norepinephrine in the management of dopamine‐resistant septic shock. Indian Journal of Critical Care Medicine2010;14(1):29‐34. [MEDLINE: 20606906] ">Jain 2010</a>; <a href="./references#CD003709-bbs2-0010" title="LauzierF , LevyB , LamarreP , LesurO . Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Medicine2006;32(11):1782‐9. [PUBMED: 17019548] ">Lauzier 2006</a>; <a href="./references#CD003709-bbs2-0011" title="LevyB , BollaertPE , CharpentierC , NaceL , AudibertG , BauerP , et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Medicine1997;23:282‐7. [PUBMED: 9083230] ">Levy 1997</a>; <a href="./references#CD003709-bbs2-0015" title="MarikPE , MohedinM . The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA1994;272:1354‐7. [PUBMED: 7933396] ">Marik 1994</a>; <a href="./references#CD003709-bbs2-0016" title="MartinC , PapazianL , PerrinG , SauxP , GouinF . Norepinephrine or dopamine for the treatment of hyperdynamic septic shock?. Chest1993;103:1826‐31. [PUBMED: 8404107] ">Martin 1993</a>; <a href="./references#CD003709-bbs2-0017" title="MathurS , DhunnaR , ChakrabortyA . Comparison of norepinephrine and dopamine in the management of septic shock using impedance cardiography. Indian Journal of Critical Care Medicine2007;11(4):186‐91. [EMBASE: 2008016347] ">Mathur 2007</a>; <a href="./references#CD003709-bbs2-0018" title="MorelliA , ErtmerC , LangeM , DuenserM , RehbergS , VanAkenH , et al. Effects of short‐term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. British Journal of Anaesthesia2008;100(4):494‐503. [PUBMED: 18308741] ">Morelli 2008a</a>; <a href="./references#CD003709-bbs2-0019" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , LaderchiA , et al. Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. Critical Care2008;12(6)(R143):1‐11. [PUBMED: 19017409 ] ">Morelli 2008b</a>; <a href="./references#CD003709-bbs2-0020" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , CecchiniV , et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Critical Care2009;13(4):R130. [PUBMED: 19664253] ">Morelli 2009</a>; <a href="./references#CD003709-bbs2-0022" title="PatelGP , GraheJS , SperryM , SinglaS , ElpernE , LateefO , et al. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock2010;33(4):375‐80. [PUBMED: 19851126] ">Patel 2010</a>; <a href="./references#CD003709-bbs2-0023" title="RuokonenE , TakalaJ , KariA , SaxenH , MertsolaJ , HansenEJ . Regional blood flow and oxygen transport in septic shock. Critical Care Medicine1993;21:1296‐303. [PUBMED: 8370292] ">Ruokonen 1993</a>; <a href="./references#CD003709-bbs2-0024" title="GordonAC , RussellJA , WalleyKR , SingerJ , AyersD , StormsMM , et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Medicine2010;36(1):83‐91. GordonAC , WangN , WalleyKR , AshbyD , RussellJA . The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest2012;142(3):593‐605. RussellJA , FjellC , HsuJL , LeeT , BoydJ , ThairS , et al. Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. American Journal of Respiratory and Critical Care Medicine2013;188:356‐64. RussellJA , WalleyKR , GordonAC , CooperDJ , HébertPC , SingerJ , et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Critical Care Medicine2009;37(3):811‐8. [PUBMED: 19237882] RussellJA , WalleyKR , SingerJ , GordonAC , HébertPC , CooperDJ , et al. Vasopressin versus norepinephrine infusion in patients with septic shock. New England Journal of Medicine2008;358(9):877‐87. [PUBMED: 18305265] ">Russell 2008</a>; <a href="./references#CD003709-bbs2-0025" title="SeguinP , BellissantE , Le‐TulzoY , LaviolleB , LessardY , ThomasR , et al. Effects of epinephrine compared with the combination of dobutamine and norepinephrine on gastric perfusion in septic shock. Clinical Pharmacology and Therapeutics2002;71:381‐8. [MEDLINE: 12011824] ">Seguin 2002</a>; <a href="./references#CD003709-bbs2-0026" title="SeguinP , LaviolleB , GuinetP , MorelI , MalledantY , BellissantE . Dopexamine and norepinephrine versus epinephrine on gastric perfusion in patients with septic shock: a randomized study [NCT00134212]. Critical Care2006;10(1)(R32):1‐8. ">Seguin 2006</a>), in critically ill participants (<a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>; <a href="./references#CD003709-bbs2-0021" title="MyburghJA , HigginsA , JovanovskaA , LipmanJ , RamakrishnanN , SantamariaJ , et al. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Medicine2008;34(12):2226‐34. [PUBMED: 18654759] ">Myburgh 2008</a>), in participants with refractory hypotension after anaesthesia (<a href="./references#CD003709-bbs2-0003" title="BoccaraG , OuattaraA , GodetG , DufresneE , BertrandM , RiouB , et al. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin‐angiotensin system inhibitors. Anesthesiology2003;98:1338‐44. [PUBMED: 12766641] ">Boccara 2003</a>) and in adult post‐operative participants (<a href="./references#CD003709-bbs2-0013" title="LucknerG , DunserMW , StadlbauerKH , MayrVD , JochbergerS , WenzelV , et al. Cutaneous vascular reactivity and flow motion response to vasopressin in advanced vasodilatory shock and severe postoperative multiple organ dysfunction syndrome. Critical Care2006;10(2):R40. [PUBMED: 16542484] ">Luckner 2006</a>). None of the comparisons revealed significant differences. <a href="./references#CD003709-bbs2-0018" title="MorelliA , ErtmerC , LangeM , DuenserM , RehbergS , VanAkenH , et al. Effects of short‐term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. British Journal of Anaesthesia2008;100(4):494‐503. [PUBMED: 18308741] ">Morelli 2008a</a> compared NPVD (including norepinephrine) versus norepinephrine + terlipressin + dobutamine and found no differences in mortality (14/20 vs 14/20; RR 1.00, 95% CI 0.67 to 1.50). The funnel plot, which is presented in <a href="#CD003709-fig-0005">Figure 5</a> shows no indication of relevant asymmetry. </p> <div class="figure" id="CD003709-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Norepinephrine, outcome: 1.1 Total mortality." data-id="CD003709-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Norepinephrine, outcome: 1.1 Total mortality.</p> </div> </div> </div> <p><i>Epinephrine was compared with norepinephrine, norepinephrine + dobutamine and norepinephrine + dopexamine</i> (six studies; 703 participants) (<a href="./references#CD003709-fig-0016" title="">Analysis 2.1</a>). Overall 298 deaths were observed among the 703 participants. Studies were performed in participants with septic shock (<a href="./references#CD003709-bbs2-0002" title="AnnaneD , VignonP , RenaultA , BollaertPE , CharpentierC , MartinC , et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet2007;370(9588):676‐84. [PUBMED: 17720019] ">Annane 2007</a>; <a href="./references#CD003709-bbs2-0011" title="LevyB , BollaertPE , CharpentierC , NaceL , AudibertG , BauerP , et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Medicine1997;23:282‐7. [PUBMED: 9083230] ">Levy 1997</a>; <a href="./references#CD003709-bbs2-0025" title="SeguinP , BellissantE , Le‐TulzoY , LaviolleB , LessardY , ThomasR , et al. Effects of epinephrine compared with the combination of dobutamine and norepinephrine on gastric perfusion in septic shock. Clinical Pharmacology and Therapeutics2002;71:381‐8. [MEDLINE: 12011824] ">Seguin 2002</a>; <a href="./references#CD003709-bbs2-0026" title="SeguinP , LaviolleB , GuinetP , MorelI , MalledantY , BellissantE . Dopexamine and norepinephrine versus epinephrine on gastric perfusion in patients with septic shock: a randomized study [NCT00134212]. Critical Care2006;10(1)(R32):1‐8. ">Seguin 2006</a>), participants with cardiogenic shock (<a href="./references#CD003709-bbs2-0012" title="LevyB , PerezP , PernyJ , ThivilierC , GerardA . Comparison of norepinephrine‐dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine2011;39(3):450‐5. [PUBMED: 21037469] ">Levy 2011</a>) and critically ill participants (<a href="./references#CD003709-bbs2-0021" title="MyburghJA , HigginsA , JovanovskaA , LipmanJ , RamakrishnanN , SantamariaJ , et al. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Medicine2008;34(12):2226‐34. [PUBMED: 18654759] ">Myburgh 2008</a>). In no comparisons was a significant difference found. </p> <p><i>Vasopressin was compared with placebo (non‐protocol vasoactive drugs), terlipressin and norepinephrine/dopamine</i> (eight studies; 1138 participants) (<a href="./references#CD003709-fig-0017" title="">Analysis 3.1</a>). In the comparisons 'versus placebo/non‐protocol vasoactive drugs', two studies actually used a placebo (<a href="./references#CD003709-bbs2-0004" title="ChoongK , BohnD , FraserDD , GabouryI , HutchisonJS , JoffeAR , et al. Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2009;180(7):632‐9. [PUBMED: 19608718] ">Choong 2009</a>; <a href="./references#CD003709-bbs2-0014" title="MalayMB , AshtonRCJr , LandryDW , TownsendRN . Low‐dose vasopressin in the treatment of vasodilatory septic shock. Journal of Trauma1999;47:699‐703. [PUBMED: 10528604] ">Malay 1999</a>), two studies (<a href="./references#CD003709-bbs2-0006" title="DünserMW , MayrAJ , UlmerH , KnotzerH , SumannG , PajkW , et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation2003;107:2313‐9. [PUBMED: 12732600] ">Dünser 2003</a>; <a href="./references#CD003709-bbs2-0020" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , CecchiniV , et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Critical Care2009;13(4):R130. [PUBMED: 19664253] ">Morelli 2009</a>) compared fixed‐dose vasopressin + variable‐dose norepinephrine versus variable‐dose norepinephrine and one study compared vasopressin versus norepinephrine or dopamine (<a href="./references#CD003709-bbs2-0007" title="HanX‐D , SunH , HuangX‐Y , ZhangS‐Y , WangY‐D , RenK , et al. [A clinical study of pituitrin versus norepinephrine in the treatment of patients with septic shock]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue/Chinese Critical Care Medicine/Zhongguo Weizhongbing Jijiuyixue2012;24(1):33‐7. ">Han 2012</a>). Overall 503 deaths were observed among 1138 participants. Studies were performed in participants with septic shock (<a href="./references#CD003709-bbs2-0006" title="DünserMW , MayrAJ , UlmerH , KnotzerH , SumannG , PajkW , et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation2003;107:2313‐9. [PUBMED: 12732600] ">Dünser 2003</a>; <a href="./references#CD003709-bbs2-0007" title="HanX‐D , SunH , HuangX‐Y , ZhangS‐Y , WangY‐D , RenK , et al. [A clinical study of pituitrin versus norepinephrine in the treatment of patients with septic shock]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue/Chinese Critical Care Medicine/Zhongguo Weizhongbing Jijiuyixue2012;24(1):33‐7. ">Han 2012</a>; <a href="./references#CD003709-bbs2-0010" title="LauzierF , LevyB , LamarreP , LesurO . Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Medicine2006;32(11):1782‐9. [PUBMED: 17019548] ">Lauzier 2006</a>; <a href="./references#CD003709-bbs2-0014" title="MalayMB , AshtonRCJr , LandryDW , TownsendRN . Low‐dose vasopressin in the treatment of vasodilatory septic shock. Journal of Trauma1999;47:699‐703. [PUBMED: 10528604] ">Malay 1999</a>; <a href="./references#CD003709-bbs2-0020" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , CecchiniV , et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Critical Care2009;13(4):R130. [PUBMED: 19664253] ">Morelli 2009</a>; <a href="./references#CD003709-bbs2-0024" title="GordonAC , RussellJA , WalleyKR , SingerJ , AyersD , StormsMM , et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Medicine2010;36(1):83‐91. GordonAC , WangN , WalleyKR , AshbyD , RussellJA . The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest2012;142(3):593‐605. RussellJA , FjellC , HsuJL , LeeT , BoydJ , ThairS , et al. Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. American Journal of Respiratory and Critical Care Medicine2013;188:356‐64. RussellJA , WalleyKR , GordonAC , CooperDJ , HébertPC , SingerJ , et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Critical Care Medicine2009;37(3):811‐8. [PUBMED: 19237882] RussellJA , WalleyKR , SingerJ , GordonAC , HébertPC , CooperDJ , et al. Vasopressin versus norepinephrine infusion in patients with septic shock. New England Journal of Medicine2008;358(9):877‐87. [PUBMED: 18305265] ">Russell 2008</a>), in adult post‐operative participants (<a href="./references#CD003709-bbs2-0013" title="LucknerG , DunserMW , StadlbauerKH , MayrVD , JochbergerS , WenzelV , et al. Cutaneous vascular reactivity and flow motion response to vasopressin in advanced vasodilatory shock and severe postoperative multiple organ dysfunction syndrome. Critical Care2006;10(2):R40. [PUBMED: 16542484] ">Luckner 2006</a>) and in paediatric participants with vasodilatory shock (<a href="./references#CD003709-bbs2-0004" title="ChoongK , BohnD , FraserDD , GabouryI , HutchisonJS , JoffeAR , et al. Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2009;180(7):632‐9. [PUBMED: 19608718] ">Choong 2009</a>). In no comparisons was a significant difference found. </p> <p><i>Terlipressin was compared with placebo (non‐protocol vasoactive drugs), norepinephrine and vasopressin</i> (seven studies; 259 participants) (<a href="./references#CD003709-fig-0019" title="">Analysis 4.1</a>). In the comparisons 'versus placebo/non‐protocol vasoactive drugs', one study actually used a placebo (<a href="./references#CD003709-bbs2-0028" title="YildizdasD , YapiciogluH , CelikU , SertdemirY , AlhanE . Terlipressin as a rescue therapy for catecholamine‐resistant septic shock in children. Intensive Care Medicine2008;34(3):511‐7. [PUBMED: 18092150] ">Yildizdas 2008</a>), and three studies (<a href="./references#CD003709-bbs2-0018" title="MorelliA , ErtmerC , LangeM , DuenserM , RehbergS , VanAkenH , et al. Effects of short‐term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. British Journal of Anaesthesia2008;100(4):494‐503. [PUBMED: 18308741] ">Morelli 2008a</a>; <a href="./references#CD003709-bbs2-0020" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , CecchiniV , et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Critical Care2009;13(4):R130. [PUBMED: 19664253] ">Morelli 2009</a>; <a href="./references#CD003709-bbs2-0027" title="SvobodaP , ScheerP , KantorovaI , DoubekJ , DudraJ , RadvanM , et al. Terlipressin in the treatment of late phase catecholamine‐resistant septic shock. Hepato‐Gastroenterology2012;59(116):1043‐7. ">Svoboda 2012</a>) compared fixed‐dose terlipressin + variable‐dose norepinephrine versus variable‐dose norepinephrine. In the same study (<a href="./references#CD003709-bbs2-0018" title="MorelliA , ErtmerC , LangeM , DuenserM , RehbergS , VanAkenH , et al. Effects of short‐term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. British Journal of Anaesthesia2008;100(4):494‐503. [PUBMED: 18308741] ">Morelli 2008a</a>), investigators compared norepinephrine + terlipressin + dobutamine versus non‐protocol vasoactive drugs and found no difference (14/20 vs 14/20; RR 1.00, 95% CI 0.67 to 1.50). In another study, terlipressin was compared with dopamine (<a href="./references#CD003709-bbs2-0008" title="HuaF , WangX , ZhuL . Terlipressin decreases vascular endothelial growth factor expression and improves oxygenation in patients with acute respiratory distress syndrome and shock. Journal of Emergency Medicine2013;44(2):434‐9. ">Hua 2013</a>). Overall 150 deaths were observed among 259 participants. Studies were performed in participants with septic shock (<a href="./references#CD003709-bbs2-0001" title="AlbaneseJ , LeoneM , DelmasA , MartinC . Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Critical Care Medicine2005;33(9):1897‐902. [PUBMED: 16148457] ">Albanese 2005</a>; <a href="./references#CD003709-bbs2-0007" title="HanX‐D , SunH , HuangX‐Y , ZhangS‐Y , WangY‐D , RenK , et al. [A clinical study of pituitrin versus norepinephrine in the treatment of patients with septic shock]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue/Chinese Critical Care Medicine/Zhongguo Weizhongbing Jijiuyixue2012;24(1):33‐7. ">Han 2012</a>; <a href="./references#CD003709-bbs2-0018" title="MorelliA , ErtmerC , LangeM , DuenserM , RehbergS , VanAkenH , et al. Effects of short‐term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. British Journal of Anaesthesia2008;100(4):494‐503. [PUBMED: 18308741] ">Morelli 2008a</a>; <a href="./references#CD003709-bbs2-0020" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , CecchiniV , et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Critical Care2009;13(4):R130. [PUBMED: 19664253] ">Morelli 2009</a>; <a href="./references#CD003709-bbs2-0027" title="SvobodaP , ScheerP , KantorovaI , DoubekJ , DudraJ , RadvanM , et al. Terlipressin in the treatment of late phase catecholamine‐resistant septic shock. Hepato‐Gastroenterology2012;59(116):1043‐7. ">Svoboda 2012</a>), in children with catecholamine‐resistant shock (<a href="./references#CD003709-bbs2-0028" title="YildizdasD , YapiciogluH , CelikU , SertdemirY , AlhanE . Terlipressin as a rescue therapy for catecholamine‐resistant septic shock in children. Intensive Care Medicine2008;34(3):511‐7. [PUBMED: 18092150] ">Yildizdas 2008</a>) and in participants with refractory hypotension after anaesthesia (<a href="./references#CD003709-bbs2-0003" title="BoccaraG , OuattaraA , GodetG , DufresneE , BertrandM , RiouB , et al. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin‐angiotensin system inhibitors. Anesthesiology2003;98:1338‐44. [PUBMED: 12766641] ">Boccara 2003</a>). No comparisons revealed a significant difference. </p> <p><i>Dopamine was compared with norepinephrine and with terlipressin</i> (seven studies; 1432 participants) (<a href="./references#CD003709-fig-0025" title="">Analysis 5.1</a>). Overall 869 deaths were observed among 1432 participants. Studies were performed in participants with septic shock (<a href="./references#CD003709-bbs2-0008" title="HuaF , WangX , ZhuL . Terlipressin decreases vascular endothelial growth factor expression and improves oxygenation in patients with acute respiratory distress syndrome and shock. Journal of Emergency Medicine2013;44(2):434‐9. ">Hua 2013</a>; <a href="./references#CD003709-bbs2-0015" title="MarikPE , MohedinM . The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA1994;272:1354‐7. [PUBMED: 7933396] ">Marik 1994</a>; <a href="./references#CD003709-bbs2-0016" title="MartinC , PapazianL , PerrinG , SauxP , GouinF . Norepinephrine or dopamine for the treatment of hyperdynamic septic shock?. Chest1993;103:1826‐31. [PUBMED: 8404107] ">Martin 1993</a>; <a href="./references#CD003709-bbs2-0017" title="MathurS , DhunnaR , ChakrabortyA . Comparison of norepinephrine and dopamine in the management of septic shock using impedance cardiography. Indian Journal of Critical Care Medicine2007;11(4):186‐91. [EMBASE: 2008016347] ">Mathur 2007</a>; <a href="./references#CD003709-bbs2-0022" title="PatelGP , GraheJS , SperryM , SinglaS , ElpernE , LateefO , et al. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock2010;33(4):375‐80. [PUBMED: 19851126] ">Patel 2010</a>; <a href="./references#CD003709-bbs2-0023" title="RuokonenE , TakalaJ , KariA , SaxenH , MertsolaJ , HansenEJ . Regional blood flow and oxygen transport in septic shock. Critical Care Medicine1993;21:1296‐303. [PUBMED: 8370292] ">Ruokonen 1993</a>) and in participants with several causes of shock (<a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>). In no comparisons was a significant difference found. </p> <p><i>Phenylephrine was compared with norepinephrine in participants with septic shock</i> (two studies; 86 participants) (<a href="./references#CD003709-bbs2-0009" title="JainG , SinghDK . Comparison of phenylephrine and norepinephrine in the management of dopamine‐resistant septic shock. Indian Journal of Critical Care Medicine2010;14(1):29‐34. [MEDLINE: 20606906] ">Jain 2010</a>; <a href="./references#CD003709-bbs2-0019" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , LaderchiA , et al. Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. Critical Care2008;12(6)(R143):1‐11. [PUBMED: 19017409 ] ">Morelli 2008b</a>) (<a href="./references#CD003709-fig-0012" title="">Analysis 1.1</a>). Overall 50 deaths were observed among 86 participants (RR 0.92, 95% CI 0.64 to 1.32). </p> <p>In a network that included vasopressors only (<a href="#CD003709-fig-0007">Figure 7</a>), we found no differences in effects of any vasopressor versus non‐protocol vasoactive drugs on mortality, as shown in the network forest plot comparing seven vasopressor regimens versus norepinephrine (<a href="#CD003709-fig-0008">Figure 8</a>) from 22 studies with 24 pair‐wise comparisons. Heterogeneity/inconsistency: tau<sup>2</sup> &lt; 0.0001; I<sup>2</sup> statistic = 0%. Test of heterogeneity/inconsistency: Q = 8.39 (d.f. 17), P value = 0.96. Likewise, no hotspots are evident in the heatplot indicating the absence of specific sources of important inconsistency in the network (see <a href="http://www.meduniwien.ac.at/user/harald.herkner/AppendixCARG029_2015.pdf" target="_blank">www.meduniwien.ac.at/user/harald.herkner/AppendixCARG029_2015.pdf</a>). For the full network assessment, including measures for characterizing a network meta‐analysis (direct evidence proportion, mean path length, minimal parallelism of mixed treatment comparisons and evidence flow per design) (see <a href="http://www.meduniwien.ac.at/user/harald.herkner/AppendixCARG029_2015.pdf" target="_blank">www.meduniwien.ac.at/user/harald.herkner/AppendixCARG029_2015.pdf</a>). </p> <div class="figure" id="CD003709-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Graphical representation of the evidence network including vasopressors showing available direct comparisons. The lines represent direct comparisons, and line thickness is proportional to precision of the estimates (1/SE)." data-id="CD003709-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Graphical representation of the evidence network including vasopressors showing available direct comparisons. The lines represent direct comparisons, and line thickness is proportional to precision of the estimates (1/SE). </p> </div> </div> </div> <div class="figure" id="CD003709-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Network forest plot comparing seven vasopressor regimens vs norepinephrine (reference) from 22 studies with 24 pair‐wise comparisons. Heterogeneity/inconsistency: tau2 &lt; 0.0001; I2 statistic = 0%. Test of heterogeneity/inconsistency: Q = 8.48 (d.f. 18), P value = 0.97; 'NPVD' denotes non‐protocol vasoactive drugs with or without placebo. RR denotes risk ratio, as calculated by a fixed‐effect model. RR &gt; 1 indicates increased mortality risk; RR &lt; 1 indicates reduced mortality risk vs norepinephrine (reference)." data-id="CD003709-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Network forest plot comparing seven vasopressor regimens vs norepinephrine (reference) from 22 studies with 24 pair‐wise comparisons. Heterogeneity/inconsistency: tau<sup>2</sup> &lt; 0.0001; I<sup>2</sup> statistic = 0%. Test of heterogeneity/inconsistency: Q = 8.48 (d.f. 18), P value = 0.97; 'NPVD' denotes non‐protocol vasoactive drugs with or without placebo. RR denotes risk ratio, as calculated by a fixed‐effect model. RR &gt; 1 indicates increased mortality risk; RR &lt; 1 indicates reduced mortality risk vs norepinephrine (reference). </p> </div> </div> </div> <p>In a network that included vasopressors and combinations with beta‐agonist action (<a href="#CD003709-fig-0009">Figure 9</a>), we found no differences in the effects of any vasopressor versus norepinephrine on mortality, as shown in the network forest plot comparing four vasopressor regimens with a beta‐agonist component versus norepinephrine (<a href="#CD003709-fig-0010">Figure 10</a>) from six studies with six pair‐wise comparisons. Heterogeneity/inconsistency: tau<sup>2</sup> &lt; 0.0001; I<sup>2</sup> statistic = 0%. Test of heterogeneity/inconsistency: Q = 0.42 (d.f. 3), P value = 0.94 (<a href="#CD003709-fig-0010">Figure 10</a>). No indication of severe heterogeneity/inconsistency was found, although several analyses were not possible with available data. For the full network assessment, see the Appendix (<a href="http://www.meduniwien.ac.at/user/harald.herkner/AppendixCARG029_2015.pdf" target="_blank">www.meduniwien.ac.at/user/harald.herkner/AppendixCARG029_2015.pdf</a>). </p> <div class="figure" id="CD003709-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Graphical representation of the evidence network including vasopressors and combinations with beta‐agonist action showing available direct comparisons. The lines represent direct comparisons, and line thickness is proportional to precision of the estimates (1/SE)." data-id="CD003709-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Graphical representation of the evidence network including vasopressors and combinations with beta‐agonist action showing available direct comparisons. The lines represent direct comparisons, and line thickness is proportional to precision of the estimates (1/SE). </p> </div> </div> </div> <div class="figure" id="CD003709-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Network forest plot comparing four vasopressor regimens with a beta‐agonist component vs norepinephrine (reference) from 6 studies with 6 pair‐wise comparisons. Heterogeneity/inconsistency: tau2 &lt; 0.0001; I2 statistic = 0%. Test of heterogeneity/inconsistency: Q = 0.42(d.f. 3), P value = 0.94; 'nor_' denotes norepinephrine added to the other drugs as described. RR denotes risk ratio, as calculated by a fixed‐effect model. RR &gt; 1 indicates increased mortality risk; RR &lt; 1 indicates reduced mortality risk vs norepinephrine (reference)." data-id="CD003709-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Network forest plot comparing four vasopressor regimens with a beta‐agonist component vs norepinephrine (reference) from 6 studies with 6 pair‐wise comparisons. Heterogeneity/inconsistency: tau<sup>2</sup> &lt; 0.0001; I<sup>2</sup> statistic = 0%. Test of heterogeneity/inconsistency: Q = 0.42(d.f. 3), P value = 0.94; 'nor_' denotes norepinephrine added to the other drugs as described. RR denotes risk ratio, as calculated by a fixed‐effect model. RR &gt; 1 indicates increased mortality risk; RR &lt; 1 indicates reduced mortality risk vs norepinephrine (reference). </p> </div> </div> </div> </section> </section> <section id="CD003709-sec-0079"> <h5 class="title">Secondary outcomes</h5> <section id="CD003709-sec-0080"> <h6 class="title">Morbidity</h6> <p>Morbidity was assessed as (1a) ICU LOS; (1b) hospital LOS; (1c) duration of vasopressor treatment; (1d) duration of mechanical ventilation; (1e) renal failure (as defined by study authors as oliguria or renal replacement therapy) and (1f) other. Renal outcomes are presented separately in <a href="#CD003709-tbl-0006">Table 1</a>. </p> <div class="table" id="CD003709-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Morbidity outcomes ‐ measures of renal function comparing several vasopressor regimens (each single vasopressor is compared with other available vasopressor regimens)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vasopressor</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparator (Reference)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Effect*</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>Norepinephrine</p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vasopressin (<a href="./references#CD003709-bbs2-0010" title="LauzierF , LevyB , LamarreP , LesurO . Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Medicine2006;32(11):1782‐9. [PUBMED: 17019548] ">Lauzier 2006</a>) </p> <p> </p> <p> </p> <p> </p> <p>Vasopressin (<a href="./references#CD003709-bbs2-0024" title="GordonAC , RussellJA , WalleyKR , SingerJ , AyersD , StormsMM , et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Medicine2010;36(1):83‐91. GordonAC , WangN , WalleyKR , AshbyD , RussellJA . The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest2012;142(3):593‐605. RussellJA , FjellC , HsuJL , LeeT , BoydJ , ThairS , et al. Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. American Journal of Respiratory and Critical Care Medicine2013;188:356‐64. RussellJA , WalleyKR , GordonAC , CooperDJ , HébertPC , SingerJ , et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Critical Care Medicine2009;37(3):811‐8. [PUBMED: 19237882] RussellJA , WalleyKR , SingerJ , GordonAC , HébertPC , CooperDJ , et al. Vasopressin versus norepinephrine infusion in patients with septic shock. New England Journal of Medicine2008;358(9):877‐87. [PUBMED: 18305265] ">Russell 2008</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Creatinine clearance</p> <p>  </p> <p> </p> <p>Days alive free of renal replacement therapy</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 mL min<sup>‐1</sup>1.73 m<sup>‐2</sup> ± 38 vs 122 mL min<sup>‐1</sup>1.73m<sup>‐2</sup> ± 66 , P value &lt; 0.001 </p> <p> </p> <p>(23 (IQR 5 to 28) vs 25 (IQR 6 to 28), P value = 0.64)</p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Norepinephrine + terlipressin + dobutamine</p> <p>(<a href="./references#CD003709-bbs2-0018" title="MorelliA , ErtmerC , LangeM , DuenserM , RehbergS , VanAkenH , et al. Effects of short‐term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. British Journal of Anaesthesia2008;100(4):494‐503. [PUBMED: 18308741] ">Morelli 2008a</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Urine output 4 hours after study start</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96 mL/h ± 48 vs 130 mL/h ± 76 (P value &lt; 0.05)</p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Norepinephrine + terlipressin</p> <p>(<a href="./references#CD003709-bbs2-0018" title="MorelliA , ErtmerC , LangeM , DuenserM , RehbergS , VanAkenH , et al. Effects of short‐term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. British Journal of Anaesthesia2008;100(4):494‐503. [PUBMED: 18308741] ">Morelli 2008a</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Urine output 4 hours after study start</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96 mL/h ± 48 vs 147 mL/h ± 119 (P value = 0.08)</p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dopamine (<a href="./references#CD003709-bbs2-0017" title="MathurS , DhunnaR , ChakrabortyA . Comparison of norepinephrine and dopamine in the management of septic shock using impedance cardiography. Indian Journal of Critical Care Medicine2007;11(4):186‐91. [EMBASE: 2008016347] ">Mathur 2007</a>) </p> <p> </p> <p> </p> <p> </p> <p> </p> <p>Dopamine (<a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>) </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Post‐treatment urine output</p> <p> </p> <p> </p> <p> </p> <p>Days free of renal support within 28 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.17 mL/kg/h ± 0.47 vs 0.81 mL/kg/h ± 0.75, P value &lt; 0.05</p> <p> </p> <p>14.0 ± 12.3 days vs 12.8 ± 12.4 days, P value = 0.07 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phenylephrine (<a href="./references#CD003709-bbs2-0019" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , LaderchiA , et al. Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. Critical Care2008;12(6)(R143):1‐11. [PUBMED: 19017409 ] ">Morelli 2008b</a>) </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Creatinine clearance</p> <p>Urine output</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference (P value = 0.61)</p> <p>No difference (P value = 0.17)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terlipressin (<a href="./references#CD003709-bbs2-0003" title="BoccaraG , OuattaraA , GodetG , DufresneE , BertrandM , RiouB , et al. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin‐angiotensin system inhibitors. Anesthesiology2003;98:1338‐44. [PUBMED: 12766641] ">Boccara 2003</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Renal failure post‐operatively</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0/10 vs 0/10)</p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terlipressin + norepinephrine and vasopressin + norepinephrine</p> <p>(<a href="./references#CD003709-bbs2-0020" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , CecchiniV , et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Critical Care2009;13(4):R130. [PUBMED: 19664253] ">Morelli 2009</a>) </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Need for renal replacement therapy</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(8/15 vs 4/15 vs 5/15, P value = 0.29)</p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epinephrine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Norepinephrine + dobutamine (<a href="./references#CD003709-bbs2-0011" title="LevyB , BollaertPE , CharpentierC , NaceL , AudibertG , BauerP , et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Medicine1997;23:282‐7. [PUBMED: 9083230] ">Levy 1997</a>) </p> <p> </p> <p> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oliguria reversal</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/12 vs 10/11</p> <p>RR 0.36 (95% CI 0.04 to 3.00)</p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Vasopressin</p> <p> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Norepinephrine (<a href="./references#CD003709-bbs2-0010" title="LauzierF , LevyB , LamarreP , LesurO . Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Medicine2006;32(11):1782‐9. [PUBMED: 17019548] ">Lauzier 2006</a>) </p> <p> </p> <p> </p> <p> </p> <p>Norepinephrine (<a href="./references#CD003709-bbs2-0024" title="GordonAC , RussellJA , WalleyKR , SingerJ , AyersD , StormsMM , et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Medicine2010;36(1):83‐91. GordonAC , WangN , WalleyKR , AshbyD , RussellJA . The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest2012;142(3):593‐605. RussellJA , FjellC , HsuJL , LeeT , BoydJ , ThairS , et al. Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. American Journal of Respiratory and Critical Care Medicine2013;188:356‐64. RussellJA , WalleyKR , GordonAC , CooperDJ , HébertPC , SingerJ , et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Critical Care Medicine2009;37(3):811‐8. [PUBMED: 19237882] RussellJA , WalleyKR , SingerJ , GordonAC , HébertPC , CooperDJ , et al. Vasopressin versus norepinephrine infusion in patients with septic shock. New England Journal of Medicine2008;358(9):877‐87. [PUBMED: 18305265] ">Russell 2008</a>) </p> <p> </p> <p> </p> <p> </p> <p> </p> <p>Norepinephrine vs terlipressin (<a href="./references#CD003709-bbs2-0020" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , CecchiniV , et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Critical Care2009;13(4):R130. [PUBMED: 19664253] ">Morelli 2009</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Creatinine clearance</p> <p> </p> <p> </p> <p> </p> <p>Days alive free of renal replacement therapy</p> <p> </p> <p> </p> <p>Need for renal replacement therapy</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122 mL min<sup>‐1</sup>1.73m<sup>‐2</sup> ± 66 vs 54 mL min<sup>‐1</sup>1.73m<sup>‐2</sup> ± 38, P value &lt; 0.001 </p> <p> </p> <p>25 (IQR 6 to 28) vs 23 (IQR 5 to 28), P value = 0.64</p> <p> </p> <p> </p> <p> </p> <p>8/15 vs 4/15 vs 5/15, P value = 0.29</p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo/non‐protocol vasoactive drugs (<a href="./references#CD003709-bbs2-0004" title="ChoongK , BohnD , FraserDD , GabouryI , HutchisonJS , JoffeAR , et al. Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2009;180(7):632‐9. [PUBMED: 19608718] ">Choong 2009</a>) </p> <p> </p> <p> </p> <p> </p> <p> </p> <p>Placebo/non‐protocol vasoactive drugs (<a href="./references#CD003709-bbs2-0014" title="MalayMB , AshtonRCJr , LandryDW , TownsendRN . Low‐dose vasopressin in the treatment of vasodilatory septic shock. Journal of Trauma1999;47:699‐703. [PUBMED: 10528604] ">Malay 1999</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Urine output</p> <p> </p> <p> </p> <p> </p> <p> </p> <p>Creatinine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7 mL/kg/h (IQR 0.7 to 3.5) vs 1.5 mL/kg/h (IQR 0.7 to 3.7), P value = 0.65</p> <p> </p> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Terlipressin</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Norepinephrine vs vasopressin (<a href="./references#CD003709-bbs2-0020" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , CecchiniV , et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Critical Care2009;13(4):R130. [PUBMED: 19664253] ">Morelli 2009</a>) </p> <p> </p> <p> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Need for renal replacement therapy</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/15 vs 4/15 vs 5/15, P value = 0.29</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo/non‐protocol vasoactive drugs in patients taking norepinephrine (<a href="./references#CD003709-bbs2-0018" title="MorelliA , ErtmerC , LangeM , DuenserM , RehbergS , VanAkenH , et al. Effects of short‐term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. British Journal of Anaesthesia2008;100(4):494‐503. [PUBMED: 18308741] ">Morelli 2008a</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Urine output 4 hours after study start</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147 mL/h ± 119 vs 96 mL/h ± 48 (P value = 0.08)</p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dopamine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Norepinephrine (<a href="./references#CD003709-bbs2-0017" title="MathurS , DhunnaR , ChakrabortyA . Comparison of norepinephrine and dopamine in the management of septic shock using impedance cardiography. Indian Journal of Critical Care Medicine2007;11(4):186‐91. [EMBASE: 2008016347] ">Mathur 2007</a>) </p> <p> </p> <p> </p> <p> </p> <p>Norepinephrine (<a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>) </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Post‐treatment urine output</p> <p> </p> <p> </p> <p>Days free of renal support within 28 days</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.81 mL/kg/h ± 0.75 vs 1.17 mL/kg/h ± 0.47, P value &lt; 0.05</p> <p> </p> <p>12.8 ± 12.4 days vs 14.0 ± 12.3 days, P value = 0.07</p> <p> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*All effects are presented as outcomes in the vasopressor group (left hand column) versus comparator (second column) with risk ratio or P value for differences between groups </p> <p>CI = confidence interval</p> <p>IQR = 25% to 75% interquartile range</p> <p>N/A = not applicable</p> <p>RR = risk ratio</p> </div> </div> <p><i>Norepinephrine was compared with dopamine, vasopressin, phenylephrine and norepinephrine + terlipressin + dobutamine</i> in terms of (1a) ICU LOS (five studies; 2781 participants) (<a href="./references#CD003709-fig-0013" title="">Analysis 1.2</a>). All studies included participants with septic shock. Investigators reported no differences in (1a) ICU LOS and (1b) hospital LOS (<a href="./references#CD003709-fig-0013" title="">Analysis 1.2</a>; <a href="./references#CD003709-fig-0014" title="">Analysis 1.3</a>). Additionally, <a href="./references#CD003709-bbs2-0024" title="GordonAC , RussellJA , WalleyKR , SingerJ , AyersD , StormsMM , et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Medicine2010;36(1):83‐91. GordonAC , WangN , WalleyKR , AshbyD , RussellJA . The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest2012;142(3):593‐605. RussellJA , FjellC , HsuJL , LeeT , BoydJ , ThairS , et al. Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. American Journal of Respiratory and Critical Care Medicine2013;188:356‐64. RussellJA , WalleyKR , GordonAC , CooperDJ , HébertPC , SingerJ , et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Critical Care Medicine2009;37(3):811‐8. [PUBMED: 19237882] RussellJA , WalleyKR , SingerJ , GordonAC , HébertPC , CooperDJ , et al. Vasopressin versus norepinephrine infusion in patients with septic shock. New England Journal of Medicine2008;358(9):877‐87. [PUBMED: 18305265] ">Russell 2008</a> compared norepinephrine versus vasopressin and found no significant differences in (1b) hospital LOS (difference 1.00 day, 95% CI ‐3.01 to 5.01). Further, they reported no significant differences in (1c) vasopressor use (17, interquartile range (IQR) 0 to 24 vs 19, IQR 0 to 24; P value = 0.61) and (1d) days alive free of mechanical ventilation (six, IQR 0 to 20 vs 9, IQR 0 to 20; P value = 0.24). <a href="./references#CD003709-bbs2-0021" title="MyburghJA , HigginsA , JovanovskaA , LipmanJ , RamakrishnanN , SantamariaJ , et al. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Medicine2008;34(12):2226‐34. [PUBMED: 18654759] ">Myburgh 2008</a> compared norepinephrine with epinephrine and found no differences in the number of (1c) vasopressor‐free days (25 days, IQR 14 to 27 vs 26 days, IQR 19 to 27; P value = 0.31). <a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a> compared norepinephrine with dopamine and found no differences in days free of mechanical ventilation within 28 days (9.5 ± 11.4 days vs 8.5 ± 11.2 days; P value = 0.13). They noted a small difference in (1c) days free of any vasopressor therapy within 28 days (14.2 ± 12.3 days vs 12.6 ± 12.5 days; P value = 0.007). The largest study by <a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a> and a smaller study by <a href="./references#CD003709-bbs2-0022" title="PatelGP , GraheJS , SperryM , SinglaS , ElpernE , LateefO , et al. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock2010;33(4):375‐80. [PUBMED: 19851126] ">Patel 2010</a> compared dopamine versus norepinephrine and found significant differences in (1f) arrhythmia (<a href="./references#CD003709-fig-0015" title="">Analysis 1.4</a>), including mostly sinus tachycardia (<a href="./references#CD003709-bbs2-0022" title="PatelGP , GraheJS , SperryM , SinglaS , ElpernE , LateefO , et al. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock2010;33(4):375‐80. [PUBMED: 19851126] ">Patel 2010</a>): 25% versus 6%; atrial fibrillation: 21% versus 11% (<a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>), 13% versus 3% (<a href="./references#CD003709-bbs2-0022" title="PatelGP , GraheJS , SperryM , SinglaS , ElpernE , LateefO , et al. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock2010;33(4):375‐80. [PUBMED: 19851126] ">Patel 2010</a>); ventricular tachycardia (<a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>): 2.4% versus 1.0%; and ventricular fibrillation (<a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>): 1.2% versus 0.5%. <a href="./references#CD003709-bbs2-0003" title="BoccaraG , OuattaraA , GodetG , DufresneE , BertrandM , RiouB , et al. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin‐angiotensin system inhibitors. Anesthesiology2003;98:1338‐44. [PUBMED: 12766641] ">Boccara 2003</a> compared noradrenaline with terlipressin and found no differences in (1b) hospital LOS (5 days, IQR 4 to 7 vs 5 days, IQR 4 to 7). </p> <p><i>Epinephrine was compared with norepinephrine + dobutamine</i> in terms of (1a) ICU LOS in participants with septic shock (one study; 330 participants) (<a href="./references#CD003709-bbs2-0002" title="AnnaneD , VignonP , RenaultA , BollaertPE , CharpentierC , MartinC , et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet2007;370(9588):676‐84. [PUBMED: 17720019] ">Annane 2007</a>). Researchers reported no significant differences in ICU LOS (difference 1.00 day, 95% CI ‐3.01 to 5.01). In the same study (<a href="./references#CD003709-bbs2-0002" title="AnnaneD , VignonP , RenaultA , BollaertPE , CharpentierC , MartinC , et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet2007;370(9588):676‐84. [PUBMED: 17720019] ">Annane 2007</a>), the number of (1c) vasopressor‐free days until day 90 was reported as a median 53 days (IQR 0 to 86) in the epinephrine group and 66 days (IQR 6 to 86) in the norepinephrine + dobutamine group (P value = 0.18). In the same study, duration of (1c) vasopressor support was presented as a Kaplan‐Meier plot (log‐rank test P value = 0.09). <a href="./references#CD003709-bbs2-0021" title="MyburghJA , HigginsA , JovanovskaA , LipmanJ , RamakrishnanN , SantamariaJ , et al. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Medicine2008;34(12):2226‐34. [PUBMED: 18654759] ">Myburgh 2008</a> compared epinephrine with norepinephrine and found no differences in the number of (1c) vasopressor‐free days (26 days, IQR 19 to 27 vs 25 days, IQR 14 to 27; P value = 0.31). </p> <p><i>Vasopressin was compared with placebo (non‐protocol vasoactive drugs), terlipressin and norepinephrine</i> in terms of (1a) ICU LOS (four studies; 1046 participants) (<a href="./references#CD003709-fig-0018" title="">Analysis 3.2</a>). Studies were performed in participants with septic shock (<a href="./references#CD003709-bbs2-0020" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , CecchiniV , et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Critical Care2009;13(4):R130. [PUBMED: 19664253] ">Morelli 2009</a>; <a href="./references#CD003709-bbs2-0024" title="GordonAC , RussellJA , WalleyKR , SingerJ , AyersD , StormsMM , et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Medicine2010;36(1):83‐91. GordonAC , WangN , WalleyKR , AshbyD , RussellJA . The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest2012;142(3):593‐605. RussellJA , FjellC , HsuJL , LeeT , BoydJ , ThairS , et al. Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. American Journal of Respiratory and Critical Care Medicine2013;188:356‐64. RussellJA , WalleyKR , GordonAC , CooperDJ , HébertPC , SingerJ , et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Critical Care Medicine2009;37(3):811‐8. [PUBMED: 19237882] RussellJA , WalleyKR , SingerJ , GordonAC , HébertPC , CooperDJ , et al. Vasopressin versus norepinephrine infusion in patients with septic shock. New England Journal of Medicine2008;358(9):877‐87. [PUBMED: 18305265] ">Russell 2008</a>) and paediatric vasodilatory shock (<a href="./references#CD003709-bbs2-0004" title="ChoongK , BohnD , FraserDD , GabouryI , HutchisonJS , JoffeAR , et al. Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2009;180(7):632‐9. [PUBMED: 19608718] ">Choong 2009</a>). In no comparison was a significant difference found. Vasopressin was compared with norepinephrine in terms of (1b) hospital LOS in one study (<a href="./references#CD003709-bbs2-0024" title="GordonAC , RussellJA , WalleyKR , SingerJ , AyersD , StormsMM , et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Medicine2010;36(1):83‐91. GordonAC , WangN , WalleyKR , AshbyD , RussellJA . The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest2012;142(3):593‐605. RussellJA , FjellC , HsuJL , LeeT , BoydJ , ThairS , et al. Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. American Journal of Respiratory and Critical Care Medicine2013;188:356‐64. RussellJA , WalleyKR , GordonAC , CooperDJ , HébertPC , SingerJ , et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Critical Care Medicine2009;37(3):811‐8. [PUBMED: 19237882] RussellJA , WalleyKR , SingerJ , GordonAC , HébertPC , CooperDJ , et al. Vasopressin versus norepinephrine infusion in patients with septic shock. New England Journal of Medicine2008;358(9):877‐87. [PUBMED: 18305265] ">Russell 2008</a>), and no significant difference was found (difference 1.00 day, 95% CI ‐3.01 to 5.01). Further, researchers noted no significant differences in (1c) vasopressor use (19, IQR 0 to 24 vs 17, IQR 0 to 24; P value = 0.61) and (1d) days alive free of mechanical ventilation (9, IQR 0 to 20 vs 6, IQR 0 to 20; P value = 0.24). <a href="./references#CD003709-bbs2-0004" title="ChoongK , BohnD , FraserDD , GabouryI , HutchisonJS , JoffeAR , et al. Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2009;180(7):632‐9. [PUBMED: 19608718] ">Choong 2009</a> compared vasopressin with placebo/non‐protocol vasoactive drugs in paediatric participants and found no differences in (1c) time to vasopressor discontinuation (50 hours, IQR 30 to 219 vs 47, IQR 26 to 87; P value = 0.85) and (1d) mechanical ventilation‐free days until day 30 (17 days, IQR 0 to 24 vs 23 days, IQR 13 to 26; P value = 0.15). <a href="./references#CD003709-bbs2-0007" title="HanX‐D , SunH , HuangX‐Y , ZhangS‐Y , WangY‐D , RenK , et al. [A clinical study of pituitrin versus norepinephrine in the treatment of patients with septic shock]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue/Chinese Critical Care Medicine/Zhongguo Weizhongbing Jijiuyixue2012;24(1):33‐7. ">Han 2012</a> compared vasopressin with non‐protocol vasoactive drugs and found no differences in (1a) LOS (five days (IQR 3 to 8) vs five days (IQR 3 to 8) and (1d) duration of mechanical ventilation (4 days (IQR 3 to 6) vs 4 days (IQR 2 to 5); P value &gt; 0.05), </p> <p><i>Terlipressin was compared with placebo (non‐protocol vasoactive drugs)</i> (six studies; 185 participants) (<a href="./references#CD003709-bbs2-0018" title="MorelliA , ErtmerC , LangeM , DuenserM , RehbergS , VanAkenH , et al. Effects of short‐term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. British Journal of Anaesthesia2008;100(4):494‐503. [PUBMED: 18308741] ">Morelli 2008a</a>; <a href="./references#CD003709-bbs2-0020" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , CecchiniV , et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Critical Care2009;13(4):R130. [PUBMED: 19664253] ">Morelli 2009</a>; <a href="./references#CD003709-bbs2-0027" title="SvobodaP , ScheerP , KantorovaI , DoubekJ , DudraJ , RadvanM , et al. Terlipressin in the treatment of late phase catecholamine‐resistant septic shock. Hepato‐Gastroenterology2012;59(116):1043‐7. ">Svoboda 2012</a>; <a href="./references#CD003709-bbs2-0028" title="YildizdasD , YapiciogluH , CelikU , SertdemirY , AlhanE . Terlipressin as a rescue therapy for catecholamine‐resistant septic shock in children. Intensive Care Medicine2008;34(3):511‐7. [PUBMED: 18092150] ">Yildizdas 2008</a>), dopamine (<a href="./references#CD003709-bbs2-0008" title="HuaF , WangX , ZhuL . Terlipressin decreases vascular endothelial growth factor expression and improves oxygenation in patients with acute respiratory distress syndrome and shock. Journal of Emergency Medicine2013;44(2):434‐9. ">Hua 2013</a>), norepinephrine (<a href="./references#CD003709-bbs2-0003" title="BoccaraG , OuattaraA , GodetG , DufresneE , BertrandM , RiouB , et al. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin‐angiotensin system inhibitors. Anesthesiology2003;98:1338‐44. [PUBMED: 12766641] ">Boccara 2003</a>) and vasopressin (<a href="./references#CD003709-bbs2-0020" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , CecchiniV , et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Critical Care2009;13(4):R130. [PUBMED: 19664253] ">Morelli 2009</a>) in terms of (1a) ICU LOS (<a href="./references#CD003709-fig-0020" title="">Analysis 4.2</a>), (1b) hospital LOS (<a href="./references#CD003709-fig-0021" title="">Analysis 4.3</a>), (1c) pressor‐free days until day 28 (<a href="./references#CD003709-fig-0023" title="">Analysis 4.5</a>), (1d) duration of mechanical ventilation (<a href="./references#CD003709-fig-0022" title="">Analysis 4.4</a>) and (1f) serious adverse events (<a href="./references#CD003709-fig-0024" title="">Analysis 4.6</a>). In comparisons summarized as 'versus placebo/non‐protocol vasoactive drugs', one study actually used placebo (<a href="./references#CD003709-bbs2-0028" title="YildizdasD , YapiciogluH , CelikU , SertdemirY , AlhanE . Terlipressin as a rescue therapy for catecholamine‐resistant septic shock in children. Intensive Care Medicine2008;34(3):511‐7. [PUBMED: 18092150] ">Yildizdas 2008</a>); in two studies (<a href="./references#CD003709-bbs2-0018" title="MorelliA , ErtmerC , LangeM , DuenserM , RehbergS , VanAkenH , et al. Effects of short‐term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. British Journal of Anaesthesia2008;100(4):494‐503. [PUBMED: 18308741] ">Morelli 2008a</a>; <a href="./references#CD003709-bbs2-0020" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , CecchiniV , et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Critical Care2009;13(4):R130. [PUBMED: 19664253] ">Morelli 2009</a>), fixed‐dose terlipressin + variable dose norepinephrine was compared with variable‐dose norepinephrine. Studies were performed in participants with septic shock (<a href="./references#CD003709-bbs2-0018" title="MorelliA , ErtmerC , LangeM , DuenserM , RehbergS , VanAkenH , et al. Effects of short‐term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. British Journal of Anaesthesia2008;100(4):494‐503. [PUBMED: 18308741] ">Morelli 2008a</a>; <a href="./references#CD003709-bbs2-0020" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , CecchiniV , et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Critical Care2009;13(4):R130. [PUBMED: 19664253] ">Morelli 2009</a>; <a href="./references#CD003709-bbs2-0027" title="SvobodaP , ScheerP , KantorovaI , DoubekJ , DudraJ , RadvanM , et al. Terlipressin in the treatment of late phase catecholamine‐resistant septic shock. Hepato‐Gastroenterology2012;59(116):1043‐7. ">Svoboda 2012</a>) and in children with catecholamine‐resistant shock (<a href="./references#CD003709-bbs2-0028" title="YildizdasD , YapiciogluH , CelikU , SertdemirY , AlhanE . Terlipressin as a rescue therapy for catecholamine‐resistant septic shock in children. Intensive Care Medicine2008;34(3):511‐7. [PUBMED: 18092150] ">Yildizdas 2008</a>), peri‐operative refractory hypotension (<a href="./references#CD003709-bbs2-0003" title="BoccaraG , OuattaraA , GodetG , DufresneE , BertrandM , RiouB , et al. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin‐angiotensin system inhibitors. Anesthesiology2003;98:1338‐44. [PUBMED: 12766641] ">Boccara 2003</a>) and acute respiratory distress syndrome (<a href="./references#CD003709-bbs2-0008" title="HuaF , WangX , ZhuL . Terlipressin decreases vascular endothelial growth factor expression and improves oxygenation in patients with acute respiratory distress syndrome and shock. Journal of Emergency Medicine2013;44(2):434‐9. ">Hua 2013</a>). In no comparison was a significant difference found. </p> <p><i>Dopamine was compared with norepinephrine</i> (two studies; 1931 participants; <a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>; <a href="./references#CD003709-bbs2-0022" title="PatelGP , GraheJS , SperryM , SinglaS , ElpernE , LateefO , et al. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock2010;33(4):375‐80. [PUBMED: 19851126] ">Patel 2010</a>) <i>and terlipressin</i> (one study; 32 participants) <a href="./references#CD003709-bbs2-0008" title="HuaF , WangX , ZhuL . Terlipressin decreases vascular endothelial growth factor expression and improves oxygenation in patients with acute respiratory distress syndrome and shock. Journal of Emergency Medicine2013;44(2):434‐9. ">Hua 2013</a>) in terms of (1a) ICU LOS (<a href="./references#CD003709-fig-0026" title="">Analysis 5.2</a>), (1b) hospital LOS (<a href="./references#CD003709-fig-0027" title="">Analysis 5.3</a>), (1c) pressor‐free days until day 28 (<a href="./references#CD003709-fig-0028" title="">Analysis 5.4</a>) and (1f) arrhythmia (<a href="./references#CD003709-fig-0029" title="">Analysis 5.5</a>). <a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a> and <a href="./references#CD003709-bbs2-0022" title="PatelGP , GraheJS , SperryM , SinglaS , ElpernE , LateefO , et al. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock2010;33(4):375‐80. [PUBMED: 19851126] ">Patel 2010</a> compared dopamine with norepinephrine and found no differences in (1a) ICU LOS and (1b) hospital LOS (<a href="./references#CD003709-fig-0026" title="">Analysis 5.2</a>; <a href="./references#CD003709-fig-0027" title="">Analysis 5.3</a>). Further, <a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a> assessed (1d) days free of mechanical ventilation within 28 days (8.5 ± 11.2 days vs 9.5 ± 11.4 days; P value = 0.13). <a href="./references#CD003709-bbs2-0008" title="HuaF , WangX , ZhuL . Terlipressin decreases vascular endothelial growth factor expression and improves oxygenation in patients with acute respiratory distress syndrome and shock. Journal of Emergency Medicine2013;44(2):434‐9. ">Hua 2013</a> compared dopamine with noradrenaline for duration of mechanical ventilation (5.3 ± 3.6 days vs 4.3 ± 2.5 days; difference 1.00, 95% CI ‐1.15 to 3.15). </p> <p><a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a> reported a small difference in (1c) days free of any vasopressor therapy within 28 days (12.6 ± 12.5 days vs 14.2 ± 12.3 days; P value = 0.007; <a href="./references#CD003709-fig-0028" title="">Analysis 5.4</a>). The largest study by <a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a> and a smaller study by <a href="./references#CD003709-bbs2-0022" title="PatelGP , GraheJS , SperryM , SinglaS , ElpernE , LateefO , et al. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock2010;33(4):375‐80. [PUBMED: 19851126] ">Patel 2010</a> compared dopamine versus norepinephrine and found significant differences in (1f) arrhythmias (<a href="./references#CD003709-fig-0029" title="">Analysis 5.5</a>), including mostly sinus tachycardia (<a href="./references#CD003709-bbs2-0022" title="PatelGP , GraheJS , SperryM , SinglaS , ElpernE , LateefO , et al. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock2010;33(4):375‐80. [PUBMED: 19851126] ">Patel 2010</a>): 25% versus 6%; atrial fibrillation: 21% versus 11% (<a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>), 13% versus 3% (<a href="./references#CD003709-bbs2-0022" title="PatelGP , GraheJS , SperryM , SinglaS , ElpernE , LateefO , et al. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock2010;33(4):375‐80. [PUBMED: 19851126] ">Patel 2010</a>); ventricular tachycardia (<a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>): 2.4% versus 1.0%; and ventricular fibrillation (<a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>): 1.2% versus 0.5%. </p> <p><i>Phenylephrine was compared with norepinephrine in participants with septic shock</i> (one study; 32 participants) (<a href="./references#CD003709-bbs2-0019" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , LaderchiA , et al. Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. Critical Care2008;12(6)(R143):1‐11. [PUBMED: 19017409 ] ">Morelli 2008b</a>). Mean (1a) ICU LOS was 16 ± 13 versus 16 ± 10 days (difference 0.00 days, 95% CI ‐8.27 to 8.27). </p> </section> <section id="CD003709-sec-0081"> <h6 class="title">Measures of health‐related quality of life and measures of anxiety and depression</h6> <p>In no studies were measures of health‐related quality of life assessed. In no studies were measures of anxiety and depression assessed. </p> </section> </section> </section> <section id="CD003709-sec-0082"> <h4 class="title">Subgroup analysis</h4> <p>Among the network of vasopressors versus combinations of vasopressors, 18 studies provided data on participants with septic shock. In 17 studies, septic shock was an eligibility criterion; in one study, data on a subgroup of participants with septic shock were available for day 28 (<a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>). Overall 20 study arms included 2706 participants with 1370 mortality outcomes. The network forest plot is presented as <a href="#CD003709-fig-0011">Figure 11</a>. In this subgroup analysis, dopamine was inferior to norepinephrine (dopamine vs norepinephrine RR 1.11, 95% CI 1.005 to 1.23). </p> <div class="figure" id="CD003709-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Subgroup analysis in patients with septic shock: network forest plot comparing 7 vasopressor regimens vs norepinephrine (reference) from 18 studies with 20 pair‐wise comparisons. Heterogeneity/inconsistency: tau2 &lt; 0.0001; I2 statistic = 0%. Test of heterogeneity/inconsistency: Q = 5.21, d.f. = 14, P value = 0.98; 'NPVD' denotes non‐protocol vasoactive drugs with or without placebo. RR denotes risk ratio, as calculated by a fixed‐effect model. RR &gt; 1 indicates increased mortality risk; RR &lt; 1 indicates reduced mortality risk vs norepinephrine (reference)." data-id="CD003709-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis in patients with septic shock: network forest plot comparing 7 vasopressor regimens vs norepinephrine (reference) from 18 studies with 20 pair‐wise comparisons. Heterogeneity/inconsistency: tau<sup>2</sup> &lt; 0.0001; I<sup>2</sup> statistic = 0%. Test of heterogeneity/inconsistency: Q = 5.21, d.f. = 14, P value = 0.98; 'NPVD' denotes non‐protocol vasoactive drugs with or without placebo. RR denotes risk ratio, as calculated by a fixed‐effect model. RR &gt; 1 indicates increased mortality risk; RR &lt; 1 indicates reduced mortality risk vs norepinephrine (reference). </p> </div> </div> </div> </section> <section id="CD003709-sec-0083"> <h4 class="title">Sensitivity analysis</h4> <p>We classified 11 studies (1148 participants) as having low risk of bias for the primary outcome of mortality (<a href="./references#CD003709-bbs2-0002" title="AnnaneD , VignonP , RenaultA , BollaertPE , CharpentierC , MartinC , et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet2007;370(9588):676‐84. [PUBMED: 17720019] ">Annane 2007</a>; <a href="./references#CD003709-bbs2-0003" title="BoccaraG , OuattaraA , GodetG , DufresneE , BertrandM , RiouB , et al. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin‐angiotensin system inhibitors. Anesthesiology2003;98:1338‐44. [PUBMED: 12766641] ">Boccara 2003</a>; <a href="./references#CD003709-bbs2-0004" title="ChoongK , BohnD , FraserDD , GabouryI , HutchisonJS , JoffeAR , et al. Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2009;180(7):632‐9. [PUBMED: 19608718] ">Choong 2009</a>; <a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>; <a href="./references#CD003709-bbs2-0010" title="LauzierF , LevyB , LamarreP , LesurO . Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Medicine2006;32(11):1782‐9. [PUBMED: 17019548] ">Lauzier 2006</a>; <a href="./references#CD003709-bbs2-0014" title="MalayMB , AshtonRCJr , LandryDW , TownsendRN . Low‐dose vasopressin in the treatment of vasodilatory septic shock. Journal of Trauma1999;47:699‐703. [PUBMED: 10528604] ">Malay 1999</a>; <a href="./references#CD003709-bbs2-0019" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , LaderchiA , et al. Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. Critical Care2008;12(6)(R143):1‐11. [PUBMED: 19017409 ] ">Morelli 2008b</a>; <a href="./references#CD003709-bbs2-0021" title="MyburghJA , HigginsA , JovanovskaA , LipmanJ , RamakrishnanN , SantamariaJ , et al. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Medicine2008;34(12):2226‐34. [PUBMED: 18654759] ">Myburgh 2008</a>; <a href="./references#CD003709-bbs2-0024" title="GordonAC , RussellJA , WalleyKR , SingerJ , AyersD , StormsMM , et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Medicine2010;36(1):83‐91. GordonAC , WangN , WalleyKR , AshbyD , RussellJA . The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest2012;142(3):593‐605. RussellJA , FjellC , HsuJL , LeeT , BoydJ , ThairS , et al. Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. American Journal of Respiratory and Critical Care Medicine2013;188:356‐64. RussellJA , WalleyKR , GordonAC , CooperDJ , HébertPC , SingerJ , et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Critical Care Medicine2009;37(3):811‐8. [PUBMED: 19237882] RussellJA , WalleyKR , SingerJ , GordonAC , HébertPC , CooperDJ , et al. Vasopressin versus norepinephrine infusion in patients with septic shock. New England Journal of Medicine2008;358(9):877‐87. [PUBMED: 18305265] ">Russell 2008</a>; <a href="./references#CD003709-bbs2-0026" title="SeguinP , LaviolleB , GuinetP , MorelI , MalledantY , BellissantE . Dopexamine and norepinephrine versus epinephrine on gastric perfusion in patients with septic shock: a randomized study [NCT00134212]. Critical Care2006;10(1)(R32):1‐8. ">Seguin 2006</a>; <a href="./references#CD003709-bbs2-0027" title="SvobodaP , ScheerP , KantorovaI , DoubekJ , DudraJ , RadvanM , et al. Terlipressin in the treatment of late phase catecholamine‐resistant septic shock. Hepato‐Gastroenterology2012;59(116):1043‐7. ">Svoboda 2012</a>); for the remaining studies, at least some risk of bias could not be excluded because information was lacking, or because high risk of bias was indicated by the study design. </p> <p>In no comparisons did within‐study risk of bias seem to affect overall estimates (<a href="./references#CD003709-fig-0030" title="">Analysis 6.1</a>; <a href="./references#CD003709-fig-0031" title="">Analysis 7.1</a>; <a href="./references#CD003709-fig-0032" title="">Analysis 8.1</a>; <a href="./references#CD003709-fig-0033" title="">Analysis 9.1</a>; <a href="./references#CD003709-fig-0034" title="">Analysis 10.1</a>). </p> <p>In all comparisons, heterogeneous mortality outcomes were included (<a href="./references#CD003709-fig-0012" title="">Analysis 1.1</a>; <a href="./references#CD003709-fig-0016" title="">Analysis 2.1</a>; <a href="./references#CD003709-fig-0017" title="">Analysis 3.1</a>; <a href="./references#CD003709-fig-0019" title="">Analysis 4.1</a>; <a href="./references#CD003709-fig-0025" title="">Analysis 5.1</a>). </p> <p>For the comparison of norepinephrine versus dopamine (six studies; 1400 participants) (<a href="./references#CD003709-fig-0012" title="">Analysis 1.1</a>), effects of using the latest mortality outcome yielded an RR of 0.93 (95% CI 0.86 to 1.01) as compared with an RR of 0.92 (95% CI 0.85 to 1.01; analysis not shown) if 28‐day mortality, hospital mortality and undetermined periods were acknowledged. </p> <p>For the comparison of epinephrine versus norepinephrine + dobutamine (four studies; 412 participants) (<a href="./references#CD003709-fig-0016" title="">Analysis 2.1</a>), effects of using the latest mortality outcome included an RR of 1.04 (95% CI 0.86 to 1.26) as compared with an RR of 1.19 (95% CI 0.92 to 1.54; analysis not shown) if 28‐day mortality and undetermined periods were acknowledged. </p> <p>For the comparison of vasopressin versus non‐protocol vasoactive drugs (five studies; 296 participants) (<a href="./references#CD003709-fig-0017" title="">Analysis 3.1</a>), effects of using the latest mortality outcome included an RR of 0.92 (95% CI 0.69 to 1.22) as compared with an RR of 0.90 (95% CI 0.06 to 12.64; analysis not shown) if restricted to studies reporting 24‐hour mortality (<a href="./references#CD003709-bbs2-0006" title="DünserMW , MayrAJ , UlmerH , KnotzerH , SumannG , PajkW , et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation2003;107:2313‐9. [PUBMED: 12732600] ">Dünser 2003</a>; <a href="./references#CD003709-bbs2-0014" title="MalayMB , AshtonRCJr , LandryDW , TownsendRN . Low‐dose vasopressin in the treatment of vasodilatory septic shock. Journal of Trauma1999;47:699‐703. [PUBMED: 10528604] ">Malay 1999</a>), and an RR of 1.05 (95% CI 0.63 to 1.75; analysis not shown) if restricted to studies reporting 30‐day or ICU mortality (<a href="./references#CD003709-bbs2-0004" title="ChoongK , BohnD , FraserDD , GabouryI , HutchisonJS , JoffeAR , et al. Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2009;180(7):632‐9. [PUBMED: 19608718] ">Choong 2009</a>; <a href="./references#CD003709-bbs2-0006" title="DünserMW , MayrAJ , UlmerH , KnotzerH , SumannG , PajkW , et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation2003;107:2313‐9. [PUBMED: 12732600] ">Dünser 2003</a>; <a href="./references#CD003709-bbs2-0020" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , CecchiniV , et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Critical Care2009;13(4):R130. [PUBMED: 19664253] ">Morelli 2009</a>). </p> <p>For the comparison of norepinephrine versus vasopressin (three studies; 812 participants) (<a href="./references#CD003709-fig-0012" title="">Analysis 1.1</a>), effects of using the latest mortality outcome included an RR of 1.12 (95% CI 0.98 to 1.29) as compared with an RR of 1.10 (95% CI 0.94 to 1.30; analysis not shown) if 28‐day mortality and ICU mortality were acknowledged. In the comparison of terlipressin and non‐protocol vasoactive drugs, ICU mortality and 90‐day mortality were combined. Choosing time points other than 90 days had no significant impact on the estimates (<a href="./references#CD003709-fig-0019" title="">Analysis 4.1</a>). </p> <p>In summary, estimates remained virtually unchanged if definitions of mortality were changed, or if studies with different mortality definitions were compared. </p> </section> <section id="CD003709-sec-0084"> <h4 class="title">Assessment of reporting bias</h4> <p>Funnel plots of the primary outcome of all comparisons did not suggest major asymmetry. We present the funnel plot for comparison 1.1 (see <a href="#CD003709-fig-0005">Figure 5</a>). We identified too few studies per comparison to sensibly perform a formal test for funnel plot asymmetry. Overall, however, reporting bias does not seem to be a major problem in this review and in particular does not explain the results. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003709-sec-0085" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003709-sec-0085">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003709-sec-0131">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003709-sec-0085"></div> <section id="CD003709-sec-0086"> <h3 class="title" id="CD003709-sec-0086">Summary of main results</h3> <p>We found 28 studies that fulfilled our inclusion criteria. Overall 3497 participants with 1773 mortality outcomes were analysed. Information was derived mainly from six studies (<a href="./references#CD003709-bbs2-0002" title="AnnaneD , VignonP , RenaultA , BollaertPE , CharpentierC , MartinC , et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet2007;370(9588):676‐84. [PUBMED: 17720019] ">Annane 2007</a>; <a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>; <a href="./references#CD003709-bbs2-0007" title="HanX‐D , SunH , HuangX‐Y , ZhangS‐Y , WangY‐D , RenK , et al. [A clinical study of pituitrin versus norepinephrine in the treatment of patients with septic shock]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue/Chinese Critical Care Medicine/Zhongguo Weizhongbing Jijiuyixue2012;24(1):33‐7. ">Han 2012</a>; <a href="./references#CD003709-bbs2-0021" title="MyburghJA , HigginsA , JovanovskaA , LipmanJ , RamakrishnanN , SantamariaJ , et al. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Medicine2008;34(12):2226‐34. [PUBMED: 18654759] ">Myburgh 2008</a>; <a href="./references#CD003709-bbs2-0022" title="PatelGP , GraheJS , SperryM , SinglaS , ElpernE , LateefO , et al. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock2010;33(4):375‐80. [PUBMED: 19851126] ">Patel 2010</a>; <a href="./references#CD003709-bbs2-0024" title="GordonAC , RussellJA , WalleyKR , SingerJ , AyersD , StormsMM , et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Medicine2010;36(1):83‐91. GordonAC , WangN , WalleyKR , AshbyD , RussellJA . The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest2012;142(3):593‐605. RussellJA , FjellC , HsuJL , LeeT , BoydJ , ThairS , et al. Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. American Journal of Respiratory and Critical Care Medicine2013;188:356‐64. RussellJA , WalleyKR , GordonAC , CooperDJ , HébertPC , SingerJ , et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Critical Care Medicine2009;37(3):811‐8. [PUBMED: 19237882] RussellJA , WalleyKR , SingerJ , GordonAC , HébertPC , CooperDJ , et al. Vasopressin versus norepinephrine infusion in patients with septic shock. New England Journal of Medicine2008;358(9):877‐87. [PUBMED: 18305265] ">Russell 2008</a>) that reported on 2797 participants (80% of total) and 1463 mortality outcomes (83% of total mortality outcomes) across all comparisons. Six different vasopressors, given alone or in combination with dobutamine or dopexamine, were compared in 12 different combinations. </p> <p>All 28 studies reported mortality outcomes. Length of stay (LOS) was reported in 12 studies (<a href="./references#CD003709-bbs2-0002" title="AnnaneD , VignonP , RenaultA , BollaertPE , CharpentierC , MartinC , et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet2007;370(9588):676‐84. [PUBMED: 17720019] ">Annane 2007</a>; <a href="./references#CD003709-bbs2-0003" title="BoccaraG , OuattaraA , GodetG , DufresneE , BertrandM , RiouB , et al. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin‐angiotensin system inhibitors. Anesthesiology2003;98:1338‐44. [PUBMED: 12766641] ">Boccara 2003</a>; <a href="./references#CD003709-bbs2-0004" title="ChoongK , BohnD , FraserDD , GabouryI , HutchisonJS , JoffeAR , et al. Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2009;180(7):632‐9. [PUBMED: 19608718] ">Choong 2009</a>; <a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>; <a href="./references#CD003709-bbs2-0007" title="HanX‐D , SunH , HuangX‐Y , ZhangS‐Y , WangY‐D , RenK , et al. [A clinical study of pituitrin versus norepinephrine in the treatment of patients with septic shock]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue/Chinese Critical Care Medicine/Zhongguo Weizhongbing Jijiuyixue2012;24(1):33‐7. ">Han 2012</a>; <a href="./references#CD003709-bbs2-0008" title="HuaF , WangX , ZhuL . Terlipressin decreases vascular endothelial growth factor expression and improves oxygenation in patients with acute respiratory distress syndrome and shock. Journal of Emergency Medicine2013;44(2):434‐9. ">Hua 2013</a>; <a href="./references#CD003709-bbs2-0018" title="MorelliA , ErtmerC , LangeM , DuenserM , RehbergS , VanAkenH , et al. Effects of short‐term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. British Journal of Anaesthesia2008;100(4):494‐503. [PUBMED: 18308741] ">Morelli 2008a</a>; <a href="./references#CD003709-bbs2-0019" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , LaderchiA , et al. Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. Critical Care2008;12(6)(R143):1‐11. [PUBMED: 19017409 ] ">Morelli 2008b</a>; <a href="./references#CD003709-bbs2-0020" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , CecchiniV , et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Critical Care2009;13(4):R130. [PUBMED: 19664253] ">Morelli 2009</a>; <a href="./references#CD003709-bbs2-0022" title="PatelGP , GraheJS , SperryM , SinglaS , ElpernE , LateefO , et al. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock2010;33(4):375‐80. [PUBMED: 19851126] ">Patel 2010</a>; <a href="./references#CD003709-bbs2-0024" title="GordonAC , RussellJA , WalleyKR , SingerJ , AyersD , StormsMM , et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Medicine2010;36(1):83‐91. GordonAC , WangN , WalleyKR , AshbyD , RussellJA . The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest2012;142(3):593‐605. RussellJA , FjellC , HsuJL , LeeT , BoydJ , ThairS , et al. Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. American Journal of Respiratory and Critical Care Medicine2013;188:356‐64. RussellJA , WalleyKR , GordonAC , CooperDJ , HébertPC , SingerJ , et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Critical Care Medicine2009;37(3):811‐8. [PUBMED: 19237882] RussellJA , WalleyKR , SingerJ , GordonAC , HébertPC , CooperDJ , et al. Vasopressin versus norepinephrine infusion in patients with septic shock. New England Journal of Medicine2008;358(9):877‐87. [PUBMED: 18305265] ">Russell 2008</a>; <a href="./references#CD003709-bbs2-0028" title="YildizdasD , YapiciogluH , CelikU , SertdemirY , AlhanE . Terlipressin as a rescue therapy for catecholamine‐resistant septic shock in children. Intensive Care Medicine2008;34(3):511‐7. [PUBMED: 18092150] ">Yildizdas 2008</a>). Other morbidity outcomes were reported in a variable and heterogeneous way. No data were available on quality of life nor on anxiety and depression outcomes. </p> <p>In summary, investigators reported no differences in mortality outcomes in any of the studies comparing different vasopressors or combinations. In particular, for the comparison between dopamine and norepinephrine, which included most participants, researchers observed no differences in mortality (<a href="./full#CD003709-tbl-0001">summary of findings Table for the main comparison</a>). The same results were obtained by our network meta‐analysis (<a href="#CD003709-fig-0009">Figure 9</a>; <a href="#CD003709-fig-0010">Figure 10</a>). </p> <p><a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a> and <a href="./references#CD003709-bbs2-0022" title="PatelGP , GraheJS , SperryM , SinglaS , ElpernE , LateefO , et al. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock2010;33(4):375‐80. [PUBMED: 19851126] ">Patel 2010</a> when comparing dopamine versus norepinephrine found higher risk of arrhythmia in the dopamine group (<a href="./references#CD003709-fig-0015" title="">Analysis 1.4</a>). In total, 347 arrhythmia episodes were documented in 1891 participants (<a href="./full#CD003709-tbl-0001">summary of findings Table for the main comparison</a>). Other adverse events such as new infectious episodes, skin ischaemias and arterial occlusion did not differ between intervention groups. </p> <p>We found no differences in other relevant morbidity outcomes within any comparisons. This finding was consistent among the few large studies identified, as well as in studies with different levels of within‐study bias risk. Overall the quality of the evidence ranged from high to very low across comparisons. </p> <p>Our review included no pre‐defined subgroup analyses; therefore, we cannot make strong inferences about whether effects of vasopressors differ across populations with different causes of shock. However, in one of the large trials comparing norepinephrine versus dopamine (<a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>), a pre‐defined subgroup analysis according to shock type revealed a beneficial effect on 28‐day mortality among participants with cardiogenic shock treated with norepinephrine. However, although subgroups were pre‐defined, randomization was not stratified; moreover the test for subgroup differences (P value = 0.87) suggests that this subgroup effect can be explained by chance alone. </p> <p>No evidence suggests that any of the investigated vasopressors are clearly superior over others. </p> <p>Nine studies can be regarded as placebo/non‐protocol vasoactive drug controlled add‐on studies. <a href="./references#CD003709-bbs2-0018" title="MorelliA , ErtmerC , LangeM , DuenserM , RehbergS , VanAkenH , et al. Effects of short‐term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. British Journal of Anaesthesia2008;100(4):494‐503. [PUBMED: 18308741] ">Morelli 2008a</a> and <a href="./references#CD003709-bbs2-0020" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , CecchiniV , et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Critical Care2009;13(4):R130. [PUBMED: 19664253] ">Morelli 2009</a> compared norepinephrine versus norepinephrine + terlipressin and dobutamine, which might be seen as add‐on therapy of terlipressin + dobutamine versus no extra vasopressor in participants receiving norepinephrine. Investigators reported no differences in mortality or in LOS. Likewise <a href="./references#CD003709-bbs2-0020" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , CecchiniV , et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Critical Care2009;13(4):R130. [PUBMED: 19664253] ">Morelli 2009</a> compared a vasopressin + norepinephrine arm versus a norepinephrine alone arm. This add‐on vasopressin therapy did not have an effect. <a href="./references#CD003709-bbs2-0028" title="YildizdasD , YapiciogluH , CelikU , SertdemirY , AlhanE . Terlipressin as a rescue therapy for catecholamine‐resistant septic shock in children. Intensive Care Medicine2008;34(3):511‐7. [PUBMED: 18092150] ">Yildizdas 2008</a> compared terlipressin versus placebo in paediatric patients with septic shock who did not respond to fluid resuscitation and high‐dose catecholamines, and found no differences in mortality but significant reduction of LOS. This effect was no longer found when data were combined with those from <a href="./references#CD003709-bbs2-0018" title="MorelliA , ErtmerC , LangeM , DuenserM , RehbergS , VanAkenH , et al. Effects of short‐term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. British Journal of Anaesthesia2008;100(4):494‐503. [PUBMED: 18308741] ">Morelli 2008a</a>. <a href="./references#CD003709-bbs2-0014" title="MalayMB , AshtonRCJr , LandryDW , TownsendRN . Low‐dose vasopressin in the treatment of vasodilatory septic shock. Journal of Trauma1999;47:699‐703. [PUBMED: 10528604] ">Malay 1999</a> and <a href="./references#CD003709-bbs2-0007" title="HanX‐D , SunH , HuangX‐Y , ZhangS‐Y , WangY‐D , RenK , et al. [A clinical study of pituitrin versus norepinephrine in the treatment of patients with septic shock]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue/Chinese Critical Care Medicine/Zhongguo Weizhongbing Jijiuyixue2012;24(1):33‐7. ">Han 2012</a> studied vasopressin versus non‐protocol vasoactive drugs in participants with septic shock who were already taking catecholamines; <a href="./references#CD003709-bbs2-0006" title="DünserMW , MayrAJ , UlmerH , KnotzerH , SumannG , PajkW , et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation2003;107:2313‐9. [PUBMED: 12732600] ">Dünser 2003</a> and <a href="./references#CD003709-bbs2-0027" title="SvobodaP , ScheerP , KantorovaI , DoubekJ , DudraJ , RadvanM , et al. Terlipressin in the treatment of late phase catecholamine‐resistant septic shock. Hepato‐Gastroenterology2012;59(116):1043‐7. ">Svoboda 2012</a> compared norepinephrine versus norepinephrine + vasopressin; <a href="./references#CD003709-bbs2-0004" title="ChoongK , BohnD , FraserDD , GabouryI , HutchisonJS , JoffeAR , et al. Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2009;180(7):632‐9. [PUBMED: 19608718] ">Choong 2009</a> compared vasopressin versus placebo in paediatric patients with vasodilatory shock after volume resuscitation under catecholamines. In none of these comparisons could a significant effect on mortality or morbidity be found. This result must not be interpreted as showing no effects of vasopressors versus placebo at all. Moreover, these results indicate that in participants requiring massive vasoactive support, additional vasopressors have no major effect. It is noteworthy that this evidence on placebo/non‐protocol vasoactive drug comparisons comes from a few small studies only and therefore must be interpreted with additional caution. </p> </section> <section id="CD003709-sec-0087"> <h3 class="title" id="CD003709-sec-0087">Overall completeness and applicability of evidence</h3> <p>Even though 28 studies met our inclusion criteria, numerous comparisons were necessary. Accordingly, the actual number of studies per comparison, as well as the number of participants in most studies, was small. Therefore, some comparisons resulted in under‐powered effects. Also only limited subgroup analyses could be performed to investigate potential sources of heterogeneity. </p> </section> <section id="CD003709-sec-0088"> <h3 class="title" id="CD003709-sec-0088">Quality of the evidence</h3> <p>Overall quality of the evidence ranged from high to very low. Only four studies (<a href="./references#CD003709-bbs2-0002" title="AnnaneD , VignonP , RenaultA , BollaertPE , CharpentierC , MartinC , et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet2007;370(9588):676‐84. [PUBMED: 17720019] ">Annane 2007</a>; <a href="./references#CD003709-bbs2-0004" title="ChoongK , BohnD , FraserDD , GabouryI , HutchisonJS , JoffeAR , et al. Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2009;180(7):632‐9. [PUBMED: 19608718] ">Choong 2009</a>; <a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>; <a href="./references#CD003709-bbs2-0024" title="GordonAC , RussellJA , WalleyKR , SingerJ , AyersD , StormsMM , et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Medicine2010;36(1):83‐91. GordonAC , WangN , WalleyKR , AshbyD , RussellJA . The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest2012;142(3):593‐605. RussellJA , FjellC , HsuJL , LeeT , BoydJ , ThairS , et al. Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. American Journal of Respiratory and Critical Care Medicine2013;188:356‐64. RussellJA , WalleyKR , GordonAC , CooperDJ , HébertPC , SingerJ , et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Critical Care Medicine2009;37(3):811‐8. [PUBMED: 19237882] RussellJA , WalleyKR , SingerJ , GordonAC , HébertPC , CooperDJ , et al. Vasopressin versus norepinephrine infusion in patients with septic shock. New England Journal of Medicine2008;358(9):877‐87. [PUBMED: 18305265] ">Russell 2008</a>) fulfilled all criteria for the risk of bias assessment (<a href="#CD003709-fig-0003">Figure 3</a>). However, when only bias items that were assumed to strongly influence the effects were considered, 11 studies were classified as having low risk of bias. Small‐study bias usually tends to overestimate a true effect, but on the other hand, in the case of a null effect, limited power to exclude the absence of an effect may matter more. Many comparisons must be interpreted with caution. In summary, however, within‐study bias does not seem to explain our findings. </p> <p>Studies were too few for review authors to examine reporting bias in detail. However, as no obvious asymmetry in funnel plots was considered, and given that the comprehensive search strategy used several electronic databases without restrictions, as well as trial registers and experts in the field, reporting bias may not be a major source of distortion. </p> <p>For the network meta‐analysis, we considered at least two possible clinical elements of concern, including type of shock (septic shock vs other shock) and variability of the set point (mean arterial pressure) for titration of vasopressors. Allowing placebo to be real placebo or an active drug in a network meta‐analysis adds another source of inconsistency, although we considered all such trials as add‐on vasopressor trials. We acknowledge the clinical heterogeneity included in our analyses, but we assume that heterogeneity comes mainly from within the single studies, and that the extra heterogeneity introduced by the network meta‐analysis is less important than the between‐single study heterogeneity. </p> </section> <section id="CD003709-sec-0089"> <h3 class="title" id="CD003709-sec-0089">Potential biases in the review process</h3> <p>Data show no relevant departures from protocol (<a href="./references#CD003709-bbs2-0112" title="MüllnerM , UrbanekB , HavelC , LosertH , GamperG . Vasopressors for shock. Cochrane Database of Systematic Reviews2002, Issue 3. [DOI: 10.1002/14651858.CD003709] ">Müllner 2002</a>) as potential sources of bias and no relevant decisions about analyses. The decision to include a network meta‐analysis was made at the time of publication of the last update (<a href="./references#CD003709-bbs2-0111" title="HavelC , ArrichJ , LosertH , GamperG , MüllnerM , HerknerH . Vasopressors for hypotensive shock. Cochrane Database of Systematic Reviews2011, Issue 5. [DOI: 10.1002/14651858.CD003709.pub3] ">Havel 2011</a> ). </p> </section> <section id="CD003709-sec-0090"> <h3 class="title" id="CD003709-sec-0090">Agreements and disagreements with other studies or reviews</h3> <p>Several cohort studies have presented different conclusions about the effects of different vasopressors. </p> <p>In a university hospital‐based cohort study, <a href="./references#CD003709-bbs2-0092" title="MartinC , ViviandX , LeoneM , ThirionX . Effect of norepinephrine on the outcome of septic shock. Critical Care Medicine2000;28(8):2758‐65. [PUBMED: 10966247] ">Martin 2000</a> studied 97 participants with septic shock. Participants were treated with a mix of catecholamines, mainly to compare high‐dose dopamine versus norepinephrine in a non‐randomized design. Norepinephrine in comparison with other vasopressors was significantly associated with better outcomes. This effect was adjusted for many potential confounders, but treatment allocation may have been poorly controlled. </p> <p>In a multi‐centre cohort study in 198 European ICUs (<a href="./references#CD003709-bbs2-0103" title="SakrY , ReinhartK , VincentJL , SprungCL , MorenoR , RanieriVM , et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Critical Care Medicine2006;34(3):589‐97. [PUBMED: 16505643] ">Sakr 2006</a>) (occurrence of sepsis in acutely ill patients (SOAP study)), the effects of norepinephrine, dopamine, dobutamine and epinephrine were assessed in 1058 participants with shock. Epinephrine and in particular dopamine were found to worsen outcomes. In a smaller subset of participants with septic shock, epinephrine was associated with poor outcomes and dopamine showed a trend towards poor outcomes. These data were derived from a very heterogeneous sample and, despite extensive multi‐variable adjustments, residual confounding may explain the effects. </p> <p><a href="./references#CD003709-bbs2-0093" title="PovoaPR , CarneiroAH , RibeiroOS , PereiraAC . Influence of vasopressor agent in septic shock mortality. Results from the Portuguese Community‐Acquired Sepsis Study (SACiUCI study). Critical Care Medicine2009;37(2):410‐6. [PUBMED: 19114885] ">Povoa 2009</a> reported a multi‐centre cohort study from 17 Portuguese ICUs, in which 897 participants with community‐acquired sepsis were studied. In this population, norepinephrine and dobutamine were associated with worse outcomes, whereas dopamine was a predictor for better outcomes. In particular, when participants who received dopamine only were compared with participants who received norepinephrine only, the latter showed significantly worse outcomes. This effect was adjusted for age, sex, admission diagnosis, SAPS II, sequential organ failure assessment score (SOFA score) and inotropic support, but residual confounding cannot reasonably be excluded. Specifically, concern was expressed that the choice of vasopressors was driven by disease severity ‐ simply that sicker participants were more likely to receive norepinephrine than dopamine. </p> <p>In contrast to the observational evidence, recent reviews (<a href="./references#CD003709-bbs2-0072" title="BealeRJ , HollenbergSM , VincentJL , ParrilloJE . Vasopressor and inotropic support in septic shock: an evidence‐based review. Critical Care Medicine2004;32 Suppl(11):455‐65. [PUBMED: 15542956] ">Beale 2004</a>; <a href="./references#CD003709-bbs2-0085" title="HolmesCL , WalleyKR . Vasoactive drugs for vasodilatory shock in ICU. Current Opinion in Critical Care2009;15(5):398‐402. [PUBMED: 19542884] ">Holmes 2009</a>; <a href="./references#CD003709-bbs2-0089" title="LeoneM , MartinC . Vasopressor use in septic shock: an update. Current Opinion in Anaesthesiology2008;21(2):141‐7. [PUBMED: 18443479] ">Leone 2008</a>) have been conservative in stating differences between several vasopressors, and have indicated that norepinephrine and dopamine are most often considered to be the vasopressors of choice for participants with shock. </p> <p>In the meta‐analysis comparing norepinephrine versus dopamine in the setting of septic shock, DeBacker reported significantly increased mortality among participants undergoing therapy with dopamine. This finding is true when only 28‐day mortality is considered, but the effect is attenuated when the latest reported mortality is taken into account (<a href="./references#CD003709-bbs2-0075" title="DeBackerD , AldecoaC , NjimiH , VincentJL . Dopamine versus norepinephrine in the treatment of septic shock: a meta‐analysis. Critical Care Medicine2012;40(3):725‐30. ">DeBacker 2012</a>). Recently, two additional concordant systematic reviews on vasopressors in septic shock were published; both included mixed treatment comparisons (<a href="./references#CD003709-bbs2-0070" title="AvniT , LadorA , LevS , LeiboviciL , PaulM , GrossmanA . Vasopressors for the treatment of septic shock: systematic review and meta‐analysis. PLoS One2015;10(8):1‐17. ">Avni 2015</a>; <a href="./references#CD003709-bbs2-0110" title="ZhouF , MaoZ , ZengX , KangH , LiuH , PanL , et al. Vasopressors in septic shock: a systematic review and network meta‐analysis. Therapeutics and Clinical Risk Management2015;11:1047‐59. ">Zhou 2015</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003709-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Comparisons including vasopressors identified from the systematic review. The 10 interventions with 31 direct comparisons were derived from 28 studies. Line thickness is proportional to the number of included participants. Boxes indicate the two networks that we formally assessed in our network meta‐analysis. npvd/'placebo' denotes non‐protocol vasoactive drugs or placebo." data-id="CD003709-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Comparisons including vasopressors identified from the systematic review. The 10 interventions with 31 direct comparisons were derived from 28 studies. Line thickness is proportional to the number of included participants. Boxes indicate the two networks that we formally assessed in our network meta‐analysis. <i>npvd/'placebo'</i> denotes <i>non‐protocol vasoactive drugs or placebo</i>. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/full#CD003709-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Search flow diagram." data-id="CD003709-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Search flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/full#CD003709-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003709-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/full#CD003709-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003709-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/full#CD003709-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 norepinephrine, outcome: 1.1 mortality." data-id="CD003709-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 norepinephrine, outcome: 1.1 mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/full#CD003709-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Norepinephrine, outcome: 1.1 Total mortality." data-id="CD003709-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Norepinephrine, outcome: 1.1 Total mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/full#CD003709-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Graphical representation of the evidence network including vasopressors showing available direct comparisons. The lines represent direct comparisons, and line thickness is proportional to precision of the estimates (1/SE)." data-id="CD003709-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Graphical representation of the evidence network including vasopressors showing available direct comparisons. The lines represent direct comparisons, and line thickness is proportional to precision of the estimates (1/SE). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/full#CD003709-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Network forest plot comparing seven vasopressor regimens vs norepinephrine (reference) from 22 studies with 24 pair‐wise comparisons. Heterogeneity/inconsistency: tau2 &lt; 0.0001; I2 statistic = 0%. Test of heterogeneity/inconsistency: Q = 8.48 (d.f. 18), P value = 0.97; 'NPVD' denotes non‐protocol vasoactive drugs with or without placebo. RR denotes risk ratio, as calculated by a fixed‐effect model. RR &gt; 1 indicates increased mortality risk; RR &lt; 1 indicates reduced mortality risk vs norepinephrine (reference)." data-id="CD003709-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Network forest plot comparing seven vasopressor regimens vs norepinephrine (reference) from 22 studies with 24 pair‐wise comparisons. Heterogeneity/inconsistency: tau<sup>2</sup> &lt; 0.0001; I<sup>2</sup> statistic = 0%. Test of heterogeneity/inconsistency: Q = 8.48 (d.f. 18), P value = 0.97; 'NPVD' denotes non‐protocol vasoactive drugs with or without placebo. RR denotes risk ratio, as calculated by a fixed‐effect model. RR &gt; 1 indicates increased mortality risk; RR &lt; 1 indicates reduced mortality risk vs norepinephrine (reference). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/full#CD003709-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Graphical representation of the evidence network including vasopressors and combinations with beta‐agonist action showing available direct comparisons. The lines represent direct comparisons, and line thickness is proportional to precision of the estimates (1/SE)." data-id="CD003709-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Graphical representation of the evidence network including vasopressors and combinations with beta‐agonist action showing available direct comparisons. The lines represent direct comparisons, and line thickness is proportional to precision of the estimates (1/SE). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/full#CD003709-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-AFig-FIG10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-AFig-FIG10.png" target="_blank"><b></b></a></p> </div><img alt="Network forest plot comparing four vasopressor regimens with a beta‐agonist component vs norepinephrine (reference) from 6 studies with 6 pair‐wise comparisons. Heterogeneity/inconsistency: tau2 &lt; 0.0001; I2 statistic = 0%. Test of heterogeneity/inconsistency: Q = 0.42(d.f. 3), P value = 0.94; 'nor_' denotes norepinephrine added to the other drugs as described. RR denotes risk ratio, as calculated by a fixed‐effect model. RR &gt; 1 indicates increased mortality risk; RR &lt; 1 indicates reduced mortality risk vs norepinephrine (reference)." data-id="CD003709-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Network forest plot comparing four vasopressor regimens with a beta‐agonist component vs norepinephrine (reference) from 6 studies with 6 pair‐wise comparisons. Heterogeneity/inconsistency: tau<sup>2</sup> &lt; 0.0001; I<sup>2</sup> statistic = 0%. Test of heterogeneity/inconsistency: Q = 0.42(d.f. 3), P value = 0.94; 'nor_' denotes norepinephrine added to the other drugs as described. RR denotes risk ratio, as calculated by a fixed‐effect model. RR &gt; 1 indicates increased mortality risk; RR &lt; 1 indicates reduced mortality risk vs norepinephrine (reference). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/full#CD003709-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-AFig-FIG11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-AFig-FIG11.png" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis in patients with septic shock: network forest plot comparing 7 vasopressor regimens vs norepinephrine (reference) from 18 studies with 20 pair‐wise comparisons. Heterogeneity/inconsistency: tau2 &lt; 0.0001; I2 statistic = 0%. Test of heterogeneity/inconsistency: Q = 5.21, d.f. = 14, P value = 0.98; 'NPVD' denotes non‐protocol vasoactive drugs with or without placebo. RR denotes risk ratio, as calculated by a fixed‐effect model. RR &gt; 1 indicates increased mortality risk; RR &lt; 1 indicates reduced mortality risk vs norepinephrine (reference)." data-id="CD003709-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Subgroup analysis in patients with septic shock: network forest plot comparing 7 vasopressor regimens vs norepinephrine (reference) from 18 studies with 20 pair‐wise comparisons. Heterogeneity/inconsistency: tau<sup>2</sup> &lt; 0.0001; I<sup>2</sup> statistic = 0%. Test of heterogeneity/inconsistency: Q = 5.21, d.f. = 14, P value = 0.98; 'NPVD' denotes non‐protocol vasoactive drugs with or without placebo. RR denotes risk ratio, as calculated by a fixed‐effect model. RR &gt; 1 indicates increased mortality risk; RR &lt; 1 indicates reduced mortality risk vs norepinephrine (reference). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/full#CD003709-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-AFig-FIG11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Norepinephrine, Outcome 1 Total mortality." data-id="CD003709-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Norepinephrine, Outcome 1 Total mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Norepinephrine, Outcome 2 LOS ICU." data-id="CD003709-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Norepinephrine, Outcome 2 LOS ICU.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Norepinephrine, Outcome 3 LOS hospital." data-id="CD003709-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Norepinephrine, Outcome 3 LOS hospital.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Norepinephrine, Outcome 4 Arrhythmia." data-id="CD003709-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Norepinephrine, Outcome 4 Arrhythmia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Epinephrine, Outcome 1 Total mortality." data-id="CD003709-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Epinephrine, Outcome 1 Total mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Vasopressin, Outcome 1 Total mortality." data-id="CD003709-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Vasopressin, Outcome 1 Total mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Vasopressin, Outcome 2 LOS ICU." data-id="CD003709-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Vasopressin, Outcome 2 LOS ICU.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Terlipressin, Outcome 1 Total mortality." data-id="CD003709-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Terlipressin, Outcome 1 Total mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Terlipressin, Outcome 2 LOS ICU." data-id="CD003709-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Terlipressin, Outcome 2 LOS ICU.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Terlipressin, Outcome 3 LOS hospital." data-id="CD003709-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Terlipressin, Outcome 3 LOS hospital.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Terlipressin, Outcome 4 Duration mechanical ventilation." data-id="CD003709-fig-0022" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Terlipressin, Outcome 4 Duration mechanical ventilation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Terlipressin, Outcome 5 Pressor‐free days." data-id="CD003709-fig-0023" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Terlipressin, Outcome 5 Pressor‐free days.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Terlipressin, Outcome 6 Serious adverse events." data-id="CD003709-fig-0024" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Terlipressin, Outcome 6 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Dopamine, Outcome 1 Total mortality." data-id="CD003709-fig-0025" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Dopamine, Outcome 1 Total mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Dopamine, Outcome 2 LOS ICU." data-id="CD003709-fig-0026" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Dopamine, Outcome 2 LOS ICU.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Dopamine, Outcome 3 LOS hospital." data-id="CD003709-fig-0027" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Dopamine, Outcome 3 LOS hospital.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Dopamine, Outcome 4 Pressor‐free days." data-id="CD003709-fig-0028" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Dopamine, Outcome 4 Pressor‐free days.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Dopamine, Outcome 5 Arrhythmia." data-id="CD003709-fig-0029" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Dopamine, Outcome 5 Arrhythmia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity analysis norepinephrine, Outcome 1 Mortality." data-id="CD003709-fig-0030" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity analysis norepinephrine, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Sensitivity analysis epinephrine, Outcome 1 Mortality." data-id="CD003709-fig-0031" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Sensitivity analysis epinephrine, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Sensitivity analysis vasopressin, Outcome 1 Mortality." data-id="CD003709-fig-0032" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Sensitivity analysis vasopressin, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Sensitivity analysis terlipressin, Outcome 1 Mortality." data-id="CD003709-fig-0033" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Sensitivity analysis terlipressin, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003709-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/urn:x-wiley:14651858:media:CD003709:CD003709-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_t/tCD003709-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Sensitivity analysis dopamine, Outcome 1 Mortality." data-id="CD003709-fig-0034" src="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Sensitivity analysis dopamine, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/media/CDSR/CD003709/image_n/nCD003709-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003709-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Dopamine compared with norepinephrine for hypotensive shock</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Dopamine compared with norepinephrine for hypotensive shock</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> hypotensive shock<br/> <b>Settings:</b> critical care units<br/> <b>Intervention:</b> dopamine<br/> <b>Comparison:</b> norepinephrine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Norepinephrine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Dopamine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total mortality<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.07<br/> (0.99 to 1.16)<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1400<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH<sup>d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>380 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>407 per 1000<br/> (376 to 441) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Arrhythmia &lt; BR/&gt; follow‐up: <br/> range 28 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<sup>f,g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.33<br/> (1.45 to 3.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1931<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH<sup>h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>177 per 1000<br/> (110 to 293) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The largest study reported 12‐month mortality, one study reported 28‐day mortality and one hospital mortality. For the remaining 3 studies, the time point of mortality assessment was undetermined. A sensitivity analysis indicates no influence on effects by differences in mortality definition<br/> <sup>b</sup><a href="./references#CD003709-bbs2-0103" title="SakrY , ReinhartK , VincentJL , SprungCL , MorenoR , RanieriVM , et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Critical Care Medicine2006;34(3):589‐97. [PUBMED: 16505643] ">Sakr 2006</a> </p> <p><sup>c</sup>Estimate from the network meta‐analysis integrating direct and indirect comparisons<br/> <sup>d</sup>Four smaller studies included up to 50 participants, each of whom did not fulfil some of the quality criteria and one high risk of bias study that contributed 252 participants. However, the summary result is mainly made up by the largest study of more than 1000 participants that fulfils all low risk of bias criteria<br/> <sup>e</sup>The main outcomes of the four smaller studies are haemodynamics and metabolic measures. Mortality is reported only at the end of the results and often is unclear timepoint‐wise. However, the study by <a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a> (which contributes mainly to the summary result) clearly defines mortality endpoints<br/> <sup>f</sup><a href="./references#CD003709-bbs2-0097" title="ReineltP Karth DG , GeppertA , HeinzG . Incidence and type of cardiac arrhythmias in critically ill patients: a single center experience in a medical‐cardiological ICU. Intensive Care Medicine2001;27:1466‐73. [PUBMED: 11685339] ">Reinelt 2001</a><br/> <sup>g</sup><a href="./references#CD003709-bbs2-0067" title="AnnaneD , SébilleV , DubocD , LeHeuzeyJY , SadoulN , BouvierE , et al. Incidence and prognosis of sustained arrhythmias in critically ill patients. American Journal of Respiratory and Critical Care Medicine2008;178:20‐5. [PUBMED: 18388358] ">Annane 2008</a><br/> <sup>h</sup>Information was obtained from 992 participants, 86% of whom were studied in a low risk of bias study (<a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>); remaining participants were included in a high risk of bias study (<a href="./references#CD003709-bbs2-0022" title="PatelGP , GraheJS , SperryM , SinglaS , ElpernE , LateefO , et al. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock2010;33(4):375‐80. [PUBMED: 19851126] ">Patel 2010</a>). Effects show into the same direction </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Dopamine compared with norepinephrine for hypotensive shock</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/full#CD003709-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003709-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Terlipressin compared with norepinephrine for hypotensive shock</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Terlipressin compared with norepinephrine for hypotensive shock</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> hypotensive shock<br/> <b>Settings:</b> critical care units<br/> <b>Intervention:</b> terlipressin<br/> <b>Comparison:</b> norepinephrine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Norepinephrine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Terlipressin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total mortality<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.93<br/> (0.69 to 1.26)<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>231<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>380 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>353 per 1000<br/> (262 to 479) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> <b>CI:</b> Confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Direct comparisons based on in‐hospital mortality and mortality at an undetermined point in time. A sensitivity analysis indicates no influence on effects by differences in mortality definition.<br/> <sup>b</sup><a href="./references#CD003709-bbs2-0103" title="SakrY , ReinhartK , VincentJL , SprungCL , MorenoR , RanieriVM , et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Critical Care Medicine2006;34(3):589‐97. [PUBMED: 16505643] ">Sakr 2006</a> </p> <p><sup>c</sup>Estimate from the network meta‐analysis integrating direct and indirect comparisons </p> <p><sup>d</sup>Risk of bias was serious with adequate allocation concealment in one small study that contributed to the estimates only; imprecision of the estimates was very serious, as direct comparisons are based on two small studies only, whereas only one contributed to the estimates </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Terlipressin compared with norepinephrine for hypotensive shock</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/full#CD003709-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003709-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Vasopressin compared with norepinephrine for hypotensive shock</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Vasopressin compared with norepinephrine for hypotensive shock</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> hypotensive shock<br/> <b>Settings:</b> critical care units<br/> <b>Intervention:</b> vasopressin<br/> <b>Comparison:</b> norepinephrine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Norepinephrine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Vasopressin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total mortality<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/> (0.78 to 1.03)<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1108<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>380 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>342 per 1000<br/> (296 to 391) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> <b>CI:</b> Confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>For the direct comparison, the largest study reported 90‐day mortality, and 2 studies contributed ICU mortality. A sensitivity analysis indicates no influence on effects by differences in mortality definition<br/> <sup>b</sup><a href="./references#CD003709-bbs2-0103" title="SakrY , ReinhartK , VincentJL , SprungCL , MorenoR , RanieriVM , et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Critical Care Medicine2006;34(3):589‐97. [PUBMED: 16505643] ">Sakr 2006</a> </p> <p><sup>c</sup>Estimate from the network meta‐analysis integrating direct and indirect comparisons </p> <p><sup>d</sup>The effect is based mainly on 1 moderately large RCT, and direct evidence comes from 3 RCTS including 812 individuals overall </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Vasopressin compared with norepinephrine for hypotensive shock</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/full#CD003709-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003709-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Phenylephrine compared with norepinephrine for hypotensive shock</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phenylephrine compared with norepinephrine for hypotensive shock</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> hypotensive shock<br/> <b>Settings:</b> critical care units<br/> <b>Intervention:</b> phenylephrine<br/> <b>Comparison:</b> norepinephrine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Norepinephrine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Phenylephrine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total mortality<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.08<br/> (0.76 to 1.55)<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>86<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>380 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>410 per 1000<br/> (289 to 589) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> <b>CI:</b> Confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>For the direct comparison, one study measured ICU mortality; for the other study, the time point of mortality assessment was undetermined<br/> <sup>b</sup><a href="./references#CD003709-bbs2-0103" title="SakrY , ReinhartK , VincentJL , SprungCL , MorenoR , RanieriVM , et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Critical Care Medicine2006;34(3):589‐97. [PUBMED: 16505643] ">Sakr 2006</a> </p> <p><sup>c</sup>Estimate from the network meta‐analysis integrating direct and indirect comparisons </p> <p><sup>d</sup>Two small studies, with 1 having unclear allocation concealment and an open intervention </p> <p><sup>e</sup>Two small studies with 86 individuals overall for the direct comparison </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Phenylephrine compared with norepinephrine for hypotensive shock</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/full#CD003709-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003709-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Epinephrine compared with norepinephrine for hypotensive shock</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Epinephrine compared with norepinephrine for hypotensive shock</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> hypotensive shock<br/> <b>Settings:</b> critical care units<br/> <b>Intervention:</b> epinephrine<br/> <b>Comparison:</b> norepinephrine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Norepinephrine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Epinephrine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total mortality<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/> (0.63 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>269<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>380 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>334 per 1000<br/> (239 to 475) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> <b>CI:</b> Confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>90‐Day mortality<br/> <sup>b</sup><a href="./references#CD003709-bbs2-0103" title="SakrY , ReinhartK , VincentJL , SprungCL , MorenoR , RanieriVM , et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Critical Care Medicine2006;34(3):589‐97. [PUBMED: 16505643] ">Sakr 2006</a> </p> <p><sup>c</sup>Effect from only 1 moderately large single RCT </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Epinephrine compared with norepinephrine for hypotensive shock</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/full#CD003709-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003709-tbl-0006"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Morbidity outcomes ‐ measures of renal function comparing several vasopressor regimens (each single vasopressor is compared with other available vasopressor regimens)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vasopressor</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparator (Reference)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Effect*</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>Norepinephrine</p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vasopressin (<a href="./references#CD003709-bbs2-0010" title="LauzierF , LevyB , LamarreP , LesurO . Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Medicine2006;32(11):1782‐9. [PUBMED: 17019548] ">Lauzier 2006</a>) </p> <p> </p> <p> </p> <p> </p> <p>Vasopressin (<a href="./references#CD003709-bbs2-0024" title="GordonAC , RussellJA , WalleyKR , SingerJ , AyersD , StormsMM , et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Medicine2010;36(1):83‐91. GordonAC , WangN , WalleyKR , AshbyD , RussellJA . The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest2012;142(3):593‐605. RussellJA , FjellC , HsuJL , LeeT , BoydJ , ThairS , et al. Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. American Journal of Respiratory and Critical Care Medicine2013;188:356‐64. RussellJA , WalleyKR , GordonAC , CooperDJ , HébertPC , SingerJ , et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Critical Care Medicine2009;37(3):811‐8. [PUBMED: 19237882] RussellJA , WalleyKR , SingerJ , GordonAC , HébertPC , CooperDJ , et al. Vasopressin versus norepinephrine infusion in patients with septic shock. New England Journal of Medicine2008;358(9):877‐87. [PUBMED: 18305265] ">Russell 2008</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Creatinine clearance</p> <p>  </p> <p> </p> <p>Days alive free of renal replacement therapy</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 mL min<sup>‐1</sup>1.73 m<sup>‐2</sup> ± 38 vs 122 mL min<sup>‐1</sup>1.73m<sup>‐2</sup> ± 66 , P value &lt; 0.001 </p> <p> </p> <p>(23 (IQR 5 to 28) vs 25 (IQR 6 to 28), P value = 0.64)</p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Norepinephrine + terlipressin + dobutamine</p> <p>(<a href="./references#CD003709-bbs2-0018" title="MorelliA , ErtmerC , LangeM , DuenserM , RehbergS , VanAkenH , et al. Effects of short‐term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. British Journal of Anaesthesia2008;100(4):494‐503. [PUBMED: 18308741] ">Morelli 2008a</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Urine output 4 hours after study start</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96 mL/h ± 48 vs 130 mL/h ± 76 (P value &lt; 0.05)</p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Norepinephrine + terlipressin</p> <p>(<a href="./references#CD003709-bbs2-0018" title="MorelliA , ErtmerC , LangeM , DuenserM , RehbergS , VanAkenH , et al. Effects of short‐term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. British Journal of Anaesthesia2008;100(4):494‐503. [PUBMED: 18308741] ">Morelli 2008a</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Urine output 4 hours after study start</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96 mL/h ± 48 vs 147 mL/h ± 119 (P value = 0.08)</p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dopamine (<a href="./references#CD003709-bbs2-0017" title="MathurS , DhunnaR , ChakrabortyA . Comparison of norepinephrine and dopamine in the management of septic shock using impedance cardiography. Indian Journal of Critical Care Medicine2007;11(4):186‐91. [EMBASE: 2008016347] ">Mathur 2007</a>) </p> <p> </p> <p> </p> <p> </p> <p> </p> <p>Dopamine (<a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>) </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Post‐treatment urine output</p> <p> </p> <p> </p> <p> </p> <p>Days free of renal support within 28 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.17 mL/kg/h ± 0.47 vs 0.81 mL/kg/h ± 0.75, P value &lt; 0.05</p> <p> </p> <p>14.0 ± 12.3 days vs 12.8 ± 12.4 days, P value = 0.07 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phenylephrine (<a href="./references#CD003709-bbs2-0019" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , LaderchiA , et al. Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. Critical Care2008;12(6)(R143):1‐11. [PUBMED: 19017409 ] ">Morelli 2008b</a>) </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Creatinine clearance</p> <p>Urine output</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference (P value = 0.61)</p> <p>No difference (P value = 0.17)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terlipressin (<a href="./references#CD003709-bbs2-0003" title="BoccaraG , OuattaraA , GodetG , DufresneE , BertrandM , RiouB , et al. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin‐angiotensin system inhibitors. Anesthesiology2003;98:1338‐44. [PUBMED: 12766641] ">Boccara 2003</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Renal failure post‐operatively</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0/10 vs 0/10)</p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terlipressin + norepinephrine and vasopressin + norepinephrine</p> <p>(<a href="./references#CD003709-bbs2-0020" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , CecchiniV , et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Critical Care2009;13(4):R130. [PUBMED: 19664253] ">Morelli 2009</a>) </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Need for renal replacement therapy</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(8/15 vs 4/15 vs 5/15, P value = 0.29)</p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epinephrine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Norepinephrine + dobutamine (<a href="./references#CD003709-bbs2-0011" title="LevyB , BollaertPE , CharpentierC , NaceL , AudibertG , BauerP , et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Medicine1997;23:282‐7. [PUBMED: 9083230] ">Levy 1997</a>) </p> <p> </p> <p> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oliguria reversal</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/12 vs 10/11</p> <p>RR 0.36 (95% CI 0.04 to 3.00)</p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Vasopressin</p> <p> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Norepinephrine (<a href="./references#CD003709-bbs2-0010" title="LauzierF , LevyB , LamarreP , LesurO . Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Medicine2006;32(11):1782‐9. [PUBMED: 17019548] ">Lauzier 2006</a>) </p> <p> </p> <p> </p> <p> </p> <p>Norepinephrine (<a href="./references#CD003709-bbs2-0024" title="GordonAC , RussellJA , WalleyKR , SingerJ , AyersD , StormsMM , et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Medicine2010;36(1):83‐91. GordonAC , WangN , WalleyKR , AshbyD , RussellJA . The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest2012;142(3):593‐605. RussellJA , FjellC , HsuJL , LeeT , BoydJ , ThairS , et al. Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. American Journal of Respiratory and Critical Care Medicine2013;188:356‐64. RussellJA , WalleyKR , GordonAC , CooperDJ , HébertPC , SingerJ , et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Critical Care Medicine2009;37(3):811‐8. [PUBMED: 19237882] RussellJA , WalleyKR , SingerJ , GordonAC , HébertPC , CooperDJ , et al. Vasopressin versus norepinephrine infusion in patients with septic shock. New England Journal of Medicine2008;358(9):877‐87. [PUBMED: 18305265] ">Russell 2008</a>) </p> <p> </p> <p> </p> <p> </p> <p> </p> <p>Norepinephrine vs terlipressin (<a href="./references#CD003709-bbs2-0020" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , CecchiniV , et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Critical Care2009;13(4):R130. [PUBMED: 19664253] ">Morelli 2009</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Creatinine clearance</p> <p> </p> <p> </p> <p> </p> <p>Days alive free of renal replacement therapy</p> <p> </p> <p> </p> <p>Need for renal replacement therapy</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122 mL min<sup>‐1</sup>1.73m<sup>‐2</sup> ± 66 vs 54 mL min<sup>‐1</sup>1.73m<sup>‐2</sup> ± 38, P value &lt; 0.001 </p> <p> </p> <p>25 (IQR 6 to 28) vs 23 (IQR 5 to 28), P value = 0.64</p> <p> </p> <p> </p> <p> </p> <p>8/15 vs 4/15 vs 5/15, P value = 0.29</p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo/non‐protocol vasoactive drugs (<a href="./references#CD003709-bbs2-0004" title="ChoongK , BohnD , FraserDD , GabouryI , HutchisonJS , JoffeAR , et al. Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2009;180(7):632‐9. [PUBMED: 19608718] ">Choong 2009</a>) </p> <p> </p> <p> </p> <p> </p> <p> </p> <p>Placebo/non‐protocol vasoactive drugs (<a href="./references#CD003709-bbs2-0014" title="MalayMB , AshtonRCJr , LandryDW , TownsendRN . Low‐dose vasopressin in the treatment of vasodilatory septic shock. Journal of Trauma1999;47:699‐703. [PUBMED: 10528604] ">Malay 1999</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Urine output</p> <p> </p> <p> </p> <p> </p> <p> </p> <p>Creatinine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7 mL/kg/h (IQR 0.7 to 3.5) vs 1.5 mL/kg/h (IQR 0.7 to 3.7), P value = 0.65</p> <p> </p> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Terlipressin</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Norepinephrine vs vasopressin (<a href="./references#CD003709-bbs2-0020" title="MorelliA , ErtmerC , RehbergS , LangeM , OrecchioniA , CecchiniV , et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Critical Care2009;13(4):R130. [PUBMED: 19664253] ">Morelli 2009</a>) </p> <p> </p> <p> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Need for renal replacement therapy</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/15 vs 4/15 vs 5/15, P value = 0.29</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo/non‐protocol vasoactive drugs in patients taking norepinephrine (<a href="./references#CD003709-bbs2-0018" title="MorelliA , ErtmerC , LangeM , DuenserM , RehbergS , VanAkenH , et al. Effects of short‐term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. British Journal of Anaesthesia2008;100(4):494‐503. [PUBMED: 18308741] ">Morelli 2008a</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Urine output 4 hours after study start</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147 mL/h ± 119 vs 96 mL/h ± 48 (P value = 0.08)</p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dopamine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Norepinephrine (<a href="./references#CD003709-bbs2-0017" title="MathurS , DhunnaR , ChakrabortyA . Comparison of norepinephrine and dopamine in the management of septic shock using impedance cardiography. Indian Journal of Critical Care Medicine2007;11(4):186‐91. [EMBASE: 2008016347] ">Mathur 2007</a>) </p> <p> </p> <p> </p> <p> </p> <p>Norepinephrine (<a href="./references#CD003709-bbs2-0005" title="DeBackerD , BistonP , DevriendtJ , MadlC , ChochradD , AldecoaC , et al. Comparison of dopamine and norepinephrine in the treatment of shock. The New England Journal of Medicine2010;362(9):779‐89. [PUBMED: 20200382] ">De Backer 2010</a>) </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Post‐treatment urine output</p> <p> </p> <p> </p> <p>Days free of renal support within 28 days</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.81 mL/kg/h ± 0.75 vs 1.17 mL/kg/h ± 0.47, P value &lt; 0.05</p> <p> </p> <p>12.8 ± 12.4 days vs 14.0 ± 12.3 days, P value = 0.07</p> <p> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>*All effects are presented as outcomes in the vasopressor group (left hand column) versus comparator (second column) with risk ratio or P value for differences between groups </p> <p>CI = confidence interval</p> <p>IQR = 25% to 75% interquartile range</p> <p>N/A = not applicable</p> <p>RR = risk ratio</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Morbidity outcomes ‐ measures of renal function comparing several vasopressor regimens (each single vasopressor is compared with other available vasopressor regimens)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/full#CD003709-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003709-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Norepinephrine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Norepinephrine vs dopamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.86, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Norepinephrine vs epinephrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.80, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Norepinephrine vs terlipressin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.8 [0.30, 2.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Norepinephrine vs vasopressin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>812</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.98, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Norepinephrine vs phenylephrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.64, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 LOS ICU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Norepinephrine vs vasopressin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>778</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [‐1.40, 3.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Norepinephrine vs norepinephrine + terlipressin + dobutamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐7.20, 5.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Norepinephrine vs phenylephrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐8.27, 8.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Norepinephrine vs dopamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1931</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.57, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 LOS hospital <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1931</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [‐0.96, 2.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Arrhythmia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1931</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.26, 0.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Norepinephrine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003709-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Epinephrine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Epinephrine vs norepinephrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.63, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Epinephrine vs norepinephrine + dobutamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.86, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Epinephrine vs norepinephrine + dopexamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.6 [0.46, 5.53]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Epinephrine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003709-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Vasopressin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Vasopressin vs placebo/non‐protocol vasoactive drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.69, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Vasopressin vs terlipressin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.56, 2.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Vasopressin vs norepinephrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>812</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.77, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 LOS ICU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Vasopressin vs terlipressin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Vasopressin vs norepinephrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Vasopressin vs placebo/non‐protocol vasoactive drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Vasopressin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003709-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Terlipressin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Terlipressin vs placebo/non‐protocol vasoactive drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.81, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Terlipressin vs norepinephrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.47, 3.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Terlipressin vs vasopressin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.43, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Terlipressin vs dopamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.42, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 LOS ICU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Terlipressin vs placebo/non‐protocol vasoactive drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.90 [‐8.61, 2.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Terlipressin vs vasopressin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.0 [‐13.21, 7.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Terlipressin vs dopamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐3.40, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 LOS hospital <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Terlipressin vs noradrenaline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Terlipressin vs dopamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Duration mechanical ventilation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Terlipressin vs placebo/non‐protocol vasoactive drug</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Terlipressin vs dopamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Pressor‐free days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Terlipressin vs dopamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Terlipressin vs placebo/non‐protocol vasoactive drug</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Terlipressin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003709-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Dopamine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.99, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Dopamine vs norepinephrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.99, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Dopamine vs terlipressin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.54, 2.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 LOS ICU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Dopamine vs norepinephrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1931</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.75, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Dopamine vs terlipressin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐3.40, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 LOS hospital <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1963</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.76 [‐2.32, 0.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Dopamine vs norepinephrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1931</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.66 [‐2.29, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Dopamine vs terlipressin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.80 [‐7.01, 3.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Pressor‐free days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Dopamine vs norepinephrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Dopamine vs terlipressin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Arrhythmia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1931</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.34 [1.46, 3.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Dopamine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003709-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Sensitivity analysis norepinephrine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Low risk of bias norepinephrine vs dopamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.87, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 No low risk of bias norepinephrine vs dopamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>364</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.72, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Low risk of bias norepinephrine vs epinephrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.80, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 No low risk of bias norepinephrine vs epinephrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Low risk of bias norepinephrine vs terlipressin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 No low risk of bias norepinephrine vs terlipressin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.8 [0.30, 2.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 Low risk of bias norepinephrine vs vasopressin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.97, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8 No low risk of bias norepinephrine vs vasopressin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.73, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9 Low risk of bias norepinephrine vs phenylephrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.9 [0.51, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10 No low risk of bias norepinephrine vs phenylephrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.59, 1.49]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Sensitivity analysis norepinephrine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003709-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Sensitivity analysis epinephrine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Low risk of bias epinephrine vs norepinephrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.63, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 No low risk of bias epinephrine vs norepinephrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Low risk of bias epinephrine vs norepinephrine + dobutamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.84, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 No low risk of bias epinephrine vs norepinephrine + dobutamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.66, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Low risk of bias epinephrine vs norepinephrine + dopexamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.6 [0.46, 5.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 No low risk of bias epinephrine vs norepinephrine + dopexamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Sensitivity analysis epinephrine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003709-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Sensitivity analysis vasopressin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Low risk of bias vasopressin vs placebo/non‐protocol vasoactive drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.11, 7.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 No low risk of bias vasopressin vs placebo/non‐protocol vasoactive drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.63, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Low risk of bias vasopressin vs terlipressin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 No low risk of bias vasopressin vs terlipressin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.56, 2.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Low risk of bias vasopressin vs norepinephrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.76, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 No low risk of bias vasopressin vs norepinephrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.61, 1.37]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Sensitivity analysis vasopressin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003709-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Sensitivity analysis terlipressin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Low risk of bias terlipressin vs placebo/non‐protocol vasoactive drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.81, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 No low risk of bias terlipressin vs placebo/non‐protocol vasoactive drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.69, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Low risk of bias terlipressin vs norepinephrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 No low risk of bias terlipressin vs norepinephrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.47, 3.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Low risk of bias terlipressin vs vasopressin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 No low risk of bias terlipressin vs vasopressin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.43, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 Low risk of bias terlipressin vs dopamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8 No low risk of bias terlipressin vs dopamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.42, 1.84]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Sensitivity analysis terlipressin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003709-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Sensitivity analysis dopamine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Low risk of bias dopamine vs norepinephrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.96, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 No low risk of bias dopamine vs norepinephrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>364</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.84, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Low risk of bias dopamine vs terlipressin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 No low risk of bias dopamine vs terlipressin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.54, 2.40]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Sensitivity analysis dopamine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003709.pub4/references#CD003709-tbl-0016">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003709.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD003709-note-0002">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD003709-note-0007">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003709-note-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003709-note-0006">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD003709-note-0017">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD003709-note-0005">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD003709-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD003709-note-0021">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD003709-note-0019">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD003709-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD003709-note-0020">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003709-note-0001">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD003709-note-0016">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003709\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003709\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003709\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003709\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003709\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003709\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003709\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003709\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003709\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003709\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003709\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003709\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003709\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003709\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003709\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003709\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003709\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003709\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Ko3zGe0H&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003709.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003709.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003709.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003709.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003709.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726076731"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003709.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726076734"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003709.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e8ad3eb1b9379',t:'MTc0MDcyNjA3Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 